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SUMMARY
The potential for the application of antibodies as analytical 
and preparative reagents was greatly expanded by the development 
of techniques for the production of monoclonal antibodies (Kohler 
and Milstein, 1975, 1976). The properties of monoclonal
antibodies are particularly suited to application in immunometric 
assays and indeed overcome all the major problems associated with 
conventional antisera. Antibodies of only moderate affinity may 
be used in sensitive immunometric assays with detection limits up 
to two orders of magnitude greater than can be achieved in 
competitive immunoassays with the same antibody (Buchegger et al, 
1981). The work of this thesis was concerned with the production 
of monoclonal antibodies to human TSH and their use in the design 
of immunometric assays for serum and neonatal blood spot TSH.
Chapter 3 deals with the production of a variety of 
monoclonal antibodies to TSH. These antibodies were characterised 
in terms of affinity, specificity and isotype. The results 
indicated that 5H8 and 2G2 may be of extreme practical value in 
the development of a two-site immunoradiometric assay (IRMA) for 
TSH. A number of such assays for the measurement of TSH in serum 
and in neonatal blood spots were then developed using both 
monoclonal and polyclonal antisera.
Chapter 4 seeks to illustrate the clinical role and 
suitability of the monoclonal - polyclonal serum TSH assay 
developed in this project. The assay successfully distinguished 
all cases of untreated primary hypothyroidism as having an 
elevated serum TSH and all cases of untreated hyperthyroidism as
having an undetectable serum TSH (<0.2 mU/1). On the basis of 
this information, together with the performance data described in 
Chapter 3, the assay was introduced in 1984 as the 'routine' serum 
TSH assay for the laboratory at Glasgow Royal Infirmary, 
processing some 20,000 serum specimens per annum.
Regarding the Scottish Screening Programme for congenital 
hypothyroidism, at the end of 1983 the monoclonal - polyclonal 
IRMA replaced the two-polyclonal IRMA of Sutherland et al (1981). 
Cumulative statistics and predictive values of the data obtained 
from The National Screening Programme with the two In-house IRMA 
TSH assays are recorded in Chapter 5 and they reveal that the 
monoclonal - polyclonal IRMA has continued to maintain the 
excellent clinical data obtained from the Scottish Screening 
Prog ramme.
Alternative high specific activity labels and the 
implications of these developments for the serum TSH assay service 
in Glasgow Royal Infirmary and the Scottish Screening Programme 
for congenital hypothyroidism are discussed in Chapter 6 . It is 
almost certain that the clinical value of a serum TSH assay will 
be enhanced by improving the detection limit from 0.2 mU/1 to 0.02 
mU/1. Such an improvement is not possible with the existing 
monoclonal and polyclonal antibodies and an 125x_^abei. The most 
straightforward way to achieve this improvement is to move to a 
non-isotopic label that is compatible with the available 
antibodies.
The work presented in Chapter 4 of this thesis (Sections V 
and VI) has shown that many patients receiving thyroxine 
replacement therapy have undetectable serum TSH levels, both in 
the in-house IRMA and using the Delfia assay. The interpretation
of these results is discussed in Chapter 6 . However, the role of 
sensitive TSH assays in monitoring patients receiving thyroxine 
replacement has still to be fully evaluated.
CHAPTER 1 
INTRODUCTION 
I GENERAL INTRODUCTION TO THE SUBJECT
The work presented in this thesis originated at a time when 
assays for TSH were becoming more topical. A two-site 
immunoradiometric assay employing two polyclonal antibodies for 
both serum and blood spot TSH had previously been developed in 
this laboratory. The prime objective of the studies now described 
was the production of monoclonal antibodies to human TSH and the 
use of these antibodies in the design, optimisation and validation 
of improved immunometric assays for the measurement of TSH in 
serum and in neonatal blood spots.
H  MONOCLONAL ANTIBODIES AS DIAGNOSTIC REAGENTS
a) Introduction
It has always been recognised that immunological methods 
suffer from several limitations which significantly 
restrict their applicability and usefulness. Firstly, there 
are often substantial practical difficulties in purification 
of antigens from human sources, for use in immunisation, 
standardisation and the isolation of specific antibodies. 
Secondly, it is not always simple to generate and continue
producing antibody with appropriate specificity and other 
properties. All conventional antisera contain complex 
mixtures of different antibodies of varying specificity and
avidity, recognising various aspects of antigenic structure.
Further, individual sera from different animals or even at
different times in a given animal, differ in the mixture of
antibodies they contain and so do not necessarily have the 
same properties. The heterogeneity of the immune response in 
vivo results from the fact that antigen indirectly stimulates 
the clonal proliferation of many different antibody - 
producing cells (McConnel et al, 1981), each one secreting a 
single antibody species (one type of heavy chain and one 
light chain). It is very difficult to resolve the complex 
(polyclonal) mixture of antibodies into its individual 
components, and only relatively crude fractionation on the 
basis of gross differences in avidity or specificity is 
generally possible.
The potential for the application of antibodies as
analytical and preparative reagents was greatly expanded by 
the development of techniques for the production of 
monoclonal antibodies (Kohler and Milstein, 1975, 1976).
Monoclonal antibodies are the products of individual cloned 
cell lines which may be grown in vitro, and as such they are 
homogeneous preparations with defined specificity and 
affinity.
Over the last decade there has been an explosion of 
publications describing the production and use of monoclonal 
antibodies in many areas of pure research and clinical 
medicine. These have been the subject of several general
reviews (Goding,- 1980; McMichael and Bastin, 1980; Edwards, 
1981; Sevier et al, 1981; Yelton and Scharff, 1981;
Eisenbarth and Jackson, 1982).
Production of Monoclonal Antibodies
1) Introduction
In retrospect the principle underlying the successful 
production of monoclonal antibodies is deceptively simple 
(Milstein, 1980). Lymphocytes from immunised animals will 
not themselves grow in vitro but by fusion with myeloma cell 
lines they may be immortalised (Figure 1.1). The hybrid 
myeloma (hybridoma) cells which result retain the important 
properties of both cell types involved in the fusion. Thus 
not only do they grow indefinitely as tumour cells like the 
myeloma but also continue to produce antibody characteristic 
of the lymphocyte. The careful choice of fusion partners was 
the key to this success, these being not only from the same 
species (originally the mouse) but the same basic cell type 
as well. As a necessary refinement the myeloma cells were 
engineered to have an enzyme deficiency so that after cell 
fusion hybrids but not parental cells survived to grow in a 
selective medium (see Section b)6). This is important 
because fusion efficiency is low (of the order of 1 in 10,000 
cells) so that initially hybrids are greatly outnumbered by 
myeloma cells. Hybrid cells may be cloned and individual 
colonies, each secreting a different homogeneous defined
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antibody, grown in tissue culture or as tumours irv- 
animals for antibody production. Cells can be maintained 
indefinitely in culture or stored frozen until required.
It is worth mentioning that the interest which led to 
the production of hybrid myeloma cells was the structure and 
organisation of immunoglobulin genes, and the molecular 
mechanism of antibody diversification (Milstein and Kohler, 
1977; Milstein, 1980). Thus, the original work used sheep 
red blood cells as a model system for which antibodies could 
be simply produced and analysed. However, the far-reaching 
implications of the technique for the whole of immunology and 
biochemistry were immediately obvious, and monoclonal 
antibodies are now produced routinely in many 
laboratories, the basic principles and procedures for cell 
fusion remaining much as first described (Kohler and 
Milstein, 1975; Galfre et al, 1977).
2) Choice of Cells for Fusion
The choice of myeloma cell line for culture and animal 
for immunisation are two interdependent variables which must 
first be considered. Stable antibody-secreting hybrids are 
generally not produced from fusions between cells of 
different species due to preferential chromosome loss from 
one or other of the parent cells. Thus the range of 
possibilities is limited by the availability of myeloma cell 
lines. It is a long and difficult process to derive these 
and is not easily accomplished with most species. The cell
lines of established value were all derived from BALB/c mice 
or Lou rats (Galfre and Milstein, 1981; Reading, 1982). Some 
myeloma lines secrete their own immunoglobulin and continue 
to synthesise this in hybrid cells where the myeloma and 
lymphocyte heavy and light chains are randomly assembled. As 
a result the specific antibody containing the correct 
combination of heavy and light chains may contribute only a 
small proportion of the immunoglobulin made by such cells. 
However, variant myeloma lines which synthesise light chains 
only or no immunoglobulin at all are now available. 
Providing they undergo efficient fusion to produce stable 
hybrids, such lines are clearly to be preferred for most 
purposes because of the simpler nature of the immunoglobulin 
produced in the hybrids. Several such lines are freely 
available, while others may only be used under licence for 
commercial purposes. All these cell lines grow vigorously in 
standard tissue culture media, either in suspension or more 
or less loosely attached to surfaces, with a doubling time of 
the order of 20 h.
Attempts at heterogeneous fusions between standard 
myeloma lines and lymphocytes of different species have been 
reported. Reasonable success has been achieved from fusions 
between rat and mouse cells (Galfre et al, 1977) and stable 
hybrids between mouse myeloma and human lymphocytes have been 
described (Schlom et al, 1980; Valente et al, 1982).
Attempts to make use of rabbit, hamster and bovine 
lymphocytes have not been very fruitful, the resulting 
hybrids generally being unstable and not necessarily
secreting normal immunoglobulins (Yarmush et al, 1981;
Sanchez-Madrid et al, 1983).
Therefore, it is necessary to immunise mice or rats in 
order to carry out cell fusions with the presently available 
myeloma lines. The most important factor determining the 
choice of animal is the relative responsiveness to a given 
antigen, and for the difficult antigens it may be necessary
to attempt immunisation of several strains of both mice and
rats, including so-called high responders (Goding, 1980; 
Ivanyi and Davies, 1982). Other things being equal, rats may 
be preferred because of the apparently greater yield of 
stable antibody-secreting hybrids (Clark and Milstein, 1981), 
and potential eventual yield of antibody from tumours grown 
in vivo (Galfre and Milstein, 1981). It is also an advantage 
to be able to use myeloma and lymphocytes from the same
inbred strain to facilitate the subsequent growth of hybrid 
cells iri vivo in this strain. Inter-strain hybrids can only 
be grown as tumours in the corresponding hybrid animals. 
Inter-species hybrids lead to still more problems and must be 
grown in vivo in 'nude" mice or rats (Noeman et al, 1982).
Normally the spleen is taken as a source of
immunocompetent lymphocytes for fusion when working with rats 
and mice. Other cells may be used, however, particularly in 
the preparation of human antibodies.
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3) Immunisation Techniques
A good Immunisation is the key to a successful fusion 
experiment. The potential yield of monoclonal antibodies is 
directly related to the size of immune response in vivo, and 
the properties of the monoclonal antibodies will on average 
reflect those detected in the immunised animal.
Mouse and rat immunisation is no different from that of 
larger animals and preferred protocols reflect the same 
mixture of prejudice, anecdote and serious study which has 
governed conventional antiserum production. Thus frequent, 
repeated injections have been employed by some workers, while 
others, perhaps more reliably, advise longer intervals, 
especially before a final boost (Goding, 1980; Galfre and 
Milstein, 1981). Similarly, quantitites of antigen used have 
been very variable. Different procedures have rarely been 
systematically investigated and in any case the optimum 
conditions will probably differ for different antigens and 
animals. The initial immunisation is generally given 
subcutaneously or intraperitoneally using an emulsion of 
microgram quantities of antigen in Freund's complete 
adjuvant. One or more boosts with emulsified or soluble 
material may be given at intervals of a few weeks. The final 
boost is given intraperitoneally or intravenously in saline 
so as to maximise the acute stimulation of spleen cells. To 
increase the chances of obtaining at least one good responder 
it is worth immunising as many animals including different 
strains, as the available antigen permits.
Immunogen purity is not in itself important as 
subsequent screening of antibodies and cell cloning can be 
used to ensure specificity of the final product. However, if 
grossly impure preparations are used the dominant antigen may 
not necessarily be the one of interest. It is usually 
desirable to substantially purify the material both for 
immunisation and screening, although antigens of as little as 
1-4% purity have occasionally been used sucessfully (Secher 
and Burke, 1980; Van den Berg et al 1982).
The way in which the antigen is presented for 
immunisation will influence the characteristics of monoclonal 
antibodies subsequently obtained just as in the production 
of conventional antisera. Thus, in the case of haptens, 
attention must be given to the chemistry of coupling to 
carrier protein to avoid masking of important chemical 
groups. Subunits or fragments may be used for immunisation 
with protein antigens in order to concentrate the immune 
response and subsequent experimental effort on particular 
epitopes. However, it is always possible that some 
monoclonal antibodies to such fragments will not react well 
with intact native molecules. It has been reported that 
monoclonal antibody specificity and affinity depends on the 
immunisation protocol used. Thus the highest affinity and 
most specific antibodies for progesterone were obtained after 
prolonged immunisation (Fantl et al, 1982).
4) Immune Response Assessment
The production of monoclonal antibodies is in no way 
'magical'. The technique of cell fusion can only immortalise 
lymphocytes and corresponding antibodies which were present 
in vivo in the immunised animal. The properties of 
antibodies made in vivo may change with time and after 
successive boosts, so that the accumulated serum antibody 
does not precisely reflect that being made by the most 
recently stimulated cells, which are selected preferentially 
in the process of fusion (Kohler and Milstein, 1976; Clark 
and Milstein, 1981). Apart from this qualification, the 
chances of obtaining a monoclonal antibody with particular 
properties will be directly related to the concentration of 
corresponding antibodies in the serum of the spleen donor. 
Hence it is necessary to screen immunised animals in order to 
select for fusion those with the best antibody titre with 
required properties.
Experience has shown that the yield of positive hybrids 
is greatest when fusions are performed 3-4 days after 
boosting, whereas serum antibody concentration does not peak 
until 7-10 days. Screening must therefore be performed at 
the optimum time after a penultimate boost, or in the very 
short time available after a final boost. For this purpose 
animals may be test bled from the tail and the serum antibody 
titre determined in a convenient screening assay. Below a 
certain titre the chances of obtaining good monoclonal 
antibodies become very small.
If it is important to obtain antibodies with a 
particular pattern of specificity, it may be worthwhile
seeking evidence for such an antibody population in serum 
(Siddle and Soos, 1981; Fantl et al, 1982). For example, in 
making antibodies to pituitary hormones such as TSH, there is 
much variability between animals in the relative incidence of 
antibodies to a and 6 subunits, independently of the overall 
titre. Those animals making antibody predominantly against a 
subunit invariably yield only similar monoclonal antibodies 
which therefore react equally with other hormones such as LH 
and FSH (Siddle and Soos, 1981).
5) Cell Fusion Techniques
It is not clear what the biochemical mechanisms
underlying cell fusion are (Knutton and Pasternak, 1979), but 
technically the process is straightforward and takes only a 
short time. An important factor in determining success at
this stage is that both types of parental cell should be in 
the best possible condition. It is necessary that myeloma 
cells are in rapid, exponential growth phase in culture, and 
lymphocytes stimulated effectively by a final boost of
antigen 4 days previously. Myeloma cells and lymphocytes 
(one mouse or half of a rat spleen) are mixed and spun down 
into a pellet. Polyethylene glycol, the fusogen, is added 
carefully and then slowly diluted out. Precise cell numbers, 
temperature, timing and polyethylene glycol concentration do
not appear to be critical and a number of different protocols 
have been described and used successfully (Galfre and 
Milstein, 1981).
The yield of viable hybrid cells is of the order of some 
hundreds or thousands representing only a small proportion of 
the parental cells. The fraction of hybrid cells secreting 
immunoglobulin varies with the myeloma line used for fusion 
(Clark and Milstein, 1981), and the proportion of these which 
secrete the required specific antibody is dependent on the 
success of the immunisation. In general, approximately 1- 
10% of hybrids may be making specific antibody although much 
higher figures have been claimed in some cases and with 
weakly immunised animals lower values are always possible.
Other methods of cell fusion include antigen-directed 
fusion using polyethylene glycol (Kranz et al, 1980),
electric field-induced fusion (Vienken and Zimmermann, 1982) 
and antigen-directed electric field-induced fusion (Lo et al, 
1984).
6) Cell Culture and Cloning
Following fusion a preliminary growth phase is normally 
preferred before cloning, although attempting to clone cells 
immediately is possible. Conditions should be made as
favourable as possible for hybrid growth with a high foetal
calf serum concentration and, if necessary, the addition of
feeder cells. It is vitally important to adopt sterile 
technique throughout as fungal infections can
spread quickly once introduced and destroy a lot of effort 
and perhaps cell lines which are irreplaceable. During the 
initial growth period of 10-14 days, hybrid cells multiply, 
doubling every day or so. The parental lymphocytes do not 
survive in culture, and the parental myeloma cells are 
selectively killed by the HAT (hypoxanthine, aminopterin, 
thymidine) medium technique (Goding, 1980; Galfre and 
Milstein, 1981). By way of explanation, cells can synthesize 
DNA in two ways, either by 'de novo' synthesis or via the so- 
called 'salvage' pathway using exogenous or endogenous 
sources of preformed bases (Figure 1.2). If myeloma cells 
are grown in the presence of a purine analogue, for example, 
8-azaguanine or 6-thioguanine, the hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT'ase) enzyme catalyses the 
incorporation of the purine analogue into DNA where it 
interferes with normal protein synthesis and so the cells 
die. The gene coding for the HGPRT'ase enzyme is on the X 
chromosome and so only a single copy per cell is expressed. 
Eventually cells will arise that are deficient in the 
HGPRT'ase gene and therefore do not incorporate the purine 
analogue. These HGPRT'ase deficient cells are unable to 
utilise hypoxanthine and so synthesise ribonucleotides only 
by 'de novo' synthesis. A selective medium containing 
aminopterin, hypoxanthine and thymidine (HAT medium) was 
introduced (Littlefield, 1967). Aminopterin is an analogue 
of folic acid and binds very tenaciously to folic acid 
reductase thus blocking the co-enzymes required for 'de novo' 
synthesis of DNA. To grow in this medium a cell must make 
DNA via the 'salvage' pathway. Thus, if myeloma cells,
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deficient in HGPRT'ase, are fused with normal lymphocytes and 
then placed in HAT medium, only the hybrids between myeloma 
and normal cells will grow; the myeloma cell provides 
immortality and the lymphocyte provides the HGPRT'ase 
enzyme.
Even during early growth it is important to segregate 
the cell fusion products into a number of different 
subcultures. This reduces competition between hybrids 
growing at different rates, facilitates identification of 
distinct antibody-positive hybrids, and simplifies the 
subsequent task of cloning. Several different strategies may 
be employed. Cells may be distributed into about 50 2 ml 
cultures, each of which will then contain many different 
hybrids. It is then, initially, a relatively small task to 
screen for positive cultures, but cloning from these cultures 
may subsequently demand the screening of very large numbers 
of clones to identify those arising from a small proportion 
of positive cells. At the other extreme, cells may be 
distributed into hundreds or even thousands of 0.2 ml 
cultures, such that each culture well contains only one or 
very few different hybrids. Initial screening is then a 
formidable task but the effort subsequently necessary to 
isolate positive clones is reduced. However, it has been 
shown that the probability of hybrid cell survival decreases 
with post-fusion cell dilution (De Bias et al, 1981), and 
initial monoclonality may be undermined by the production of 
non-secreting variants in an originally positive culture.
Cloning should be carried out as soon as possible after 
positive subcultures have been identified. This may be
achieved by growing hybrids at limiting dilution in micro- 
titre trays with feeder cells, such that some wells receive 
only a single hybrid cell which develops into a more or less 
compact colony after a few days. Alternatively, cells may be 
grown at low dilution in semi-solid agar as a way of 
physically separating the clones of cells until they are 
large enough to be transferred individually to culture 
wells.
During hybrid growth and cloning it is often found that 
antibody secretion appears unstable. This may be due to 
overgrowth by negative cells so that the fraction of positive 
cells and antibody concentration decreases in successive 
subcultures. Also, chromosome loss from hybrid cells, 
especially in the early days after fusion may give rise to 
non-secreting variants. Failure to obtain positive clones 
even from subcultures which appear strongly positive may 
reflect a low proportion of positive cells, or an inherently 
poor cloning efficiency of some cell lines which will not 
grow well from low concentrations. Some degree of hybrid 
instability may persist indefinitely, necessitating periodic 
recloning to ensure maintenance of overwhelmingly positive 
cells. Chromosome loss, however, decreases with time, and 
initially it is normally sufficient to perform two clonings 
to ensure and confirm that a monoclonal cell line has been 
obtained.
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7) Screening Assays
It is necessary, both in the initial screening of 
subcultures, and in the subsequent identification of positive 
clones, to have a good assay for the detection of specific 
antibody. There are a lot of possible types of screening 
assay depending on the nature and availability of antigen 
(Galfre and Milstein, 1981). The chosen assay must be 
sensitive enough to enable antibody at concentrations of less 
than 1 ug/ml in supernatant medium from cell cultures to be 
detected. Also, it must be simple enough to give quick 
answers on very large numbers of samples. However, it need 
not be precisely quantitative nor at this stage totally 
specific.
Most generally applicable are the assays which make use 
of either insolubilised or labelled antigen (Figure 1.3). 
Protein antigens may be adsorbed onto a solid phase, often 
the wells of plastic microtitre trays, and successively 
incubated with putative monoclonal antibody and then second 
(anti-immunoglobulin) antibody or protein A, which is 
radioactively labelled or conjugated to an enzyme which is 
easily assayable. Relatively large (milligram) amounts of 
antigen which need not be pure, are required for this method. 
Alternatively, soluble antigen may be labelled for reaction 
with monoclonal antibody, which has been previously or is 
subsequently bound to solidphase linked second antibody or 
protein A. Very small (microgram) quantitie-S of antigen are 
required for this method, which preferably should be 
relatively pure. Either type of assay may pick up false
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Principle of commonly used screening assays for the detection of 
monoclonal antibodies. Antigen, represented as X, is either suitably 
labelled (a) or bound to solid phase (b) before reaction with mono­
clonal antibody M a x .  The presence of monoclonal antibody is 
detected by addition of a second, anti-immunoglobulin antibody Sp a 
M, which is either coupled to solid phase (a) or labelled (b)
positives due to antibodies directed against impurities if 
the same impure antigen is used for immunisation and 
screening. Some additional confirmation of antibody 
specificity will eventually be required in this case.
Other screening methods with general applicability 
include haemagglutination using antigen-coated erythrocytes 
(Coombs, 1981) and complement - dependent lysis with antigens 
present in or attached to cell surfaces. In some cases, 
assays may be based on the biological activity of an antigen, 
in particular enzyme activity, and the ability of antibody to 
precipitate, bind or inhibit this activity.
Potential cross-reacting or interfering compounds may be 
included in screening assays so as competitively to inhibit 
reaction of non-specific antibodies with antigen.
8) Bulk Production and Purification of Antibodies
Cloned cell lines can be grown in quantity for antibody 
production either in vitro or in vivo, and the preferred 
method depends on available facilities, scale of operation 
and eventual purity required. Before large-scale
culture, cells should be adapted to grow in medium 
supplemented with the lowest possible concentration of foetal 
calf serum, to ease antibody purification and reduce expense. 
Litre quantities per day of spent medium containing antibody 
at 10-100 ug/ml can be produced in spinner cultures. 
Alternatively, cells may be grown as intraperitoneal 
(ascites) tumours in animals, depending on the availability
of compatible recipient strains as described previously. 
Ascitic fluid and serum from tumour bearing animals contains 
relatively concentrated antibody at 1-10 mg/ml, mice yielding 
approximately 10 ml of fluid per animal in sequential taps 
over 2-3 weeks and rats considerably more. Tumour fluid 
antibody is contaminated by rodent serum proteins including 
immunoglobulins which may present problems if it is necessary 
to purify antibodies to homogeneity.
Monoclonal antibodies may be obtained in fairly pure 
form by simple physicochemical methods such as salt 
precipitation, ion exchange chromatography and gel filtration 
(Goding, 1980; Galfre and Milstein, 1981; Bruck et al, 1982; 
Parham et al, 1982). Affinity chromatography on protein A - 
Sepharose (Pharmacia) can yield very pure antibody from spent 
medium but not all immunoglobulin classes bind well to 
protein A, particularly in the rat, and the capacity is 
limited by the expense of reagents. Affinity purification on 
immobilised antigen or anti-immunoglobulin antibody also has 
a relatively limited capacity and may require potentially 
damaging conditions for elution of monoclonal antibody.
Properties of Monoclonal Antibodies
1) Introduction
I
The properties of monoclonal antibodies are not 
intrinsically different from those of normal serum 
immunoglobulins. Apparent differences result from the fact
that the behaviour of serum antibodies reflects the mean or 
composite properties of a mixture, whereas each monoclonal 
antibody has the particular physical and biological 
properties conferred by its unique molecular structure and 
single epitope recognition. The properties of an antibody 
from a cloned cell line should be unchanging. It is possible 
that an antibody may be susceptible to some form of 
processing in vivo (such as limited proteolysis) which would 
change the properties of tumour fluid antibody relative to 
that produced by cells in vitro. However, only rarely have 
differences between ascites and culture fluid antibody been 
reported (Wang et al, 1982). Monoclonal antibody
characterisation is necessary to assign priorities for 
culture and antibody production, and to assess suitability 
for a particular application. This requires the 
determination of concentration, affinity, fine specificity, 
epitope recognition and isotype, while also looking out for 
unusual physical properties.
2) Concentration and Avidity
Just as for antiserum, the titre of monoclonal 
antibodies in culture or tumour fluids is determined by 
assessing the effect of serial dilution on the performance in 
any convenient screening assay. The titre (dilution for 
half-maximal reactivity) is a function of both the 
concentration and avidity of antibody, and these parameters 
may both be determined by Scatchard analysis. By studying
the binding of antigen to a limiting amount of antibody as a 
function of antigen concentration, data for such a plot are 
obtained. Monoclonal antibodies for monovalent antigens 
should give linear Scatchard plots indicative of a 
bimolecular reaction with a single binding affinity. With 
multivalent antigens the situation is more complex because of 
the possibilities for formation of ternary and higher order 
complexes (Jacobsen et al, 1982).
Affinities reported of monoclonal antibodies for 
monovalent antigens vary over nearly four orders of magnitude 
(107 - 10H M-l). It is often said that monoclonal
antibodies are of low affinity, and compared to the best 
available polyclonal antisera this is frequently correct. 
The isolation of monoclonal antibodies of relatively low 
affinity partly reflects the preponderance of such antibodies 
in vivo in most animals. In monoclonal antibody populations, 
as for serum antibodies, high affinities are usually in the 
mi no ri ty.
3) Fine Specificity
Antibody fine specificity in discriminating between the
antigen of interest and related compounds may be investigated
in several ways. Direct binding of radioiodinated materials 
to antibody can be tested. By comparing the potencies of 
unlabelled compounds to inhibit binding of labelled antigen
to antibody, a quantitative estimate of relative affinities
may be obtained. Alternatively, potential cross-reactants 
may be tested for their ability to prevent binding of 
antibody to immobilised antigen.
In theory, it is possible that monoclonal antibodies may 
show reactivity towards molecules completely unrelated to the 
antigen of interest, because of the chance occurrence of 
epitopes with similar chemical groupings. Such cross­
reaction would not be a serious problem with a polyclonal 
antiserum for which overall reactivity depends on the 
recognition of many different epitopes on a molecule by a 
heterogeneous mixture of antibodies. In practice, such 
unforeseen cross-reactions have not been found with 
monoclonal antibodies, indicating that chance homology of 
epitopes on unrelated molecules occurs rarely if at all.
4) Epitope Definition
It is particularly useful in relation to methods of 
application requiring compatible pairs or mixtures of 
antibodies to define the epitopes recognised by different 
antibodies on a given antigen. Differences in fine 
specificity of antibodies for structurally related molecules 
or fragments of antigen may indicate distinct epitopes 
(Retegui et al, 1982; Lillehoj et al, 1982), though not 
necessarily sites which are sufficiently separated in space 
to allow simultaneous binding of the corresponding antibodies 
(Ivanyi, 1982; Soos and Siddle, 1983). Spatially separated 
epitopes may be resolved by competition binding studies.
However, the existence of competition between two antibodies 
in binding to antigen does not prove identity of epitope, but 
merely proximity considering the large size of immunoglobulin 
molecules and the potential for steric hindrance over a 
substantial part of the antigen. Epitope analysis may be 
performed by testing for competition either between labelled 
and unlabelled antibodies for binding to immobilised 
antigen, or between soluble and immobilised antibodies for 
binding of labelled antigen (Ivanyi, 1982; Soos and Siddle, 
1983). The two methods may not give identical results 
because of additional steric hindrance resulting from 
immobilisation of antigen. Antibodies to distinct epitopes 
may also be identified by their ability to complement one 
another in systems which require multivalent recognition of 
antigen, such as precipitation or agglutination (Miggiano et 
al, 1981). Monoclonal antibodies may be encountered for
multiple distinct epitopes or a small number of dominant 
antigenic determinants depending on the size and nature of 
individual antigens. Moreover, as a result of differences in 
the predominant antibodies produced in individual animals, 
the spectrum may vary between fusions.
5) Isotype Determination
The class and subclass of immunoglobulin heavy chain 
substantially influence the biological and physical 
properties of monoclonal antibodies, including their ability 
to fix complement (McConnell et al, 1981) and the conditions
under which nlonovalent or bivalent antibody fragments may be 
produced (Parham et al, 1982). The isotype may be determined 
by several methods, which make use of differences in 
electrophoretic mobility, reactivity with protein A or 
recognition by subclass - specific antisera in binding, 
precipitation or haemagglutination assays. Most mouse 
monoclonal antibodies are of the IgG^ subclass, reflecting 
the major type of immunoglobulin in serum but other classes 
are encountered not infrequently. IgM antibodies are 
obtained particularly when fusions are performed after a 
single immunisation, because of the importance of IgM in the 
primary immune response.
6) Physical Properties
Conventional antisera differ little in their mean 
physical properties such as stability on freezing and 
thawing, storage or iodination, susceptibility to changes in 
buffer concentration and pH, and ease of salt 
precipitability. Unusual sensitivity of a subpopulation of 
serum antibodies to some particular treatment may pass 
unnoticed against a background of predominantly stable 
antibody. However, when similarly treated, a sensitive 
monoclonal antibody may lose activity completely. Thus 
although most monoclonal antibodies are, like antisera, 
stable reagents which can be easily handled, atypical 
behaviour may be encountered. Physical properties which 
affect ease of adsorption or conjugation of antibodies on to
solid phase, and long-term stability, are by no means trivial 
considerations for routine diagnostic assays (Davis et al,
1983). Even the choice of buffer may be crucial for the 
optimal performance of some monoclonal antibodies (Buchegger 
et al, 1982b). It is difficult and usually unnecessary to 
investigate systematically the properties of every monoclonal 
antibody under a wide range of conditions, but as a 
precaution any new procedure should first be tested on a 
small scale before committing a large amount of potentially 
valuable antibody.
Application of Monoclonal Antibodies in Diagnostic Assays
In principle, monoclonal antibodies either singly or in 
combination, can be used in place of conventional antisera in 
any type of assay. However, in situations where adequate 
sensitivity, specificity and convenience are already provided 
by assays employing freely available polyclonal antibodies, 
there is not much to be gained by the expensive pursuit of 
monoclonal antibodies which may ultimately prove inferior to 
existing reagents.
The bulk of assays utilising antibodies may be broadly 
classified into competitive immunoassays, in which the 
analyte is the labelled component, or immunometric assays, in 
which antibody is labelled (Figure 1.4). In either type of 
assay, radioactive isotopes, enzymes, fluorescent molecules 
or luminescent compounds may be used as label.
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In competitive immunoassays, standard or unknown antigen 
competes with labelled antigen for binding to a limiting 
amount of antibody. A separation step is normally required 
in order to determine the distribution of label between 
'bound' and 'free' fractions. This may be achieved, for 
instance, by coupling antibody to solid phase, by use of 
a second (anti-immunoglobulin) antibody, or by some other 
means of selective precipitation or adsorption of antibody or 
antigen.
Immunometric assays in principle provide a direct 
measure of antigen by its combination with labelled antibody 
present in excess; a separation step is usually required to 
determine the amount of label bound. Originally this was 
achieved by addition of excess antigen coupled to solid phase 
to remove unbound antibody (Miles and Hales, 1968). More 
commonly, a two-site assay protocol is used (Woodhead et al, 
1974) in which antigen is adsorbed on to a solid phase 
containing a second specific antibody before or after 
reaction with labelled antibody. This requires that antigen 
binds simultaneously to two different antibody molecules and 
places a lower limit on the size of antigen which may be 
quantitated in this way. Homogeneous assays using labelled 
antibodies without a separation step have been proposed 
(Sevier et al, 1981) but not as yet put to practical use.
The theoretical and practical advantages of immunometric 
assays over competitive immunoassays have now been amply 
documented (Miles and Hales, 1968; Woodhead et al, 1974; 
Ekins, 1981; Hunter and Budd, 1981; Hunter et al, 1983).
These include improvement in speed, increased sensitivity,
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wider working range, and greater specificity for intact, 
biologically active molecules. Other points in favour of the 
immunometric assay are the lack of dependence on purification 
and labelling of antigen, which may alter its 
immunoreactivity, and the convenience of a separation step 
based on the two-site principle. Labelled polyclonal serum 
antibodies have, however, found only relatively restricted 
application in immunometric assays. Several factors have 
contributed to this. Firstly, such assays consume large 
amounts of antibodies, because these are used as excess 
rather than limiting reagents. Secondly, antibody must be 
purified from the bulk of serum immunoglobulin, of which it 
may constitute as little as 1%, for labelling to high 
specific activity. Purification is achieved by specific 
adsorption to and elution from immobilised antigen, a process 
which itself requires substantial amounts of purified antigen 
(Hales and Woodhead, 1980). The elution of bound antibody, 
usually at low pH, may damage its reactivity or fail to 
recover the fraction with highest avidity. A final problem 
with two-s-ite assays is their requirement for two antibodies 
which compete minimally for binding sites on the antigen. 
Such antisera may arise by chance in different animals, 
although polyclonal antibodies usually at best show 
substantial overlap in epitope reactivity. Distinct epitope 
reactivities may sometimes be engineered by immunisation 
with, or adsorption of sera against, specific fragments of 
antigen.
It is obvious that the properties of monoclonal 
antibodies are particularly suited to application in 
immunometric assays, and indeed overcome all the major 
problems associated with conventional antisera. Thus, 
monoclonal antibodies for multiple distinct epitopes on a 
given antigen may be produced in large quantitites, and 
easily purified. Antibodies of only moderate affinity may be 
used in sensitive immunometric assays with detection limits 
up to two orders of magnitude greater than can be achieved in 
competitive immunoassays with the same antibody (Buchegger et 
al, 1981; Weeks et al, 1981; Bosch et al, 1982; Van den Berg
et al, 1982; Hunter et al, 1983). In contrast, monoclonal 
antibodies have few advantages over polyclonal antisera for 
use in conventional immunoassays. Many monoclonal antibodies 
of indifferent affinity will produce immunoassays of inferior 
sensitivity, and only in terms of specificity is there any 
benefit to be expected.
Monoclonal Antibodies in Two-Site Immunometric Assays
1) Introduction
Two-site assays using monoclonal antibodies have been 
established for several antigens with a variety of different 
methods for labelling, types of solid phase, and incubation 
protocols. The particular configuration chosen usually 
reflects local preferences and expertise, and in any case the 
best conditions will differ for each antigen and antibody.
There are advantages in having monoclonal antibodies for both 
solid phase and labelled reagents, although they have also 
been used in conjunction with polyclonal antisera (Weeks et 
al, 1981; Brock et al, 1982; Buchegger et al, 1982a; Hunter
et al, 1982). In some cases this is simply due to the lack 
of availability of two suitable monoclonal antibodies. In 
others, polyclonal antibodies have been deliberately 
preferred for coupling to solid phase in spite of lower 
purity, because of better avidity (Hunter et al, 1983).
2) Labelling of Monoclonal Antibodies
Monoclonal antibodies were originally labelled either by 
radioiodination (Hurrell et al, 1981; Secher, 1981; Weeks et 
al, 1981; Hunter et al, 1982; Shimuzu et al, 1982) or by
conjugation with enzymes (Uotila et al, 1981; Brock et al, 
1982; Wada et al, 1982). Monoclonal antibody labelling 
techniques, and the relative advantages of different labels 
are much the same as in applications of other labelled 
proteins (Schall and Tenoso, 1981). Ease of preparation, 
shelf-life, effect of labelling on antibody activity, 
sensitivity of detection and instrumentation availability 
must be considered. Owing to the development of microplate 
photometers for rapid quantitation of large numbers of 
samples, and in response to propaganda about the hazards of 
radioactivity, the popularity of enzyme labels has increased. 
The sensitivity of enzyme methods may be considerably 
increased by the introduction of amplification steps in which
the primary product of the antibody - conjugated enzyme is 
used as a recycled cofactor in a subsequent colour-generating 
reaction (Self, 1985).
Other forms of labelling with luminescent compounds 
(Woodhead et al, 1982) or fluorescent molecules (Sioni and 
Kojola, 1983), are now finding their way into routine use. 
They are likely to increase in significance as relevant 
detection systems improve and become more widely available. 
The potential for much greater sensitivity using such labels, 
arising from the magnitude of effective signal per labelled 
antibody molecule, has been demonstrated (Weeks et al, 1983a, 
1983b; Petterson et al, 1983).
3) Solid Phase Linked Monoclonal Antibodies
Several different matrices have been used for coupling 
of antibody to produce solid phase reagent. Antibody may 
simply be adsorbed on to plastic surfaces such as the wells 
of microtitre trays (Uotila et al, 1981; Brock et al, 1982). 
The incubation vessel then provides the solid phase. This 
greatly facilitates washing procedures and is conveniently 
linked to spectrophotometric detection of end points by 
plate-readers. Long-term stability of adsorbed antibody and 
standardisation on a large scale may, however, give rise to 
problems. Various particulate materials have also been used 
for covalent coupling or adsorption of antibodies, including 
cellulose (Weeks et al, 1981), Sepharose (Hurrell et al, 
1981), polystyrene (Buchegger et al, 1982b), glass (Gard et
al, 1983) or'various plastics (Gard et al, 1984; Soos et al,
1984). Depending on the nature of the particles, separation 
and washing may be achieved by sedimentation or filtration 
techniques. The use of finely - divided cellulose or 
Sepharose beads has the advantage that these may be 
conveniently manipulated by automated immunoassay equipment 
(Bagshawe and Mitchell, 1983). The choice of solid phase 
will also be influenced by the assay protocol, and whether it 
is desired to carry out incubations with solid phase and 
labelled antibodies simultaneously or sequentially.
The available matrices differ in their capacity for 
coupling of antibody, and in their tendency to bind material 
non-specifically. The amount of effective antibody bound to
solid phase should be optimised in order to give an adequate 
capacity for antigen with the smallest possible quantity of 
solid phase, so that non-specific binding of labelled 
antibody is minimised. The avidity of solid phase antibody 
is also important in this context. Mixtures of different 
antibodies of relatively low affinity can be used to produce 
a high avidity solid phase which binds antigens 
simultaneously at two sites (Buchegger et al, 1982b).
4) Standard Diluent and Assay Buffers
In principle, standard solutions must be diluted in the 
same medium as constitutes the samples to be added in the 
assay. For measurement of human serum samples, it is 
therefore necessary to have access to analyte-free serum for
preparation of standards, unless it can be shown that there 
are no non-specific effects of serum, compared to a chosen 
buffer medium, on the assay reactions. Serum effects are 
generally less pronounced in immunometric assays than in 
competitive immunoassays. This is because minor
perturbations of the antigen-antibody reaction are not so 
serious when antibody excess drives the binding reaction to 
completion. Moreover, it is possible, if necessary, to carry 
out the critical reaction with labelled antibody after prior 
adsorption of antigen on to solid phase, and washing to 
remove any interfering serum components. It may be possible 
to obtain antigen-free serum under particular physiological 
or pathological conditions for use as a diluent, when serum 
effects are a problem. Traces of immunoreactive material may 
be removed from serum by immunoadsorption using specific 
immobilised monoclonal antibodies, or sometimes, and less 
satisfactorily, by non-specific adsorption on to material 
such as activated charcoal. Alternatively, non-human serum 
may be employed from a species in which the corresponding 
antigen is absent or at least does not cross-react with the 
antibodies used.
The nature and exact pH of assay buffer is normally not 
a critical parameter. Protein or detergent may be added to 
assay and washing buffers with the aim of decreasing the non­
specific binding of labelled antibody to solid phase (Uotila 
et al, 1981). Direct binding of labelled antibody to solid 
phase, independent of antigen, can also arise because of 
cross-linking by anti-immunoglobulin antibodies present in a 
small proportion of human sera, and would potentially produce
false high assay values (Buchegger et al, 1982b; Hunter et 
al, 1983). Prevention of this artefact is possible by the
addition of non-immune mouse or other appropriate serum in 
the assay buffer to saturate any anti-immunoglobulin 
activity.
5) Incubation Protocols
The reactions of antigen with labelled and solid phase 
antibodies may be allowed to occur simultaneously or 
sequentially. The incubation times necessary depend on the 
kinetics of individual antibody-antigen reactions, and thus 
on the properties and concentration of each antibody. It may 
take many hours to reach true equilibrium in two-site assays, 
but typically incubation times of the order of 1-16 h for 
each incubation step have been used. However, shorter 
incubations are possible but there is a progressive loss of 
sensitivity as the binding achieved decreases.
In principle, because solid phase and labelled 
antibodies are deliberately chosen not to compete for binding 
sites, monoclonal antibodies lend themselves particularly to 
single-step, simultaneous incubation protocols. The great 
advantage of such a method is its simplicity, but it is not 
without its problems. Very high levels of antigen may exceed 
the binding capacity of solid phase within the assay 
incubation, resulting in a biphasic standard curve, with 
limited useful working range (Normura et al, 1982; Wada et 
al, 1982; Davis et al, 1983; Hunter et al, 1983). This is a
practical problem only with analytes such as HCG and AFP 
which potentially may vary in concentration over several 
orders of magnitude. A real possibility of ambiguity in 
interpretation of a given level of binding of labelled 
antibody then exists. In these circumstances it is 
impractical to add enough solid phase to guarantee excess 
under all conditions. To resolve the ambiguity suspect 
values may be reassayed at one or more dilutions, or a two- 
step assay protocol may be used so as to avoid it (Nomura et 
al, 1982; Davis et al, 1983).
In a forward two-step protocol, antigen is first bound 
to solid phase, which is then washed to remove excess antigen 
or interfering compounds before reaction with labelled 
antibody. Difficulties with excess antigen do not arise as 
the response reaches a plateau at high antigen 
concentrations, although for precise quantitation it may 
still be necessary to assay 'high' samples at several 
dilutions. If polyclonal antiserum is used on solid phase, 
it is likely that at least some of the antigen will be bound 
in such a way that the binding site for labelled monoclonal 
antibody is no longer accessible, with consequent loss of 
sensi tivity.
Potential competition between polyclonal solid phase and 
monoclonal labelled antibody is avoided in the reverse two- 
step protocol, in which antigen is reacted with labelled 
antibody before addition of solid phase.
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6) Specificity and Standardisation of Two-Site Assays
The interference from cross-reacting substances in two- 
site assays depends on whether these are recognised by one or 
both of the antibodies. If a cross-reactant is bound to some 
extent by both antibodies, a 'false' positive signal will 
result and the assay will be more or less non-specific. The 
magnitude of cross-reaction within the assay may be greater 
than that expected from the relative affinity with individual 
antibodies, because of the use of excess reagent conditions 
(Wada et al, 1982). In the limit, a cross-reactant may 
render the same assay response as an equivalent concentration 
of analyte, although binding to one or both antibodies with 
much lower affinity (Ekins, 1981). No modification of assay 
design can easily overcome this problem, and the specificity 
of individual antibodies therefore becomes of paramount 
importance.
If one antibody is effectively completely specific but 
the other shows a strong cross-reaction with material other 
than the analyte of interest, a different problem arises. 
Cross-reactant then competes with analyte for binding to the 
non-specific antibody and leads to an artefactually low 
estimate of analyte concentration in the two-site assay. 
Such interference has been noted for instance in a TSH assay 
where the solid phase antibody reacts also with LH and HCG 
(Wada et al, 1982). This problem can be solved by using the 
non-specific antibody in such an excess that the binding of 
cross-reactant becomes unimportant. However, in practice 
this may be very difficult. As an alternative, an assay
configuration’ may be chosen so that the sample is first 
reacted with specific antibody on solid phase in a forward 
two-step protocol. Potentially cross-reacting material can 
then be removed by washing before addition of 'non-specific' 
labelled antibody. The best solution is to avoid the use of 
cross-reacting antibodies completely. In the case of 
glycoprotein hormones for instance, antibodies for multiple 
hormone-specific epitopes can be obtained so that the use of 
antibodies to the common a -subunit in two-site assays is 
unnecessary (Gard et al, 1984; Soos et al, 1984).
Standardisation of monoclonal antibody two-site assays, 
and correlation with existing assays which employ polyclonal 
antibodies may also present problems if the analyte in 
standards or samples is potentially heterogeneous (Bangham, 
1983). Two-site assays can be designed which are specific in 
their measurement of intact biologically active polypeptides 
and do not detect fragments, aggregates or otherwise modified 
antigen such as might give a response in other assays. In 
some circumstances this specificity may be an asset but a 
potential problem in others, depending on whether the 
heterogeneity is naturally occurring or introduced during 
processing and storage, and on whether total immunoreactivity 
or the concentration of specific forms of antigen provides 
the better diagnostic index. Therefore, it is most important 
that the results obtained using any new assay with monoclonal 
antibodies be thoroughly compared with those from assays in 
previous use. Where differences do arise, in overall 
quantitation or with particular samples, further 
investigation must decide which of two conflicting values is
more valid as a physiological measure or diagnostic 
criterion. It should never be assumed that a monoclonal 
antibody assay value is unreliable just because it is 
different, when actually it may be an earlier assay taken as 
reference which is prone to previously unrecognised 
problems.
7) Assay Optimisation
Two-site assay optimisation requires consideration 
mainly of achievable sensitivity and breadth of working 
range, along with speed and convenience. The factors 
affecting assay performance include concentration and 
affinity of antibodies, specific activity of labelled 
antibody, magnitude of non-specific binding, incubation times 
and technical reproducibility (Ekins, 1981; Hunter at al, 
1982, 1983; Jackson et al, 1983). In practice the optimum
conditions chosen are a compromise between the conflicting 
requirements of sensitivity, working range and speed. The 
practical value of precision profiles in the objective 
comparison of different assay protocols has been well 
documented (Hunter et al, 1982, 1983; Ekins, 1983).
In a two-site assay the detection limit is determined by 
the smallest amount of specific binding of labelled antibody 
which can be significantly resolved from non-specific (zero 
antigen) binding. This will depend on the absolute and 
relative magnitudes, and the reproducibility, of both 
specific and non-specific binding. In the limit when antigen
is saturated with labelled antibody, the signal from specific 
binding is a function only of antigen concentration and the 
specific activity of labelled antibody. In practice 
conditions approaching saturation can be achieved with 
antibodies of high affinity, indicating that the factor then 
limiting sensitivity is specific activity. This places a 
limit on the achievable sensitivity with radioactive labels 
within reasonable counting times whatever the relative level 
of non-specific binding. Only by the use of other methods of 
labelling can greater sensitivity be obtained, for instance 
with luminescent and fluorescent compounds, which offer a 
higher specific activity, in terms of measurable signal per 
mole of antibody.
Binding of antibody to antigen, in theory, may always be 
driven to completion regardless of affinity, by use of a 
sufficient excess of antibody. The non-specific binding, 
however, will also rise with increasing concentration of 
antibody, and if anything the ratio of specific to non­
specific binding will decrease. Thus, although immunometric 
assays are theoretically reagent excess methods, in practice 
sensitivity may be greatest at limiting antibody 
concentration. Although low affinity antibodies added in 
excess can yield assays of reasonable sensitivity, these can 
never match the performance with antibodies of high affinity 
which produce a higher level of specific binding at a given 
antibody concentration.
The theoretical limit, at the upper end of the working 
range is dictated by the antibody concentration available, 
and the point at which antigen excess is reached. Thus, in
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contrast to sensitivity, breadth of working range is favoured 
by high concentrations of antibody. The speed of reaction, 
similarly, may be increased, and the incubation time 
decreased, by use of high antibody concentrations.
In practice it is clear that the sensitivity of many 
assays is limited by the magnitude of 'non-specific binding' 
of labelled antibody, or the measured signal at zero antigen. 
This is a function of the background on detection systems as 
well as the true antigen-independent binding of labelled 
reagent to solid phase or incubation vessel. It is therefore 
an aspect of assay performance which merits attention at 
least as much as the concentration and affinity of antibodies 
to be used, and conditions should always be chosen to give 
the lowest possible non-specific binding.
Ill EVOLUTION OF ASSAYS FOR THE MEASUREMENT OF TSH
a) Historical Aspects
Estimation of TSH was originally performed using
bioassay techniques. Subsequently, immunoassays and 
receptor assays have been employed. These assays can be 
classified as either structurally or functionally specific 
(Ekins, 1977).
Functional assays assess the effects of the hormone on a
specific biological system as a measure of analyte activity.
The original TSH bioassays were of this type and are,
historically,' the first examples of quantitative TSH assays 
(Table 1.1). TSH bioassays can be further subdivided into 
two groups; those relying upon changes in thyroidal 
histology, and those employing radioisotopic methods to 
monitor thyroid responsivity. An example of the former is 
that of D'Angelo and Gordon (1950) in which the 
stimulatory effect of repeated intraperitoneal injection of 
test sera into starved tadpoles, on the height of thyroid 
acinar cells was determined. Histological methods, however, 
were gradually superseded by the technically simpler 
radioisotopic techniques. The best known example here is the 
McKenzie mouse bioassay (1960) in which mice fed a low iodine 
diet and primed with radioiodine are injected with the sample 
and the subsequent radioiodine released from the thyroid into 
the circulation expressed as a percentage increase over 
control values. Since 1960, the focus has been on the 
development of in vitro bioassay techniques since the use of 
thyroid slices, cells or plasma membranes, rather than whole 
animals, was expected to achieve greater sensitivity and 
reproducibility. Brown and Munro (1967) introduced the main 
in vitro assay competitor to the McKenzie in vivo assay. 
Here, thyroid lobes were removed from mice previously fed on 
a low iodine diet and injected with radioiodine in vivo to 
label intrathyroidal iodine stores prior to incubation in 
vitro with thyroid stimulating hormone. Radioiodine released 
in vitro was then employed to quantitate the degree of 
stimulation. The original sensitivity claimed was 100 mU/l 
but this was improved by Williams and Wolff (1971) to about 
30 mU/l by decreasing assay incubation times. A detection
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limit of 70 mU/l was achieved by Kirkham (1962) using 
isolated guinea pig thyroids and radioiodine organification 
in vitro following organification inhibition in vivo. 
Modifications of this technique gave sensitivities down to 5 
mU/l (Table 1.1).
In the early 1970"s another form of functionally 
specific assay came into use. This type of assay relied upon 
the specific interaction of the hormone with its receptor on 
isolated thyroid cell membranes and the consequent activation 
of adenyl cyclase. TSH activity being quantitated as cAMP 
production. A TSH assay with a sensitivity of 370 mU/l was 
produced by Lissitsky (1973) with porcine thyroid cells or 
membranes. Sensitivities approaching 10 mU/l have been 
achieved by Kasagi et al, (1982) with improved techniques 
based on cAMP production.
A TSH assay which returned to the measurement of the 
effect of TSH on stimulating colloid endocytosis was 
described by Bitensky et al (1963). Here, phagolysosomes 
which form on fusion of colloid droplets and lysosomes 
exhibit an increased permeability to the compound leucyl- 
beta-naphthylamide in the presence of TSH. In the lysosome, 
protease activity releases beta-naphthylamide which can then 
complex with copper-fast-blue reagent. The intensity of the 
blue colour detected by integrating scanning 
microdensitometry, is proportional to TSH added. This system 
proved to be very sensitive, giving minimum detection limits 
of 0.001 mU/l.
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However,1 the majority of functionally specific assays 
are deficient in either sensitivity (McKenzie assay) or 
sample capacity (cytochemical assay).
Potentially larger sample capacity is offered by 
structurally specific assays where the number of molecules 
which have a unique structural component rather than a 
biological effect are measured. Unlike functionally specific 
assays, results can, therefore, be expressed in terms of mass 
or moles. Immunoassays belong to this category since they 
depend upon the specific reagent (antibody), recognising and 
interacting with a unique part of the analyte molecule. It 
has been suggested by Ekins (1977) that structurally specific 
assays are only valid if both the standard and unknown 
materials are structurally unique and identical. TSH 
preparations are, however, a heterogeneous mixture of large 
molecules and it is likely that different molecular forms 
(isohormones) and subunits of TSH exist in samples and 
standards. TSH standard preparations can exhibit different 
relative potencies in bio- and immuno-assay, reflecting their 
heterogeneous composition (and differences of assay 
specificity). To allow comparisons, TSH assays are 
standardised against an international reference preparation 
(IRP) currently WHO 80/558 and results are expressed as units 
of biological activity (mU/l) rather than mass (moles/1).
The two main types of structurally specific assays are 
based on the reaction of TSH with either a specific antibody 
in the case of immunoassay or thyroid membrane receptors in 
the case of radioreceptor assays. The latter depends on the 
reaction of labelled and sample TSH with the receptor and
following incubation, the quantitation of the bound or free 
fraction. Using labelled TSH pre-purified with a crude 
thyroid homogenate, Manley et al, (1974) obtained an assay 
sensitivity of 125 mU/l. This detection limit was improved 
to 0.128 mU/l by Mehdi and Nussey (1975) following the 
preparation of a highly purified receptor by detergent 
solubilisation of the cell membrane.
Immunoassay is the most widely used structurally 
specific assay. The earliest radioimmunoassay (RIA) for TSH 
was published by Odell et al (1965). They achieved an assay 
sensitivity of approximately 25 mU/l. Various technical 
refinements including improvements in antisera and tracers 
have given assays of greater sensitivity, Hall et al, (1971) 
achieving a sensitivity of 0.5 mU/l. Although TSH RIA's 
proved to be more reliable than the earlier bioassays, the 
mean assay coefficient of variation is of the. order of 10% in 
the best systems and the prolonged incubation times required 
meant that few centres were able to obtain a result within 2- 
3 days of receiving the sample. In 1971 Addison introduced 
the concept of the two-site immunoradiometric assay (IRMA). 
This followed Miles and Hales (1968) pioneering work on the 
original single-site immunoradiometric assay and provided the 
potential for improved analytical performance.
Relative Merits of Competitive and Immunometric Assays for
the Immunoassay of TSH
One of the major drawbacks associated with the use of 
competitive assays for the measurement of TSH has been their 
lack of sensitivity, typically of the order of 1 to 4 mU/l 
(Durham, 1985), resulting in a proportion of normal subjects 
having undetectable TSH levels. With such systems, 
generally, around 3 days were required to produce a result 
due to the prolonged incubation times necessary, and only a 
limited working range was possible (typically 5-15 mU/l TSH). 
At low TSH levels between laboratory - agreement was very 
poor yielding a C.V. of approximately 80% at a TSH level of 2 
mU/l compared with a between laboratory C.V. of 15% at 20 
mU/l TSH. This was because these methods were prone to non­
specific matrix effects at low levels and also due to the 
fact that early cross-reacted with HCG. Thus the
investigation of suppressed, subnormal TSH levels was beyond 
most routine methods and TSH measurements were, therefore, 
applied to the detection and monitoring of primary 
hypothyroid ism.
The introduction of the two-site immunoradiometric assay 
provided the potential for improved analytical performance. 
Among the advantages offered by such systems were that of 
greater speed, wider working range (typically 0.5-200 mU/l 
TSH), lack of serum effects and increased sensitivity. By 
replacing polyclonal antisera with specific monoclonal 
antibodies and by employing alternative non-isotopic labels, 
the sensitivity of TSH assays was further improved.
Detection limits of <0.05 mU/l have been quoted by 
manufacturers and the sensitivity is such that discrimination 
between euthyroid and hyperthyroid patients is now possible 
(Caldwell et al, 1985). Also of clinical significance is the 
fact that improvements in TSH methodology have reduced the 
need for TRH tests to clarify borderline results (Durham, 
1985).
With these systems a rigorous definition of assay 
sensitivity became necessary which was applicable to 
individual batches of reagents such that deterioration and 
changes in reagents would not compromise assay performance. 
The assessment of assay sensitivity by precision profile 
analysis is described in the next section.
Immunoassay Design and Evaluation
The first published radioimmunoassay, for insulin, by 
Berson and Yalow in 1959 was followed by Ekins in 1960 with 
the presentation of a saturation assay for serum T4 . Since 
then both groups have differed in their approach to 
immunoassay design. Assay sensitivity was assessed by Berson 
and Yalow, in terms of the slope of the dose response curve 
(Berson et al, 1964). Ekins, (1977; 1976) on the other 
hand, pointed out that the slope of a dose response curve 
changes depending on the parameters (% B, B/F, F/B versus 
concentration plotted arithmetically or logarithmically). If 
the slope is assessed in the absence of statistical
considerations contradictory results relating to assay 
precision may be obtained. The statistical approach 
advocated by Ekins can be applied to both RIA's and IRMA's.
The basis of this technique is to obtain estimates of 
the error associated with each dose. The errors in the 
response (R) for a given dose (D) (Figure 1.5) are assumed to 
be normally distributed around a mean value and this 
variation can be defined algebraically (Equation 1). The 
slope and/or the error ( R) changes with dose, implying that
S.D. of dose estimation (a D)
= S.D. of response (aR)
slope of dose - response curve ____  (1)
= a R___
dR/dD
the observed a D will differ over the concentration range of 
interest. This changing relationship between a D and D is the 
precision profile and is a fundamental indicator of assay 
performance. It can be used not only for the direct 
comparison of assays for the same analyte, but also to assess 
the effects of minor protocol changes on assay performance. 
The precision profile is derived as follows. Replicate 
estimations of a given dose allow the standard deviation of 
the response (a R) to be obtained. A linear response-error- 
relationship (RER) is derived by plotting the response versus
Response
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Figure 1.5
Diagrammatic representation of mathematical components used for 
calculation of assay errors: Dose (D); Response (R); Error in Dose 
(a D ) ; Error in Response (AR); Gradient of Curve (dR/dD)
the obtained-aR, pooled from a number of assays. Therefore, 
for a given dose, D, the response obtained, R (Figure 1.6a) 
will have an error in response a R  derived from the RER 
(Figure 1.6b). By substituting a R  into Equation 1 the 
absolute error in the measurement of dose D can be obtained. 
A plot of the relative error (aD/D x 100%: coefficient of
variation [C.V.]) obtained for a range of doses gives the 
heteroscedastic precision profile (Figure 1.6c).
The Performance Characteristics of Radioimmunoassay Versus 
Immunometric Assay for TSH
There have been substantial changes in the techniques 
for thyroid hormone measurement in recent years, most notably 
a move to non-isotopic and coated tube methods. It is for 
TSH that two-site immunometric assays (IMA) have had the most 
profound impact on laboratory practice and performance. The 
performance characteristics of radioimmunoassay versus 
immunometric assay for TSH have been studied by Mackenzie et 
al (1988). The main conclusions are recorded below.
The first immunometric assay for TSH was the Corning 
Immophase System which used purified polyclonal antisera, and 
although it was a good system at the time it was gradually 
superseded by the newer and ever more numerous two-site 
monoclonal kits. Between 1983 and 1987 there has been a move 
away from in-house to kit assays and, within kit assays, a 
move from RIA to IMA with the result that by the end of 1987 
over 80% of laboratories were using IMA assays.
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Diagrammatic representation of the major plots used for error 
analysis in saturation analysis (dark line) and excess reagent 
assays (light line)
Log D
Concurrent with the availability of these new kits, 
there has been an increase in the number of laboratories 
performing TSH assay. This reflects increased clinical 
applicability and changes in testing strategy. The "high 
sensitivity" TSH assays are claimed to be more sensitive, 
specific and robust than their RIA counterparts, with 
between-batch CVs typically around 5% at 1 mU/1.
When sera which contained low levels of TSH such as 
sera from T3 - suppressed and thyrotoxic subjects were 
spiked with the 1st IRP, it was shown that there was almost 
quantitative recovery on all specimens with a concentration 
above 5 mU/1. At lower TSH levels there was apparent over­
recovery due to loss of assay specificity and precision near 
the detection limit, and the target, the All-Laboratory 
Trimmed Mean (ALTM) was not reliable below 5 mU/1.
In 1982 the calculation and reporting of cumulative bias
(BIAS) and variability of bias (VAR) for individual 
participants was introduced. Even at concentrations above 5 
mU/1 less than 20% of laboratories could achieve a VAR below 
10%. This reflected the imprecision of RIA procedures at 
that time.
After the improvement in 1983, more material with
concentrations at the lower end of the range, was distributed 
by the UK EQAS, to allow laboratories to assess their
performance critically. Initially the BIAS and especially 
the VAR worsened, but as a greater proportion of laboratories 
adopted IMA procedures overall performance improved.
In 1985 it was shown that the already sizeable group of 
IMA users obtained quantitative recovery at levels between
1.0 and 5.0 mU/1 when T3 - suppressed sera were spiked with 
the 2nd IRP.
It is interesting to note that the method groups with a 
positive bias also tend to over-recover added TSH (2nd IRP) 
while those with a negative bias under-recover. Since 
virtually all methods show good parallelism, standardisation 
procedures seem to account for these differences.
Occasionally users of a single kit method will, for a 
particular specimen pool, uniformly obtain results which are 
out of consensus with the other methods. This suggests the 
presence of interfering factors eg. human anti-mouse 
antibodies, which affect the monoclonal antibodies of that 
kit only. This problem is not seen in methods based on 
polyclonal antibodies.
At subnormal TSH levels, even highly sensitive assays 
can be affected by the matrix composition. Such an effect of 
matrix on IMA has been demonstrated by T3 - suppressed, 
immunoabsorbed and thyrotoxic sera giving slightly different 
results with different systems (Swift et al, 1985).
The use of different detection systems, including 
chemiluminescence, enzyme endpoint or dissociation-enhanced 
lanthanide fluorescent procedures, does not appear to be 
associated with any characteristic pattern of performance. 
However, there is a tendency for non-isotopic methods to 
under-recover added TSH. It is difficult to determine 
whether this is inherent in the detection system or the 
methodology, or simply reflects the standardisation 
procedures used. Similarly, some of the newer methodologies 
appear to be more precise than their isotopic counterparts,
but again this may simply be due to their being used in a 
dedicated system with little, if any, scope for procedural 
manipulation.
There has also been a move towards the use of IMA in 
screening for neonatal hypothyroidism. Major analytical 
problems, primarily of under-recovery and imprecision have 
been highlighted by the UK EQAS for Neonatal Blood Spot TSH. 
Although unsatisfactory, these do not appear to have been 
translated into serious errors in classification, ie. false 
negatives.
Non-Isotopic Immunoassay Methods for TSH
1) Introduction
At present, the only viable alternatives to a 
radioisotopic label are those using some form of optical end 
point. Of the many such methods available those employing 
enzymes or enzyme cofactors as labels are well established 
(O'Sullivan et al, 1979), whilst other families of assays 
rely on the quantitation of fluorescent (Smith et al, 1981)
or chemiluminescent (Collins et al, 1983) emitted light.
The theoretical advantage of an optical immunoassay is 
that a very large signal can be obtained in a short period of 
time from a label that has a long shelf-life. However, 
optical immunoassays are very prone to 'blank' problems 
caused by non-specific factors in biological fluids which can 
scatter, quench or enhance light emission. As a result, the
signal:noise ratio of many optical immunoassays has been 
disappointingly low and has limited the potential sensitivity 
of the system.
2) Enzyme Immunoassay
The main potential advantage of using an enzyme as a 
label is the amplification of signal effected by the enzyme 
acting on several substrate molecules. Many enzyme 
immunoassay techniques have become established, of which 
'ELISA' has proved to be useful in the measurement of TSH.
The 'ELISA' (enzyme-linked immunosorbent assay), in its 
most popular form, uses the principle of two-site 
immunometric analysis with one antibody coated to the wells 
of a microtitre plate. Antigen binds to this antibody. The 
second antibody, bearing the enzyme label, binds to a 
different epitope on the antigen to complete 'sandwich' 
formation. The unbound label is removed by aspiration and 
washing, the colour is developed by substrate addition and 
quantitated by spectrophotometric scanning of the plate. 
Several commercial systems of this type are available for TSH 
measurement including BCL 'ENZYMUN' and 'SOPHEIA' (Diagnostic 
Products Corporation), both employing solid phase Ab-coated 
tubes, as well as Hybrii^-C-h 'TANDEM', a monoclonal IRMA with 
a 'bead' separation step.
A novel two-site immunometric assay, the
Novoclone^ 'AELIA^' (amplified enzyme linked
immunoassay, Novo Biolabs), has been described for serum TSH
based on the principle of enzyme amplification (Wheatley et 
al, 1987). One antibody is labelled with alkaline
phosphatase which, at the end of the immunoassay, is used to 
catalyse a chain of reactions with signal amplification at 
each stage (Roddis et al, 1985). The sensitivity of the 
system looks better than that of a good IRMA. The Boots 
Celltech 'CHEMELIA' (chemical enzyme linked immunoassay) 
system is another assay adopting a modified enzyme approach. 
In this coated well assay no 'stop reagent' is used, leading 
to improvement in assay performance as it removes a step 
which is prone to error (Reid et al, 1988). The Serono 
'SEROZYME' assay can also be placed in this group. In this 
system one antibody is labelled with alkaline phosphatase, 
the other with fluorescein isothiocynate (FITC). Separation 
is achieved by incubation with anti-FITC antibodies coated 
onto magnetic particles. After washing and incubation with 
the enzyme substrate, phenolphthalein monophosphate, the 
reaction is stopped by the addition of 'stop reagent'. 
Finally, the tubes are read at three wavelengths, 630 nm (to 
blank), 550 nm and 492 nm.
3) Fluorescence Immunoassay
Fluorimetry is the technique whereby incident light at 
one wavelength is absorbed by a fluorophore and emitted at a 
higher wavelength.
In this area of optical immunoassay, the most promising 
development is time-resolved fluorescence immunoassay as
illustrated by the Pharmacia 'DELFIA' (dissociation-enhanced 
lanthanide fluoroimmunoassay system). Two approaches have 
been used to reduce background fluorescence and so increase 
sensitivity. Firstly, europium chelates have been used as 
the fluorophore. These have a large Stokes shift (difference 
in wavelength between incident and emitted light) and a 
relatively long-lived fluorescence. Secondly, a fluorimeter 
has been designed which delays the measurement of the emitted 
light by 400 jis, during which time non-specific background 
fluorescence will largely have disappeared (Soini and 
Hemmila, 1979). This combined approach has allowed a two- 
site immunofluorometric assay for TSH to be developed. The 
DELFIA serum TSH assay has a signal:noise ratio in excess of 
103 giving great sensitivity, at least as sensitive as the
best IRMA, with a counting time of only 1 s per well.
4) Chemiluminescence Immunoassay
Chemiluminescence is the light emitted as a consequence 
of the de-excitation of a reactant or a product of a
particular chemical reaction. The emission of photons from a
chemical reaction is less affected by background interference 
than is the case for other optical techniques, and the 
efficient counting of the photons should permit sensitive 
immunoassays to be developed around chemiluminescent labels. 
One disadvantage of the technique is that the chemical 
reaction can only take place once - in other words, an assay 
cannot be recounted.
The original work in chemiluminescence immunoassay was 
based on the luminol family of labels but recently aryl 
acridinium esters have been preferred, and it has been 
possible to develop the most sensitive assays yet reported 
for peptide hormones by the use of these esters in two-site 
immunometric assays (Weeks et al, 1984). Ciba— Corning 
Diagnostics have adopted this technology in their TSH 
'MAGICLITE' assay. The system also uses a solid phase 
separation method based on magnetic particles.
5) Enhanced Luminescence Immunoassay
A novel non-isotopic immunoassay system has been 
reported folowing the observation that the horseradish 
peroxidase catalysed chemiluminescence of a luminol 
derivative could be enhanced several fold by the addition of 
D-luciferin, a synthetic component of the firefly 
bioluminescence system (Whitehead et al, 1983).
Such a system, 'AMERLITE' has recently been launched by 
Araersham International for the measurement of TSH by two-site 
immunometric analysis. The assay offers a sensitivity of
0.04 mU/1 with a working range of 0.09 to 200 mU/1 (Squire 
and Gimlette, 1987).
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IV THE CONTROL OF TSH SECRETION AND ITS ROLE IN NORMAL THYROID 
PHYSIOLOGY
a) Hypothalamic Control of TSH Secretion
While the dominant hypothalamic control over TSH is 
stimulatory via thyrotrophin releasing hormone (TRH), thyroid 
hormones exert a powerful, dose-related negative feedback 
control over TSH synthesis and release, acting at pituitary 
and possibly hypothalamic levels (Snyder and Utiger, 1972). 
As small increases in serum triiodothyronine (T3 ) and 
thyroxine (T4) levels reduce basal and TRH-stimulated levels, 
small decreases in T3 and T4 levels induced by short-term 
administration of pharmacological doses of iodide, lead to 
elevation in basal and TRH-stimulated TSH levels (Saberi and 
Utiger, 1975).
Recent evidence indicates, however, that the central 
neurotransmitter, dopamine (DA), has a physiological 
inhibitory role in the control of TSH secretion in man 
(Scanlon et al, 1980a); there is also evidence of a similar 
role for somatostatin (growth hormone release-inhibiting 
hormone, GHRIH) (Peters et al, 1983). Thus, hypothalamic
control over TSH synthesis and release in man is more 
complex than previously envisaged and has both stimulatory 
and inhibitory components. Oestrogens and glucocorticoids 
may each have a role in the modulation of hypothalamic- 
pituitary- thyroid function and must be considered in the 
overall picture of TSH regulation (Figure 1.7).
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Figure 1.7
Schematic outline of some of the major pathways and interactions 
which control TSH secretion
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b) Circadian Variation in Normal Subjects
There is a clear and well documented circadian variation 
in basal TSH levels in normal subjects (Weeke, 1973; Weeke 
and Laurberg, 1976; Chan et al, 1978). TSH levels rise 
during the evening before the onset of sleep reaching a 
zenith at about 2300-2400 hours. Thereafter levels decline 
slowly to a nadir around 1100 hours. The mechanisms 
underlying this circadian TSH change are unknown. Certainly 
the rise in TSH levels during the evening before the onset of 
sleep is not due to a decline in dopaminergic inhibition of 
TSH release. Recent studies have demonstrated that the 
dopaminergic inhibition of TSH release is greater at night 
than during the day (Scanlon et al, 1980b) and DA may be
acting to reduce the degree of nocturnal elevation in TSH 
levels.
c) Neural Regulation of Thyroid Hormone Secretion
During the last few years, evidence has accumulated 
showing that the thyroid gland is richly innervated not only 
by adrenergic and cholinergic nerves, but also by peptidergic 
nerves. The physiological role of these nerves is, however, 
not clear, but it is evident that TSH is not the only 
regulator of thyroid hormone secretion (Ahren, 1986).
As of now, these neural influences are as follows: 1)
Adrenergic nerves stimulate basal thyroid hormone secretion
by both a - and 8 - adrenoceptor mechanisms; 2) Adrenergic 
nerves inhibit TSH - induced thyroid hormone secretion 
mediated by norepinephrine and possibly neuropeptide Y (NPY);
3) Cholinergic nerves impair TSH - induced thyroid hormone 
secretion; and 4) Vasoactive intestinal peptidergic nerves 
stimulate basal and potentiate TSH-induced thyroid hormone
secretion. The exact role of these nerves in thyroid 
physiology remains to be elucidated.
Actions of TSH on the Thyroid
TSH influences many aspects of thyroid structure and 
function: the size and vascularity of the gland, the height 
and activity of the follicular epithelium, and the amount of 
colloid are all controlled by TSH. Every step of the 
thyroid hormone biosynthetic pathway (Figure 1.8) is 
stimulated by TSH, as are numerous aspects of cell metabolism 
eg. glucose utilisation, oxygen consumption, phospholipid 
synthesis, and RNA synthesis. These actions begin within a 
few minutes of administration of TSH and have been attributed 
to activation of adenyl cyclase after combination with a 
receptor site on the cell surface. The resulting formation 
of cyclic AMP leads, via an effect on messenger RNA, to 
synthesis of proteins concerned in the individual steps of
thyroid hormone synthesis - ie. the iodide trap, iodine 
incorporation into thyroglobulin and thyroid-hormone release 
into the circulation.
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Synthesis/ storage and secretion of thyroid hormones
ADAPTATION OF TSH ASSAYS TO SCREENING FOR CONGENITAL
HYPOTHYROIDISM
Congenital Hypothyroidism
Congenital hypothyroidism (CH) is a term coined to 
describe a variety of conditions associated with an 
underactive thyroid gland at the time of birth. If untreated 
within a few weeks the baby will become mentally deficient 
(cretinism). The incidence of CH in the UK is now
established as 1:3500 births (John, 1987). For some years
now screening of all neonates has been advocated to identify 
this readily treatable condition, although there have been 
differences between centres in the nature of the specimen
used and the hormone measured (See Chapter 5).
Specimen Collection
The earliest specimen that can be collected from a 
neonate is a sample of cord blood and this specimen has been 
used by some groups for screening for CH (Walfish, 1983). 
However, the collection of cord blood is not a routine 
practice and it is, therefore, susceptible to problems of 
logistics. Furthermore, thyroid physiology changes markedly 
within the first few hours of birth such that reference 
ranges for the thyroid related hormones tend to be very wide,
leading to a greater chance of overlap between normal
neonates and those affected with CH in the perinatal period
(John, 1987). Consequently, the use of cord blood is less 
favoured than the use of heel prick blood collected onto 
filter paper cards. As such specimens were already being 
collected from virtually all neonates in the UK and in the 
USA for the phenylketonuria screening programme it has proved 
logistically very simple to use a further aliquot of this 
specimen for screening for CH. In the USA and in Europe heel 
prick blood samples are collected between 3 and 7 days after 
birth, in the UK the specimens are collected between 6 and 10 
days, either in hospital or by a visiting midwife. Results 
of screening programmes are available within 14-30 days of 
birth - in adequate time to minimise the risk of severe 
mental retardation. The collection of heel prick blood 
specimens in the UK is now so well organised that >95% of 
babies have a suitable sample submitted for screening.
Screening Assay
In the first screening programmes the assay of T4 in 
filter paper blood spots was adopted and its ability to 
detect hypothyroid infants was confirmed. However, it was 
soon realised that using T4 alone was not sufficient as many 
of the affected cases, particularly with ectopic thyroid
tissue, had normal T4 values and around 30% of hypothyroid
infants could be missed. Conversely, normal pre-term infants 
were found to have levels of T4 similar to levels of T4 in
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hypothyroid infants. As well as prematurity, low birth
weight, thyroxine binding globulin deficiency and congenital 
or acute illnesses were all causes of a low concentration of 
T4 . Recall rates of between 1.5 and 5% have been reported in 
those programmes using T4 alone as the screening assay (John, 
1987). By taking a second blood spot from the original PKU 
card and analysing for TSH, this recall rate can be reduced. 
The number of samples which had to be assayed for TSH varied 
in the different programmes but was between 3 and 20%. This 
approach had the advantage of using the cheaper and simpler 
T4 assay for all the samples whilst reserving a TSH assay for 
fewer specimens. Ten years ago, TSH reagents for large
screening programmes were difficult to prepare, good antisera 
were scarce and the methods generally took 2-5 days to 
produce results. However, this did not deter some European 
centres from setting up screening programmes utilising a TSH 
assay as the primary test (Illig et al, 1977). This appears 
to be the most sensible choice as TSH is the most sensitive 
indicator of primary hypothyroidism in adults and would
probably be so in infants. In cases of infants with ectopic 
thyroid glands in whom thyroid function may still be 
compensated, T4 levels may be normal but TSH is generally 
raised. In Europe, using TSH alone, the recall rate varied 
between 0.03 and 0.9%.
In the UK, all screening laboratories rely on TSH as the 
screening assay, except East Anglia where screening is based 
on a total T4 with a supplemental TSH assay on those 
specimens within the lowest 20% of T4 values. In those
screening centres more experienced in immunoassay, in-house
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(generally immunoradiometric) assays were set up (Sutherland 
et al, 1982; John and Woodhead, 1982), others developed
radioimmunoassays (Edwards et al, 1980; Moore and McMillan, 
1983; Griffiths et al, 1985) but most used commerical kits. 
Two-site assays were preferable as screening assays because 
results could be available within 24 h of receipt of a 
sample. Other advantages were high sensitivity, ease of 
automation and, particularly in dealing with large sample 
numbers, their robust methodology. The Japanese have been 
very successful at introducing enzyme immunoassays (Naruse 
and Irie, 1983) for mass screening and future developments 
should see the gradual replacement of two-site TSH assays 
based on radioiodine labels with alternative non-isotopic 
labels.
In routine use the between batch imprecision of the TSH 
assay for filter paper blood spots is rarely better than 20% 
but since there is virtually no overlap in TSH values between 
hypothyroid and normal infants this level of imprecision is 
adequate. It follows, therefore, that it is not necessary to 
assay samples in duplicate and many centres use only a single 
blood spot sample without detriment to their screening 
programme.
Secondary hypothyroidism is a rare condition which 
occurs only in one in 100,000 births. Most infants have a 
deficiency of multiple pituitary hormones, ie. have panhypo­
pituitarism, and will invariably present with other clinical 
symptoms such as hypoglycaemia, micropenis in the male or 
central nervous system abnormalities, cranial vault or facial 
structures. Only in those screening programmes which utilise
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T4 as the initial screening test will secondary cases be 
detected but, screening programmes are now directed to 
identifying cases of primary hypothyroidism because of the 
very much higher incidence.
VI AIMS OF THE WORK DESCRIBED IN THIS THESIS
1. To develop techniques for the production of mouse monoclonal
antibodies to human TSH.
2. To establish methods for the characterisation of monoclonal 
antibodies to human TSH such that selection may be made of 
those reagents suitable for use in immunometric assays.
3. To develop a variety of two-site immunometric assays for
human TSH based on the monoclonal antibodies produced and/or 
available polyclonal antisera.
4. To optimise one or more two-site immunometric assays for
human TSH and to validate their use for the measurement of 
TSH in serum and in neonatal blood spots.
5. To assess the value of two-site immunometric assays for human 
TSH in a variety of clinically based situations.
CHAPTER 2
MATERIALS AND METHODS 
I PRODUCTION OF MONOCLONAL ANTIBODIES
a) IMMUNISATION
Human TSH (Calbiochem, Iodination grade, potency 5.5 
IU/mg), 20 ug in 0.2 ml saline was emulsified (by 
sonication in an ice bath) with 0.6 ml Freund's complete 
adjuvant (FCA). Six balb/c mice were given primary
immunisations by intraperitoneal injection (26 g V* 
hypodermic needle) of 2.5 ug TSH in 0.1 ml FCA followed 
by a minimum of two "booster" immunisations of identical 
dose and mode of injection in Freund's incomplete 
adjuvant (FIA). Time intervals of three weeks were
allowed between injections.
Three days prior to fusion a donor mouse was injected 
intravenously (via the tail vein) with 2.5 ug TSH in 0.1 
ml sterile physiological saline.
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b) SERUM ANTIBODY EVALUATION
1) BLOOD SAMPLING
Mice were anaesthetised with ether, the ventral 
tail vein punctured with a sterile 23 g needle and 
the exuding blood absorbed onto filter paper card 
to form a discrete spot. All the experimental mice 
were colour coded to aid identification.
2) BLOOD SPOT ELUTION
The blood spot was allowed to dry and a 6 mm disc 
punched into a test tube containing 1.0 ml 0.9% 
NaCl. This approximated to an initial dilution of 
1:500, ie. 0.002 ml serum/6 mm disc.
3) ANTIBODY DILUTION CURVES
(i) REAGENTS
(1) Assay diluent:- 0.05 mol/1 sodium 
phosphate buffer containing 0.154 mol/1 NaCl, 
0.1 % (w/v) BSA and 0.05% (w/v) NaN3 at pH
7.4.
(2) Iodinated TSH antigen:- stock labelled
was diluted to give 30,000 cpm/0.1 
ml (See Section Ila).
(3) Sheep anti-mouse y globulin immuno- 
adsorbent:- the stock solution (20 mg/ml) was 
diluted 1:4 with assay buffer to give a 
working solution of 1 mg/0.2 ml (See Section 
IIIc).
(ii) ASSAY
12 mm diameter tubes, Sarstedt 55.484, were 
used throughout.
Test sera were analysed in duplicate at final 
dilutions of 1:1000, 1:2000, 1:4000, 1:8000,
1:16000, 1:32000 as follows. Total count
tubes were also prepared.
(1) 0.1 ml test serum at appropriate
dilution.
(2) 0.1 ml 125i_fSH (approx. 30,000 cpm).
The tubes were vortexed and incubated
overnight at ambient temperature. Sheep anti­
mouse ^ globulin (1 mg/0.2 ml) was added and 
the tubes incubated on an orbital shaker at 
300 rpm for 60 minutes also at ambient 
temperature. The incubation tubes were given
three wash, centrifugation, aspiration cycles 
with 2 ml 0.9% NaCl containing 0.2% Tween 20 
and the immunoadsorbent pellets (bound 
fractions) counted on a gamma counter (Nuclear 
Enterprises 1600) set on the normalised mode. 
Binding expressed as percentage of total 
counts was then plotted against dilution (log 
scale) for each animal.
4) DISPLACEMENT STUDIES
To give an indication of antibody avidity, 
displacement was assessed using a modification 
of the assay protocol outlined above. Two 
sets of diluted test sera were set up, one 
with 0.05 ml unlabelled, purified TSH (code no 
80/558, dose 25 mU/1), the other with 0.05 ml 
assay diluent.
The mouse yielding antibody of highest titre 
and greatest displacement (highest avidity by 
definition) was selected for hybridisation.
PREPARATION OF CELL CULTURE MEDIA
All cell culture media components were purchased from 
Flow Laboratories (UK) and combined under aseptic 
conditions as required.
1) MYELOMA CELL MEDIUM
100 ml RPMI - 1640 (Roswell Park Memorial 
Institute) buffered with 20 mmol/1 HEPES (N-2- 
Hydroxyethylpiperazine - N' - 2-ethanesulfonic 
acid).
10 ml heat inactivated foetal bovine serum 
(approx. 10%).
1 ml 200 mmol/1 - Glutamine (2mM).
2 ml Penicillin/Streptomycin (100 u/ml, 100 
ug/ml respectively).
1 ml Fungizone (250 ug/ml) (2.5 ug/ml).
2) HYBRIDISATION MEDIUM (2 X HAT MEDIUM)
100 ml RPMI - 1640 buffered with 20 mmol/1
HEPES.
20 ml foetal bovine serum (approx. 20%).
1 ml 200 mmol/1 - Glutamine (2mM).
2 ml Penicillin/Streptomycin (100 u/ml, 100 
ug/ml respectively).
1 ml Fungizone (2.5 ug/ml).
4 ml (50 x concentrate) HAT (Hypoxanthine; 
Aminopterin; Thymidine).
PREPARATION AND MAINTENANCE OF MOUSE MYELOMA CELL LINE
FROM FROZEN STOCK
1) PREPARATION
The mouse myeloma cell line X63. Ag8 - 653 (Flow 
Laboratories) was used in all hybridisations. 
Aliquots of cells (10 x 10^ cells/ml) were stored 
in liquid nitrogen (-196°C). An aliquot was 
removed, as required, from storage, thawed rapidly 
by immersion in a 37°C water bath and transferred 
aseptically to a 20 ml sterile universal bottle. 
Prewarmed myeloma cell medium (5 ml) was added 
dropwise slowly with gentle agitation. The 
universal bottle was then centrifuged (5 min, 800 
rpm) and the supernatant discarded. The washing 
procedure was repeated and then a further 5 ml of 
medium was added to the washed pellet and the cells 
counted by haemocytometer. The concentration of 
cells was then adjusted to approximately 200,000 
cells/ml with further medium and transferred to 25 
ml flasks, stoppered and incubated at 37°C.
2) MAINTENANCE
The myeloma cells were maintained in logarithmic 
growth (minimum density 2.5 x 10^ cells/ml, maximum 
density 1.5 x 10^ cells/ml, doubling time 
approximately 16-24 hours) gradually expanding
the volume before transference to a continuous 
spinner flask culture (Techne) and further 
expansion prior to fusion. Cells were counted and 
viability assessed daily by haemocytometer and 
trypan blue dye exclusion (Flow Laboratories). 
When sufficient cells (150 x 10^) of high viability 
(>90%) were obtained hybridisation was performed.
HYBRIDISATION
1) MYELOMA CELLS
In general 3 fusions were performed simultaneously. 
The required volume of medium containing 150 x 10^ 
myeloma cells was centrifuged at 800 rpm for 5 
minutes and the supernatant discarded. The cell 
pellet was washed once in RPMI, resuspended in 15 
ml RPMI and split into 3 x 5 ml aliquots of 50 x 
10  ^myeloma cells in sterile universal bottles.
2) SPLEEN LYMPHOCYTES
The spleen from an immunised mouse preselected for 
the presence of high avidity antibody was removed 
under sterile conditions, placed in a petri dish 
(5.5 cm diameter) containing 10 ml RPMI and 
carefully teased with scalpel blades to yield a 
cell suspension. The contents of the dish were
then transferred to a sterile universal bottle and 
the large fragments of tissue allowed to settle. 
The supernatant cells were removed, centrifuged at 
800 rpm for 10 minutes and resuspended in 15 ml 
RPMI. After lysing the red cells, spleen cells
were counted and adjusted to approximately 150 x
106 cells. Three aliquots of spleen cells (5 ml), 
each of 50 x 10& cells, were prepared so that each 
hybridisation would have identical numbers of 
myeloma and spleen cells.
POLYETHYLENE GLYCOL 1500 (PEG)
Polyethylene glycol 1500 (BDH 29575, 500 g fused 
solid, melting point 46°C) (10 g) was weighed into 
a 20 ml measuring cylinder and 5-6 ml RPMI - 1640
added. After heating in a 50°C water bath until 
all the PEG dissolved, the pH was adjusted to pH 7 
with 0.1 mol/1 NaOH. Additional warmed RPMI - 1640 
was added to a total volume of 20 ml (ie. 50% 
solution). The PEG solution was then sterilised 
either by membrane filtration (0.22 u) into a 
sterile universal bottle or by preparing 5 ml
aliquots in bijoux vials and autoclaving for 15
minutes (120°C).
PREPARATION OF PERITONEAL MACROPHAGES (FEEDER
CELLS)
RPMI - 1640 (3 x 5 ml) was prepared in syringes 
with 19 g needles. Three balb/c mice were killed 
and dissected to reveal the abdominal skin and 5 ml 
RPMI injected by entering above the sternum and 
allowing the needle to lie over the right lobe of 
the liver. The abdomen was massaged to suspend 
peritoneal cells and RPMI withdrawn into the 
syringe very slowly. The three peritoneal washings 
were pooled into a 20 ml sterile universal bottle, 
centrifuged for 5 minutes at 800 rpm, resuspended 
and counted. The cells were then diluted in 
hybridisation medium to a density of 30,000 
cells/ml and distributed to wells and flasks as 
appropriate.
HYBRIDISATION PROTOCOL
The 5 ml aliquots of spleen and myeloma cells were 
mixed and centrifuged for 10 minutes at 800 rpm. 
The supernatant was decanted and the universal 
bottle containing the cell pellet placed in a 
beaker of water at 37°C. PEG (0.8 ml) was added 
dropwise over 1 minute and after a further minute 
10 ml warm RPMI was added over 5 minutes at a 
gradually increasing rate of addition. The mixture
of cells was centrifuged for 10 minutes at 800 rpm, 
washed in RPMI and resuspended in 60 ml prewarmed 
hybridisation medium (2 x HAT medium).
HAT SELECTION
The hybridisation products were plated out, by 
Transplate 96 (COSTAR), into 5 x 96 well microtitre 
plates (0.2 ml/well), pre-prepared 24 hours earlier with 
peritoneal macrophage feeder cells in 2 x HAT medium. 
All plates were sealed with sellotape and incubated at 
37°C for 10-14 days before examination for the presence 
of growing hybrids and subsequent screening for 
antibody. '
SCREENING FOR TSH ANTIBODY
All wells with growing hybrids were screened for 
antibody by radioimmunoassay using a solid-phase second 
antibody separation technique.
Approximately 0.2 ml of cell supernatant was removed 
aseptically from each well of each fusion plate and 
fresh medium replaced. All plates were resealed with 
sellotape and incubated at 37°C.
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1) REAGENTS
(i) Assay diluent:- 0.05 mol/1 sodium phosphate 
buffer containing 0.154 mol/1 NaCl, 0.1% (w/v) BSA 
and 0.05% (w/v) NaN3 at pH 7.4
(ii) Iodinated TSH antigen:- stock labelled 125j- 
TSH was diluted to give 30,000 cpm/0.1 ml.
(iii) Sheep anti-mouse Y globulin immuno- 
adsorbent:- the stock solution (20 mg/ml) was 
diluted 1:4 with assay buffer to give a working 
solution of 1 mg/0.2 ml.
2) ASSAY:
12 mm diameter tubes, Sarstedt 55.484, were used 
throughout. Total count tubes and assay test 
samples were prepared in singleton owing to the low 
volumes of supernatant available.
(i) 0.05 ml cell supernatant.
(ii) 0.1 ml 1251-tsh (approx. 30,000 cpm).
The tubes were vortexed and incubated overnight at 
ambient temperature. Sheep anti-mouse Y globulin 
(1 mg/0.2 ml) was added and the tubes incubated on
an orbital shaker at 300 rpm for 60 minutes also at 
ambient temperature. The incubation tubes were
given three wash, centrifugation, aspiration cycles 
with 2 ml 0.9% NaCl containing 0.2% Tween 20 (v/v) 
and the immunoadsorbent pellets (bound fractions) 
counted on a gamma counter (Nuclear Enterprises 
1600) set on the normalised mode. Binding 
expressed as percentage of total counts was then 
calculated for each well.
In general, depending on the number of positive 
wells obtained, cell supernatants yielding binding 
greater than 10% were subjected to a second line 
test to assess antibody avidity by displacement 
analysis. Here, cell culture supernatants were 
diluted 1:2, 1:4, 1:8 etc and analysed in the
presence or absence of a displacement dose of 
standard TSH (code no 80/558, dose 100 mU/1 [0.05 
ml/tube]). The displacement was calculated (Bo- 
Bd/Bo x 100% where Bo = binding in the absence of 
TSH and Bd = binding in the presence of TSH) at 
each dilution with those wells giving the greatest 
displacement (highest avidity by definition) 
selected for cloning.
SPECIFICITY STUDIES
To determine antibody specificity, cell culture 
supernatants were diluted 1:2, 1:4, 1:8 etc and
analysed in the presence or absence of Human
Chorionic Gonadotropin (HCG) (dose 25,000 u/1, 0.05
ml/tube).
CLONING
Cell lines were cloned by limiting dilution. An initial 
dilution was made in hybridisation medium to obtain
approximately 800 cells/ml. Doubling dilutions were
then performed in a 24 x 2 ml well plate to give 8
dilutions in total. Ninety-six well microtitre plates
containing 0.1 ml macrophages (approx. 3,000 cells) were 
used for cloning (1 plate/cell line). 0.05 ml of each 
dilution was pipetted into a row of 12 wells, the plates 
sealed with sellotape and incubated at 37°C. 
Approximately ten days later plates were examined for
cell growth and screened for antibody (screening as 
described in Section Ig). Positive clones grown from 
few cells were selected for further cloning, each cell 
line being subjected to at least 2 cloning stages before 
expansion and ascitic fluid production.
EXPANSION OF SELECTED CLONES
Selected clones were transferred from clone plates to 2
ml wells and allowed to expand before seeding in 25 ml 
and 100 ml flasks. Expansion was continued in further
flasks until sufficient cells were obtained for cell 
freezing (to conserve the cells line) and ascites 
production in balb/c mice.
(1) PRISTANE PRIMING OF BALB/C MICE
Pristane (tetramethyl pentadecane, Sigma 
T7640, 0.5 ml per mouse) was injected intra-
peritoneally at least 1 week before the 
injection of hybrids to form ascitic fluid 
(single injections of pristane create a 
favourable environment for the growth of 
hybridomas).
(2) PREPARATION OF HYBRIDS FOR INJECTION
Sufficient cells for the injection of 10 mice 
at 10 x 10  ^ cells/mouse were centrifuged, the 
supernatant removed and the pellet washed once 
in RPMI. The hybrids were resuspended in a 
further 5 ml RPMI and injected intra- 
peri tone ally at 0.5 ml/mouse.
(3) PRODUCTION OF ASCITIC FLUID
At time intervals of 10-14 days after 
innoculation the abdomen of each mouse was 
punctured with a 19G needle and the ascitic 
fluid (approximately 5 ml) allowed to drain
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into a universal bottle. The ascitic fluid 
was clarified by centrifugation and stored at 
-20°C until required. In general this 
procedure was repeated every 2-3 days
throughout the remaining life-span of the
animals.
j) DETERMINATION OF CLASS AND SUBCLASS SPECIFICITY OF ANTI­
BODIES BY THE OUCHTERLONY IMMUNODIFFUSION TECHNIQUE
Mouse monoclonal typing kits (Serotec) were used 
for antibody class and subclass determination.
1) PRINCIPLE
The concentrations of mouse monoclonal 
immunoglobulins in growing hybridoma culture
supernatants vary between 1-20 mg/1 when antibody 
producing clones are established. SEROTEC sheep 
anti-mouse immunoglobulins (G, A, M and light 
chains) sera detect immunoglobulin production but 
not the individual immunoglobulin specificity.
The test comprises diffusing the six antisera 
(directed against the mouse classes and subclasses 
IgGl, IgG2a, IgG2B, IgG3, IgA and IgM) against the 
neat culture supernatants in the immunodiffusion 
plates.
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2) PREPARATION
The plate was removed from the container and the 
lid opened for 5-10 minutes at room temperature so 
that any condensation water could evaporate from 
the gel surface or the wells.
3) TEST PROCEDURE
Approximately 0.075 ml of the test culture
supernatant was pipetted into the large central
well of one of the rosettes. 0.01 ml of each of 
the six antisera, IgGl, IgG2a, IgG2b, IgG3, IgA and 
IgM were then pipetted, in a documented fashion, 
into each of the outer 6 wells of the same rosette. 
The plate was then tightly closed and stored flat 
at room temperature, for 24-48 hours. After this 
time the immunoprecipitate relevant to the immuno­
globulin specificity was visible. For
concentrations of monoclonal immunoglobulin below 1 
mg/1 more culture supernatant was pipetted into the 
central well and left for a further 24 hours. For 
concentrations greater than 20 mg/1 , samples were 
diluted into the test range since protein 
concentrations greater than the indicated ranges 
may have prevented the development of precipitates 
due to antigen excess.
PURIFICATION PREPARATION OF IgG FROM MOUSE ASCITIC 
FLUID
In general ascitic fluid of the same tap number (^3) 
were pooled to a volume of 20 ml and adjusted to pH 5 
with 0.1 mol/1 acetic acid. N-octanoic acid, BDH (1.76 
ml/20 ml ascitic fluid) was added dropwise with 
stirring. After stirring for 30 minutes the material 
was centrifuged at 1500 g for 20 minutes and the 
supernatant (IgG) retained. The pellet was washed with 
20 ml 0.1 mol/1 sodium bicarbonate pH 8 , the 
centrifugation repeated and the supernatants pooled. 
The IgG was thoroughly dialysed against 0.01 mol/1 
NaHC03 pH concentrated by ultrafiltration (Amicon
Corporation) and the protein concentration measured 
(Schachterle, 1^ 73).The material was stored at -20°C until 
required.
CELL FREEZING
Aliquots (5 ml) of Dimethyl Sulphoxide (DMSO), Sigma 
D5879 (1 ml = 1.10 g) in glass universal bottles were
autoclaved (120°C for 15 minutes) and stored at room 
temperature. As required a 10% solution of DMSO in ice 
cold foetal bovine serum was prepared for the cryo- 
preservation of cells. Cells for freezing were 
centrifuged, the medium discarded and the pellet washed
once in RPMI. The freezing mixture was added dropwise 
to the cell pellet with continuous shaking and the cells 
aliquoted into labelled freezing vials at a density of 
10 x 10^ cells/ml. The vials were sealed in a 1 cm 
thick polystyrene box and allowed to freeze overnight at 
-70°C after which they were stored in liquid nitrogen (- 
1960C) until required.
IOPINATIONS
a) PREPARATION OF LABELLED 125I-TSH
TSH was iodinated by an enzymatic (lactoperoxidase) 
solid-phase method, (Karonen et al, 1975).
1) PROCEDURE
Sodium phosphate buffer pH 7.4 (0.5 mol/1, 0.02 ml) was 
added to 2 ug-(0.01 ml) TSH (SFA [3-5] ASF), courtesy 
Professor W Butt, Birmingham and Midland Hospital for 
Women, followed by 0.005 ml ^2^I-Na (0.5 mCi, carrier- 
free, Amersham IMS 30) and 0.01 ml locally prepared 
solid-phase lactoperoxidase (0.01 ml stock diluted in 1 
ml 0.05 mol/1 sodium phosphate buffer pH 7.4, 200 ng).
The reaction was started by the addition of 0.01 ml 
hydrogen peroxide (H2O2 , approx. 30% w/v, BDH, Analar, 
0.01 ml in 250 ml distilled water, 120 ng) and allowed
to proceed for 30 minutes, vortexing every 5 minutes. 
The reaction was quenched by the addition of 0.02 ml TSH 
assay diluent (0.05 mol/1 sodium phosphate buffer pH 7.4 
containing 0.9% [w/v] NaCl, 0.1% [w/v] BSA and 0.05%
[w/v] NaN3 ).
PURIFICATION OF l25l-TSH
The reaction mixture was applied to a 74 x 1 cm column 
of Ultrogel AcA 54 (LKB 2204-540 UK) stored in 0.05 
mol/1 sodium phosphate buffer pH 7.4 and primed prior to 
use with TSH assay diluent. Fractions (100 x 1 ml) were 
collected overnight on a FRAC-300 fraction collector 
with P-l peristaltic pump (Pharmacia) and counted for 10 
seconds on a gamma radioisotope counter (Wilj). A 
profile of counts against fraction number was plotted 
and the monomer TSH peak identified (see Figure 2.1). 
Approximately 8 fractions containing monomer l^j-TSH 
were pooled and a 0.01 ml sample counted for 1 minute on 
a Nuclear Enterprises 1600 gamma counter to calculate 
the dilution which would be required to give 30,000 
cpm/0.1 ml. Aliquots (0.5 ml) were prepared and stored 
at -20°C until required (shelf-life was found to be at 
least 4 weeks).
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Figure 2.1
Ultrogel AcA 54 chromatography of iodinated TSH
PREPARATION OF LABELLED 125I-TSH POLYCLONAL ANTIBODY
1) PREPARATION OF SOLID-PHASE COUPLED TSH FOR IMMUNQ- 
SELECTION
Carbonyldiimidazole (CDI) activated cellulose (100 
mg) was rotated end over end overnight in a 12 mm 
diameter tube (Sarstedt 55.484) with 1 ml of 0.05 
mol/1 barbitone buffer pH 8 containing 100 ug TSH 
(Calbiochem, Iodination grade, potency: 5.5 IU/mg). 
The contents of the tube were then washed into a 
polypropylene tube (Henley) with 0.5 mol/1 sodium 
bicarbonate pH 8 , centrifuged at 2000 g for 20 
minutes and the supernatant discarded. This was 
followed by 3 x 20 minute washes with 0.5 mol/1 
sodium bicarbonate pH 8 (10 ml) and 2 sodium
acetate buffer pH 4 (10 ml) washes of 20 minutes 
and 60 minutes respectively. The solid-phase 
coupled TSH was sonicated (3 x 45 seconds) in 5 ml 
acetate buffer, centrifuged and the supernatant 
discarded before a further 10 ml wash in the same 
buffer overnight. The material was then washed 3 
times in 10 ml 0.1 mol/1 borate buffer pH 8 , 
resuspended in 0.5 ml and stored at 4°C until 
required.
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2) IMMUNOSELECTION OF TSH ANTIBODY
Sheep TSH antiserum (S1779, 0.1 ml, courtesy of 
Professor R P Ekins, the Middlesex Hospital Medical 
School, London, UK) was rotated end over end 
overnight with solid-phase coupled TSH in 0.1 mol/1 
borate buffer pH 8 (0.5 ml). The material was
washed 3 times with 10 ml 0.05 mol/1 sodium 
phosphate buffer pH 7.4 containing 0.9% (w/v) NaCl, 
once with 10 ml 0.9% (w/v) NaCl containing 0.2% 
(v/v) Tween 20 and 3 times with 10 ml 0.05 mol/1 
sodium phosphate buffer pH 7.4. Finally the solid-
phase pellet was resuspended in a further 1 ml of
0.05 mol/1 sodium phosphate buffer pH 7.4 and 
stored at 4°C until required.
3) TOP IN ATI ON AND PURIFICATION OF IMMUNOS ELECTED TSH
ANTIBODY
Sodium phosphate buffer pH 7.4 (0.5 mol/1, 0.125 
ml) was added to 0.25 ml of immunoselected sheep 
anti-TSH in a 10 ml conical polypropylene tube
(Henley), followed by 0.05 ml l^I-Na (Amersham 
IMS.30) (5 mCi). The reaction was started by
pipetting 0.05 ml freshly prepared chloramine T (4 
mg/ml in 0.05 mol/1 sodium phosphate buffer pH 7.4) 
into the reaction tube. After stirring for 40 
seconds employing a triangular spinbar (Radleys, 
UK), the reaction was quenched with 5 ml of assay
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buffer (0.1 mol/1 borate buffer pH 8 containing 
0.2% (v/v) Tween 20, 0.5% (v/v) normal sheep serum
and 0.05% (w/v) NaN3 ). The tube was centrifuged, 
the supernatant discarded and the solid-phase 
pellet washed 4 times in 5 ml of 0.001 N HC1 pH 3, 
discarding all supernatants. HC1 pH 2 (0.01 N, 1 
ml) was added to the pellet, mixed, centrifuged and 
the supernatant placed in a further 10 ml tube 
containing 0.5 ml of 0.5 mol/1 borate buffer pH 
8.0. Sodium bicarbonate pH 8.0 (0.1 mol/1) was
then added to the solid-phase pellet, mixed, 
centrifuged and the supernatant pooled with 
previously collected material. The pellet was 
discarded and the retained supernatants in borate 
buffer applied to a 100 x 1.6 cm C type column 
containing Sepharose 6B (Pharmacia) primed prior to 
use with assay buffer (as above). Fractions were 
collected (200 x 30 drops [about 1 ml]) at a flow 
rate of approximately 10 ml/hour, on a FRAC-300 
fraction collector with P-l peristaltic pump 
(Pharmacia). A column profile was plotted (see 
Figure 2.2), fractions containing anti-TSH were 
identified, pooled and mixed. The iodinated TSH 
antibody was then stored in aliquots at -20°C until 
required. Each aliquot contained sufficient radio- 
iodinated antibody for 300 tubes at 25,000 cpm 
ini tially.
PREPARATION OF LABELLED i25I-TSH MONOCLONAL ANTIBODY
TSH monoclonal antibody (5H8) was iodinated by an 
enzymatic (lactoperoxidase) solid-phase method.
1) PROCEDURE
Sodium phosphate buffer pH 7.4 (0.5 mol/1, 0.01 ml) 
was added to 20 ug (0.01 ml) 5H8 IgG followed by 
0.005 ml 125j-Na (0.5 mCi, carrier free, Amersham 
IMS 30) and 0.01 ml locally prepared solid-phase 
lactoperoxidase (0.01 ml stock diluted in 1 ml 0.05 
mol/1 sodium phosphate buffer pH 7.4, 200 ng). The 
reaction was started by the addition of 0.01 ml 
hydrogen peroxide (H2O2 , approx. 30% w/v, BDH, 
Analar, 0.01 ml in 250 ml distilled water, 120 ng) 
and allowed to proceed for 30 minutes, vortexing 
every 5 minutes. The reaction was then quenched by 
the addition of 0.02 ml assay diluent (0.1 mol/1 
EPPS (N-[2-Hydroxyet hyl]-piperazine-N^-3-propane-
sulphonic acid) buffer pH 8.0 containing 0.2% 
(v/v) Tween 20, 0.5% (v/v) normal sheep serum and
0.05% (w/v) NaN3).
2) PURIFICATION OF IODINATED ANTIBODY
The reaction mixture was applied to a 35 x 1.5 cm 
column of Sepharose 6B (Pharmacia) stored in 0.1 
mol/1 EPPS buffer pH 8.0 and primed prior to use
with’ assay diluent (as above). Fractions (100 x 1 
ml) were collected overnight on a FRAC-300 fraction 
collector with P-l peristaltic pump (Pharmacia) and 
counted for 10 seconds on a gamma counter (Wilj). 
A profile of counts against fraction number was 
plotted and the 5H8 peak identified. Approximately 
8 fractions containing 125i-tsH monoclonal antibody 
were pooled and a 0.01 ml sample counted for 1 
minute on a Nuclear Enterprises 1600 gamma counter 
to calculate the dilution which would be required 
to give 100,000 cpm/0.2 ml. Aliquots (0.5 ml)
were prepared and stored at -20°C until required.
Ill) PREPARATION OF SOLID-PHASE ANTIBODIES
a) CELLULOSE SOLID-PHASE TSH ANTIBODY
1) IgG FRACTIONATION
The caprylic acid precipitation method of Steinbuch 
and Audran (1969) was used to prepare an IgG 
fraction from sheep TSH antiserum.
Sheep TSH antiserum (S-117, 60 ml) was titrated to 
pH 5.0 with 0.1 mol/1 acetic acid and 3.6 ml of a 
91% solution of n-octanoic acid (BDH) was added 
drop-wise. After stirring for 30 minutes the
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Sepharose 6B gel chromatography of immunoselected TSH antibody
material was centrifuged for 45 minutes at 2,000 g, 
the supernatant recovered and the pellet washed 
with 30 ml of 0.1 mol/1 sodium bicarbonate pH 8 . 
Following re-centrifugation of the washed pellet, 
the supernatants were pooled and dialysed overnight 
at ambient temperature against 4 1 of 0.01 mol/1 
sodium bicarbonate, pH 8 . The resultant solution 
had a volume of approximately 80 ml and a protein 
concentration of approximately 80 mg/ml.
CARBONYLDIIMIDAZOLE ACTIVATION OF MICROPARTICULATE 
CELLULOSE
Carbonyldiimidazole activation was carried out 
essentially by the method of Chapman and Ratcliffe 
(1981) in an anhydrous organic solvent with the 
introduction of imidazolyl carbamate groups into 
the polymer (Figure 2.3). The remaining imidazole 
groups are then reacted with peptide amino groups
in aqueous alkaline medium to give an N-alkyl-
carbamate derivative of the immobilised peptide.
Microparticulate cellulose (Sigmacell Type 20, 
Sigma, 5 g) was weighed into a 50 ml conical flask
fitted with a ground glass stopper, CDI (Sigma)
(0.61 g/25 ml acetone, 0.15 mol/1) added and the
reaction left to proceed for 60 minutes at 20°C 
with vigorous stirring. The activated cellulose 
was recovered by filtration over a glass microfibre
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Figure 2.3
Activation of cellulose by the carbonyldiimidazole method
filter (Whatman GF/A, retention efficiency 2 
microns) and washed with 3 x 100 ml aliquots of 
acetone. The activated cellulose was then allowed 
to dry in air, and stored in a tightly sealed 
container at -20°C.
Prior to coupling the activated cellulose was 
allowed to reach ambient temperature. One gram was 
weighed into a polystyrene tube and mixed with 5 ml 
of IgG solution (10 mg/ml in 0.05 mol/1 barbitone 
buffer pH 8.0), briefly vortexed to form a mobile 
slurry, stoppered and rotated end over end for 16- 
18 hours at ambient temperature. The subsequent 
washing procedure followed that of Wide (1969). 
The protein remaining in solution was recovered by 
centrifugation and the immunoadsorbant washed 
repeatedly with 50 ml aliquots of the buffers shown 
below and recovered by centrifugation (10 minutes 
at 1,500 g) between each wash cycle.
1. 0.5 mol/1 sodium bicarbonate buffer pH 8.0, 
rotate 20 minutes.
2. Repeat.
3. 0.1 mol/1 acetate buffer pH 4.0, rotate 60 
minutes.
4. 0.1 mol/1 acetate buffer pH 4.0, sonicate for 
30 seconds, rotate 16-20 hours.
5. 0.9% NaCl, rotate 20 minutes.
6 . Re pe at.
The immunoadsorbant was then stored in isotonic 
saline at 4°C until required. Larger preparations 
were accomplished simply by increasing the volumes 
of coupling and wash solutions.
SEPHAROSE SOLID-PHASE TSH ANTIBODY
1) CARBONYLDIIMIDAZOLE ACTIVATION OF SEPHAROSE
Activation of Sepharose was carried out by the CDI 
method of Chapman and Ratcliffe (1981), as for 
microparticulate cellulose.
Calibrated Sepharose CL-4B solution (200 ml) (=100 
ml settled gel, Pharmacia) was transferred to a 
sintered glass funnel (porosity 3, capacity >500 
ml) and dehydrated by washing the gel successively 
with 500 ml aliquots of distilled water, 30%, 50%, 
70% and 100% acetone (Analar, BDH). The gel was 
gently stirred when fresh wash solutions were added 
and not allowed to dry at any stage. The 
dehydrated gel slurry was transferred, by careful 
resuspension in further acetone, to a 200 ml
calibrated conical flask and 4.87 g 
carbonyldiimidazole (Sigma) (0.15 mol/1) added. 
The flask was sealed with a ground glass stopper 
and stirred for 60 minutes before transferring the 
activated gel back to the sintered glass funnel and 
rehydrating by washing successively with 500 ml of 
100%, 70%, 50%, 30% acetone, distilled water and
finally EPPS coupling buffer (Sigma) (0.1 mol/1 
EPPS, pH 8 containing 0.05% (w/v) NaN3 ). Again the 
gel was not allowed to dry and was resuspended 
gently between washes. The activated gel was then 
transferred to a poly-carbonate bottle (calibrated 
to 200 ml) by washing with coupling buffer and 120 
mg TSH IgG was added prior to rotation end over end 
for 18-24 hours.
WASHING PROCEDURE
The subsequent washing procedure followed that of 
Wide (1969). The protein remaining in solution was 
recovered by centrifugation and the gel washed 
repeatedly with 100 ml aliquots of the buffers 
shown below and recovered by centrifugation (15 
minutes at 1,200 g) between each wash cycle as 
follows
1. 0.5 mol/1 sodium bicarbonate buffer pH 8.0,
rotate 20 minutes.
2. Repeat.
3. 0.1 mol/1 acetate buffer pH 4.0, rotate 60
minutes.
4. 0.1 mol/1 acetate buffer pH 4.0, rotate 16-20
hours.
5. 0.9% NaCl, rotate 20 minutes.
6 . Repeat.
The gel was then stored in isotonic saline at 4°C 
until required. Larger preparations were 
accomplished simply by increasing the volumes of 
coupling and wash solutions.
SEPHAROSE SOLID-PHASE SHEEP ANTI-MOUSE GAMMA-GLOBULIN
Solid-phase sheep anti-mouse gamma-globulin (SAM) was 
prepared in a similar fashion to that of Sepharose 
solid-phase TSH antibody except that 25 ml of sheep 
antiserum to mouse gamma-globulin (SAPU, Law Hospital, 
Carluke) was coupled by rotation end over end for 18-24 
hours with the activated gel. The gel was stored at 4°C 
in 0.9% saline until required.
STANDARDS
a) PREPARATION OF DRIED BLOOD-SPOT TSH STANDARDS
Standard TSH (2nd I.R.P. hTSH, code no 80/558) was
dissolved in 50 ml TSH free human serum to give a
concentration of 740 mU/1 TSH. Aliquots (5 ml) were
prepared in polypropylene tubes (Henley) and stored at - 
20°C. As required, usually at 2 monthly intervals, 5 ml 
of the stored TSH standard was removed and diluted with 
5 ml packed human red blood cells (courtesy of the 
Glasgow and West of Scotland Blood Transfusion Service, 
Law Hospital, Lanarkshire) previously washed 3 times 
with 0.9% (w/v) saline to give a stock standard of 375 
mU/1 TSH in whole blood.
Further dilutions in simulated whole blood (50% packed 
cells, 50% TSH free serum) gave a series of standard 
concentations 375, 188, 94, 47, 23, 12, 6 , 0 mU/1 whole 
blood. Blood spots (0.025 ml) were prepared on filter 
paper cards (Schleisser and Schuell grade 2992, old 
number 903, cellulose) which were then allowed to dry 
overnight at ambient temperature. Post air drying the 
spots were sealed in polythene with silica gel dessicant 
(6-20 mesh, BDH) and stored at -20°C until required.
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b) PREPARATION OF TSH DRIED BLOOD-SPOT QUALITY CONTROL
POOLS
Standard TSH (80/558) was diluted in TSH free human 
serum to give TSH concentrations of 185, 92.5 and 46.25 
mU/1 respectively and aliquots (1 ml) of the calibrated 
serum were prepared and stored at -20°C until required. 
Packed cells (1 ml) were added to yield a set of quality
controls with values of 92.5, 46.25 and 23.13 mU/1
whole blood respectively and blood-spots (0.025 ml) were 
prepared on filter paper cards. The cards were allowed 
to dry overnight at ambient temperature prior to sealing 
in polythene with silica gel desiccArvf" and storage at 
-20°C until required.
c) PREPARATION OF TSH DRIED BLOOD-SPOT DRIFT QUALITY
CONTROL POOL
Packed cells (15 ml) were added to calibrated serum (74 
mU/1 TSH) to give a drift value of 37 mU/1 whole blood. 
Blood-spots (0.025 ml) were prepared as above.
d) PREPARATION OF TSH HORSE SERUM STANDARDS
The contents of an ampoule of TSH standard (2nd I.R.P. 
hTSH, code no 80/558) were dissolved in 0.5 ml of 0.05 
mol/1 sodium phosphate buffer pH 7.4. The solution was
made up volumetrically to 200 ml with TSH free horse 
serum (Gibco, Paisley, UK) to give a stock standard of 
185 mU/1 TSH which was then double diluted in further 
horse serum (100 ml) to obtain standard values of 185, 
92.5, 46.25, 23.1, 11.6, 5.8, 2.9, 1.4, 0.72, 0.36 and
0.18 mU/1 TSH respectively. Aliquots (0.5 ml) were 
prepared and stored at -20OC until required.
ASSAY PROTOCOLS
a) TWO-SITE IRMA FOR BLOOD-SPOT TSH
The assay protocol for the measurement of TSH from dried 
blood discs is shown in Figure 2.4. The assay diluent 
used was 0.1 mol/1 borate buffer, pH 8.0 containing 0.5% 
(v/v) normal sheep serum (SAPU, Law Hospital, Carluke), 
0.2% (v/v) Tween 20 (Sigma) and 0.05% (w/v) NaN3 «
b) TWO-SITE IRMA FOR SERUM TSH EMPLOYING 2 POLYCLONAL ANTI­
BODIES
Sarstedt 55.484 tubes (12 mm diameter) were used 
throughout and standards, quality controls (Lyphochek, 
BIO-RAD), samples and total counts were all set up in 
duplicate. The assay diluent used was 0.1 mol/1 borate
5/6 mm diameter disc
0.2 ml labelled antibody 
(polyclonal - 25/000 cpm; 
monoclonal - 100/000 cpm)
V
16 hours at ambient temperature
0.2 ml cellulose/Sepharose 
solid - phase antibody 
(ca. 1 mg)
H/
90 minutes agitation
4 x 3 ml wash/centrifuge
count/calculate
Figure 2.4
Assay protocol for the measurement of TSH from dried blood discs
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buffer, pH 8.0 containing 0.5% (v/v) normal sheep serum, 
0.2% (v/v) Tween 20 and 0.05% (w/v) NaNg. The assay
protocol is shown in Figure 2.5.
c) TWO-SITE IRMA FOR SERUM TSH EMPLOYING MONOCLONAL AND 
POLYCLONAL ANTIBODIES
Sarstedt 55.484 tubes (12 mm diameter) were used 
throughout and standards, quality controls, samples and 
total counts were all set up in duplicate. The assay 
diluent used was 0.1 mol/1 EPPS buffer, pH 8.0 
containing 0.5% (v/v) normal sheep serum, 0.2% (v/v)
Tween 20 and 0.05% (w/v) NaNg. The assay protocol is 
shown in Figure 2.6. The same protocol was adopted when 
a monoclonal antibody replaced the solid-phase poly­
clonal antibody.
d) ALTERNATIVE SEPARATION PROCEDURE - SUCROSE LAYERING 
TECHNIQUE
To achieve greater assay sensitivity sucrose layering 
separation was adopted (Wright and Hunter, 1983).
1) PRINCIPLE
Sepharose CL-4B solid-phase is a dense particle and 
sediments relatively quickly under gravity without
0.1 ml sample/std./QC
0.2 ml labelled antibody 
(25/000 cpm)
90 minutes at ambient temperature
0.2 ml solid - phase 
antibody (ca. 1 mg)
90 minutes agitation
4 x 2 ml wash/centrifuge 
(0.9% NaCl + 0.2% Tween 20)
count/calculate
Figure 2.5
Assay protocol for serum TSH employing 2 polyclonal antibodies
0.1 ml sample/std./QC
0.2 ml labelled monoclonal 
antibody (100/000 cpm)
2 hours at ambient temperature
0.2 ml solid - phase 
—  polyclonal antibody (ca. 1 mg)
V
60 minutes agitation
4 x 2 ml wash/centrifuge 
(0.9% NaCl)
count/calculate
Figure 2.6
Assay protocol for serum TSH employing monoclonal and polyclonal 
Antibodies
the need for centrifugation. At the end of the 
agitation incubation ( D, wash buffer is added and 
the solid-phase is allowed to settle for about 5 
minutes This step enhances separation
efficiency as particles of solid-phase are washed 
off the sides of the tube. A relatively dense 
sucrose solution is then layered below the incubate 
by running it through a hollow probe resting on the 
bottom of the tube O). This raises the incubate 
above the surface layer and lifts the solid-phase 
(bound fraction) at the interface of the two 
layers. Over a period of 15 minutes the 
particulate solid-phase falls through the
sucrose, leaving behind the incubate and the 
remaining labelled antibody (free fraction) (^). 
The upper layer of incubate and most of the sucrose 
are now removed by aspiration through a second 
probe (5). This leaves 0.3-0.5 ml sucrose 
containing all the solid-phase at the bottom of the 
tube, ready for counting (6). por optimum 
sensitivity and precision this separation procedure 
is repeated. By performing the separation step 
twice a lower blank can be achieved.
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2) REAGENTS
Wash buffer: 0.9% (w/v) NaCl containing 1% (v/v)
Tween 20.
Sucrose solution: 10% (w/v) sucrose containing 1% 
(v/v) Tween 20 and 0.1% (w/v) NaN3 .
3) METHOD
Sarstedt 55.526 tubes (12 mm diameter, volume = 5
ml) were used throughout. The method was as
follows:-
1. Add 1 ml wash buffer.
2. Allow solid-phase to settle for about 5
minutes.
3. Add 3 ml sucrose solution.
4. Wait 15 minutes.
5. Aspirate upper layer of incubate and most of 
sucrose.
6 . Repeat steps 1 to 5.
OTHER METHODS
a) PROTEIN ESTIMATION
Protein estimations were carried out with appropriate 
buffer blanks essentially by the method of Schacterle 
and Pollack (1973), based on the original work by Lowry 
et al (1951).
Reagents: Alkaline copper reagent (A); 20 g Na2 CO3 ,
4 g NaOH, 200 mg sodium tartrate and 100 mg copper 
sulphate 5H20 were separately dissolved and 
sequentially made up to a final volume of 200 ml with 
distilled water (dH20).
Folin-Ciocalteau reagent (B); pre-prepared (BDH) was 
diluted 1:25 with distilled H2O prior to use.
Protein standards: A stock solution of 50 mg bovine
serum albumin (BSA)/50 ml distilled H2O was double 
diluted (x 4) prior to use (Figure 2.7).
Protocol: 0.20 ml standardj buffer blank or test was
mixed with 0.20 ml reagent A, vortexed, and allowed to 
stand at 22°C for 10 minutes. 1.0 ml of reagent B was s 
added, the solution vortexed, incubated for 5 minutes at 
55°C, cooled and absorbance measured (A650).
(u
ju
oS9) 
eoueqjosqv
0.5-
0.0
1.00.0 0.2 0.4 0.6 0.8 1.2
Protein (mg/ml)
Figure 2.7
Protein standard curve
CHAPTER 3
PRODUCTION AND CHARACTERISATION OF MONOCLONAL ANTIBODIES TO HUMAN 
TSH AND THE DEVELOPMENT OF A VARIETY OF TWO-SITE IMMUNOMETRIC 
ASSAYS FOR THE MEASUREMENT OF TSH IN SERUM AND IN NEONATAL BLOOD 
SPOTS
I MOUSE SERUM ANTIBODY EVALUATION
Selection of a single mouse (usually from a batch of 6) for 
use in a fusion experiment was based on an assessment of 
antibody titre and avidity. Avidity was assessed by analysis 
with a dose of 25 mU/1 TSH (WHO 68/38). The mouse yielding 
the best titre and displacement was chosen for fusion. 
Antibody dilution and displacement curves were set up for 
each mouse as described in Chapter 2, Section lb. Figure
3.1 shows typical results from a mouse subsequently selected
for fusion. The lower curves represent initial blood samples 
from the mouse (3 weeks post primary immunisation), whilst 
the upper curves are identical representations several weeks 
later following two further booster immunisations. Figure
3.2 shows typical antibody dilution and displacement curves 
from a mouse rejected due to poor titre and displacement.
Since the chances of obtaining a monoclonal antibody with 
particular properties is directly related to the
concentration of corresponding antibodies in the serum of the
% Bound
30-
Bleed 1
Bleed 1 (+25)
Bleed 2
Bleed 2(+25)
IQ-
100000100001000
Final Dilution
Figure 3.1
Antibody dilution and displacement curves from a mouse subsequently 
selected for fusion
% Bound ■
30-
Bleed 1
Bleed 1 (+25)
Bleed 2
Bleed 2(+25)
IQ-
1000 10000 100000
Final Dilution
Figure 3.2
Antibody dilution and displacement curves from a mouse rejected 
from fusion due to poor titre and displacement
spleen donor, during splenectomy blood was removed by cardiac 
puncture and antibody dilution and displacement curves (10, 
25 and 100 mU/1 TSH) performed on the serum (Figure 3.3). 
The spleen from this mouse yielded a large number of antibody 
secreting hybrids on fusion.
SELECTION OF ANTIBODIES POST-FUSION
a) OVERALL OUTCOME OF CELL FUSION EXPERIMENTS
A total of 6 monoclonal antibodies to TSH were obtained 
from 25 fusions. Additional positive hybridomas were 
identified in initial screening assays. Some of these 
were not cloned because preliminary tests for binding of 
hCG showed the antibodies to be non-specific, or because 
the level of 125j-TSH binding was suggestive of low 
affinity antibody. There were also a few hybridomas for 
which attempts at cloning failed and occasionally 
contamination destroyed potentially useful cell lines.
b) PRODUCTION OF MONOCLONAL ANTIBODY TD.5H8.C5.D8
5H8 was the product of a fusion whose initial screening 
for binding to 125i_tsh gave 155 hybridomas with binding 
levels >5% from a total of 1500 wells (10%). Sixty 
seven hybridomas bound ^10% ^^I-TSH (5%). These 
were subsequently reanalysed to determine antibody
80
% Bound
60
-*■ 10
-a- 25
40
-o- 100
20
0 4—  
1000 10000 100000
Final Dilution
Figure 3.3
Antibody dilution and displacement curves performed on the serum of 
a spleen donor mouse
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avidity by displacement analysis. Table 3.1 shows a 
typical distribution of positive hybridomas in a 96 well 
plate screened for TSH antibody. 5H8 (D5/H8) with a 
binding level of 71.0% is highlighted. Table 3.2 shows 
the displacement analysis results for those hybridomas 
eventually selected for cloning, ie. those hybridomas 
producing the most avid antibodies. The 7 hybridomas 
were further assessed at 3 dilutions (1:3, 1:9 and 1:27) 
in the presence of hCG to determine the specificity of 
the antibodies obtained (Table 3.3). All 7 hybridomas 
were established in 2 ml wells prior to cloning. 
However, 5 hybridomas had lost their ability to produce 
TSH antibody after primary cloning, probably due to 
overgrowth by non-secreting hybridomas in a single 
culture containing multiple hybridomas, together with 
chromosome segregation conspiring against stability of 
expression (Galfre and Milstein, 1981). Attempts at 
recloning from 2 ml wells were not attempted since D5/H8 
and E3/G1, the remaining hybridomas were considered the 
most useful. Table 3.4 shows results after initial 
cloning for the 2 remaining positive hybridomas (D5/H8 
and E3/G1). Cells from 3 of the wells of the D5/H8 
clone plate and 2 wells of the E3/G1 plate were then 
subjected to a second cloning stage. Positive plates 
are shown in Table 3.5 (D5/H8/C5 and E3/G1/B8). From 
these plates cells from 10 wells were expanded into 
flasks. Antibody dilution analysis was conducted on all 
flask supernatants in the presence and absence of hCG 
(dose 20,000 u/1) and TSH (25 and 100 mU/1). One of the
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TABLE 3.3
DETERMINATION OF ANTIBODY SPECIFICITY
DILUTION BO BTSH BhCG
C2/A2
neat 53.9 54.9 52.1
1:3 47.8 47.6 47.7
1:9 40.1 39.4 36.3
1:27 28.5 28.2 29.8
D1/H3
neat 63.0 63.8 62.8
1:3 52.8 54.4 54.4
1:9 41.4 42.3 39.1
1:27 24.6 25.0 24.8
*D5/H8*
neat 56.1 55.7 55.2
1:3 51.3 48.2 51.4
1:9 44.8 44.6 46.3
1:27 40.3 38.3 39.7
E1/E5
neat 55.8 56.2 57.2
1:3 44.2 43.7 43.9
1:9 33.9 32.2 34.1
1:27 21.6 21.6 21.2
E1/E6
neat 53.8 54.3 57.6
1:3 52.0 50.7 51.7
1:9 45.4 43.0 44.2
1:27 36.4 36.6 36.6
E3/G1
neat 24.9 15.0 2.0
1:3 18.3 5.6 1.1
1:9 9.1 2.7 1.3
1:27 4.8 1.5 1.4
F2/D4
neat 52.7 54.4 51.4
1:3 38.9 39.2 32.4
1:9 23.3 23.8 17.2
1:27 12.5 12.1 7.0
TABLE 3.4
RESULTS AFTER INITIAL CLONING FOR D5/H8 AND E3/G1
PLATE D5/H8
1 2 3 4 5 6  7 8 9 10 11 12
A
B 1.3 0.9 10.3 2.8
0.6 0.9 2.0 1.8
0.8 0.9 1.0 1.1
1.3 0.7 1.3 0.8
C 2.5 63.8 2.4
2.5 60.6 2.3
1.0 29.4 0.9
0.6 6.6 0.6
D 0.9 2.4 0.7 67.9 1.2 0.5
0.8 0.7 0.6 62.8 0.8 0.7
0.7 1.0 0.7 38.8 0.6 0.7
1.2 0.7 0.9 13.9 0.8 0.6
TABLE 3.4 CONTINUED:
PLATE E3/G1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.7 0.7 0.7 0.6 0.6 1.0
0.5 0.5 0.4 0.6 0.8 0.3
0.6 0.6 0.8 1.0 0.8 0.7
0.9 0.8 0.5 0.6 0.6 0.4
B 0.5 0.7 0.6 57.0 0.6 0.6 0.7
0.5 0.6 0.5 58.3 0.8 0.7 0.5
0.7 0.9 0.5 28.6 0.6 0.6 0.6
0.9 0.6 0.6 10.5 0.5 0.6 0.7
C 0.7 0.6 0.6 15.5 0.8 0.5 0.9 0.6
0.4 0.4 0.6 3.0 0.4 0.5 0.4 0.6
0.6 0.8 0.5 1.6 0.7 0.6 0.9 0.6
0.6 0.5 0.5 0.6 0.6 1.0 0.5 0.6
D 1.6 0.7 0.5 0.5 0.9 0.6 0.6 0.6
0.6 0.4 0.5 0.7 0.7 0.7 0.6 0.7
0.8 0.6 0.8 0.7 0.7 0.7 0.7 0.6
0.4 0.8 0.8 0.7 0.8 0.8 0.6 0.6
TABLE 3.5
RESULTS AFTER SECOND CLONING FOR D5/H8/C5 AND E3/G1/B8 
PLATE D5/H8/C5
1 2 3 4 5 6  7 8 9 10 11 12
A
30.8
14.1
7.0
1.1
32.1
17.5
7.4
1.7
25.6
7.1
3.0
1.3
20.1
4.2
3.4
0.9
44.6
43.9
30.8
12.9
20.7
5.2
2.3
1.2
40.3
37.8
19.6
3.6
34.5
24.6
9.5
1.7
TABLE 3.5 CONTINUED
PLATE E3/G1/B8
1 2 3 4 5 6  7 8 9 10 11 12
A
1.3
1.3
0.8
0.6
2.4
1.4
9.1
1.3
16.3
2.8
1.8
1.0
11.7
2.1
2.3
0.8
D 1.1 1.3
2.8 1.2
1.1 1.7
1.2 1.1
hybridomas (E3/G1) had lost its ability to produce TSH 
antibody but 5H8, potentially the most useful cell line 
was still producing antibody (Figure 3.4). All the 
results indicated that 5H8 was an antibody directed 
against the 8 subunit of TSH which after full 
characterisation may be of practical value in a two-site 
IRMA for TSH.
PRODUCTION OF MONOCLONAL ANTIBODIES TQ5, TR2 AND TS5
Selection of TQ5, TR2 and TS5 was performed in a similar 
manner to 5H8. Cells from an immunised mouse spleen 
weighing 295 mg were fused with myeloma cells (viability 
90%) yielding 98 positives (^10% binding), ie. 7%. Of 
these 98 positives, 52 (3%) bound ^20% 125x-TSH and
were subsequently subjected to displacement analysis 
(dose 500 mU/1 TSH) to determine antibody avidity. The 
52 positives were also assessed in the presence of hCG 
(dose 20,000 u/1) to determine antibody specificity.
Results are shown in Table 3.6 for 6 hybridomas which 
were considered most suitable for cloning. Before 
second cloning, displacement and specificity analysis 
was repeated. Results are shown in Table 3.7 for 4 
hybridomas selected for further cloning. Prior to 
expansion 3 of the 4 hybridomas were established in 2 ml 
wells and reassessed as previously described (Table
80 i
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Figure 3.4
Antibody dilution analysis of 5H8 post second cloning and expansion
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3.8). A full characterisation of the 3 products from 
this fusion was performed at a later stage, the results 
of which are presented in Section III.
d) PRODUCTION OF MONOCLONAL ANTIBODIES TX.2G2 AND TW.4F12
Myeloma cells of 99% viability were fused with spleen 
cells from an immunised mouse (weight of spleen = 0.5
g). In the initial screening assay 18 (1%) positive
hybridomas were identified (binding ^10% 125i-t s h )
(Figure 3.5). The majority (72%) of the positive cell 
lines were poor binders (10-14.9% 125x-TSH) suggestive
of low affinity antibody. Only one hybridoma (2G2) 
bound greater than 50% of the label. Several hybridomas 
were cloned once but only 2G2 and 4F12 were selected for 
further cloning and expansion. Both hybridomas were 
injected into mice to produce ascitic fluid. The fusion 
products were fully characterised at a later stage, the 
results of which are presented in Section III.
CHARACTERISATION OF MONOCLONAL ANTIBODIES
a) INTRODUCTION
The glycoprotein hormones thyroid stimulating hormone, 
luteinising hormone, chorionic gonadotrophin and
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Figure 3.5
Positive hybridomas identified in the intitial screening assay 
leading to the production of monoclonal antibodies TX.2G2 and TW.4F12
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follicle stimulating hormone constitute a family of 
structurally related polypeptides (Pierce and 
Parsons, 1981). They share a common alpha-subunit, and 
have variable degrees of sequence homology in their 
specific 3 -subunits. All the hormones have complex 
carbohydrate groups attached to both subunits.
The similarities in primary sequence and tertiary 
structure are reflected in the immunological properties 
of the hormones. Thus antisera raised against one
hormone normally cross-react with others of the group
(Vaitukaitis et al, 1976). More specific antisera have 
been obtained by adsorption to remove cross-reacting 
antibodies, or by immunisation with isolated subunits, 
peptide fragments or chemically modified preparations 
rather than intact native molecules (Vaitukaitis et al, 
1976; Swaminathan and Braunstein, 1978; Ghai et al,
1980). However, it remains difficult to obtain
conventional ant/'bodies of defined specificity for use 
in sensitive immunoassay. It is to be expected that 
suitable monoclonal antibodies (Galfre and Milstein,
1981) might be highly specific for a given hormone if 
directed against a unique structural feature. The ease 
with which such antibodies may be obtained will depend 
on the relative immunogenicity of specific and 
homologous structures in a given hormone.
ANTIBODY AFFINITY AND SPECIFICITY
IgG fractions of ascitic fluid were used as a source of 
antibody. The dilution of each IgG fraction which bound 
half-maximally 100 pg of ^5];_-psH (30,000 cpm) was
determined (Figure 3.6) and used in experiments to 
determine antibody affinity and specificity.
Standard curves were performed in duplicate. Standard 
TSH (SFA (3-5) ASF standard range 0-10,000 mU/1, 0.1 ml) 
and antibody (0.1 ml) were incubated overnight with 
approximately 100 pg of 125j-TSH (0.1 ml). Solid-phase 
sheep anti-mouse gamma globulin (0.2 ml) was added and 
the reaction tubes agitated for 60 minutes prior to 
washing and counting. Figure 3.7 displays standard 
curves for each of the 6 monoclonal antibodies. The 
data for binding in the presence of TSH were used to 
construct Scatchard plots (Figure 3.8) from which the 
avidity and concentration of the antibody were 
estimated. Avidities ranged from 1.7 x 10^ (4F12) to
6.3 x 109 1/mol (5H8) (Table 3.9).
Antibody specificity, with respect to cross-reaction 
with LH, FSH and HCG, was assessed by testing for 
displacement of binding between unlabelled hormones and 
125J-TSH. Specificity analysis was performed on 5H8 and 
2G2, the antibodies of highest avidity. Standard 
hormone (0.1 ml), TSH (SFA [3-5] ASF, 0-2,000 ug/1), LH 
(LH10, 0-1,000 ug/1), FSH (FSHCPDS-30, 0-1,000 ug/1) (Dr
1 0 01
% Bound
80H
2G2
Poly
TS5601
TQ5
-o- TR2
401
4F12
2 0 1
Dilution
Figure 3.6
Determination of the dilution of each IgG fraction which bound half- 
maximally 100 pg of I-TSH (30/000 cpm)
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Standard curves for each of the 6 monoclonal antibodies
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TABLE 3.9
ANTIBODY AFFINITY AND CONCENTRATION
ANTIBODY AFFINITY
(litres/mole)
[BINDING SITES] 
(moles/1)
9 . -11
5H8 6.3 x 10 9.60 x 10
2G2 3.3 x 108 1.05 x 10~9
8 ,~-9
TQ5 1.6 x 10 1.24 x 10
8 ,~-9
TR2 1.0 x 10 1.58 x 10
7 . -9
TS5 9.7 x 10 2.85 x 10
4F12 1.7 x 107 1.21 x 10"8
S Lynch, Birmingham and Midland Hospital for Women) or 
HCG (BCL, Lewes, UK, 0-10,000 ug/1) was incubated
overnight with 5H8 or 2G2 antibody (0.1 ml) and ^^5x—TSH 
(0.1 ml). Solid-phase sheep anti-mouse gamma globulin 
(0.2 ml) was added and the reaction tubes agitated for 
60 minutes prior to washing and counting. The 
concentration of each hormone producing 50% inhibition 
of 125i-TSH binding was determined. 5H8 showed no cross 
reactivity with any of the hormones (Figure 3.9) whereas 
2G2 cross-reacted with all 3, LH (97.1%), FSH (82.6%) 
and HCG (84.9%) (Figure 3.10).
5H8 and 2G2 were then subjected to incubation with 
preparations of a (N-745-A) and 8 (AFP-3292B) TSH
(National Hormone and Pituitary Programme (NIDDK), 
University of Maryland School of Medicine, USA) in a 
similar fashion to that outlined above and % bound 
versus log concentration (ug/1) plotted (Figure 3.11 and 
3.12 respectively). The results indicated that 5H8 was 
an antibody specific for the 8-subunit of TSH whereas 
2G2 was specific for the u-subunit. Slight displace­
ment was observed with high concentations of « TSH in 
the case of 5H8. A similar effect was noted for 2G2 
with high concentrations of 8 TSH. This was attributed 
to a small degree of contamination with whole TSH 
(approximately 4% in each case).
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Specificity analysis of monoclonal antibody 5H8
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Specificity analysis of monoclonal antibody 2G2
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Subunit specificity analysis of monoclonal antibody 2G2
The above results indicate that in terms of avidity and 
specificity 5H8 and 2G2 may be of extreme practical 
value in the development of a two-site IRMA for TSH.
c) ISOTYPE ANALYSIS
Culture supernatants from suspensions of twice-cloned 
hybrid cells, grown to maximum density, were used as a 
source of antibody. The isotype of all 6 antibodies was 
determined. Results are shown in Table 3.10. It was of 
interest to note that the two antibodies, 5H8 and 2G2, 
of highest affinity were both of the IgG^ subclass.
PREPARATION OF 125I~LABELLED TSH MONOCLONAL ANTIBODY
Iodination of monoclonal antibody 5H8 was performed as 
described in Chapter 2, Section IIIc. 5H8 IgG fractions (20 
ug, tap ^3) were iodinated with 0.25 and 0.5 mCi carrier- 
free radioiodine yielding labels with specific activities 
estimated as 9 and 21 uCi/ug respectively (based on 
incorporation of radioiodine into the protein) (Figure 3.13). 
Both labels were incubated at various count rates (100,000, 
200,000 and 400,000 cpm/0.2 ml) with buffer ( ' o '  TSH
standard) and 30 mU/1 TSH and the signal:noise ratios 
calculated (Table 3.11). All blanks were higher than 
expected due to the washing procedure not being optimised at
TABLE 3.10
DETERMINATION OF ISOTYPE
ANTIBODY ISOTYPE
5H8 IgGl
2G2 IgGl
TQ5 IgG2a
TR2 IgG2b
TS5 IgG2b
4F12 IgG2a
5H8 0.25 mCi
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Figure 3.13
Profiles from the iodination of monoclonal antibody 5H8 with 0.25 
and 0.5 mCi 125I
TABLE 3.11
EFFECT OF SPECIFIC ACTIVITY AND LABEL MASS ON ASSAY SIGNAL: 
NOISE RATIO
21 pCi/pg LABEL 
COUNTS ADDED APPROX. MASS OF LABEL SIGNAL: 
NOISE RATIO 
(30/0)
400/000 cpm 
200/000 cpm 
100/000 cpm
16 ng 
8 ng 
4 ng
4.2
11.0
20.0
9 pCi/pg LABEL 
COUNTS ADDED APPROX. MASS OF LABEL SIGNAL: 
NOISE RATIO 
(30/0)
400/000 cpm 
200/000 cpm 
100/000 cpm
40 ng 
20 ng 
10 ng
3.1
8.8
13.0
this stage but the results strongly suggested that the higher 
specific activity label at 100,000 cpm/tube (approximately 4 
ng) would render the better assay system and was therefore 
used in future experiments.
DEVELOPMENT OF A TWO-SITE IRMA FOR SERUM TSH EMPLOYING 
LABELLED MONOCLONAL ANTIBODIES AND SOLIP-PHASE POLYCLONAL 
ANTISERA
a) INTRODUCTION
In the optimisation of a two-site assay it is necessary 
to consider chiefly the achievable sensitivity and 
breadth of working range, together with speed and 
convenience. The factors which affect assay performance 
include affinity and concentration of antibodies, 
specific activity of labelled antibody, magnitude of 
non-specific binding, incubation times and technical 
reproducibility (Ekins, 1981; Hunter et al, 1982, 1983; 
Jackson et al, 1983). In reality, the optimum 
conditions chosen are a compromise between the 
conflicting requirements of sensitivity, working range 
and speed.
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b) CELLULOSE OR SEPHAROSE AS SOLID-PHASE MATERIAL?
Buffer standard curves (0-100 mU/1 TSH (WHO 80/558) in 
0.1 mol/1 borate buffer pH 8.0 containing 0.5% normal 
sheep serum, 0.2% Tween 20 and 0.05% sodium azide) were 
set up in duplicate using monoclonal antibody 5H8 as the 
labelled reagent. Standard and label were incubated for 
90 minutes at ambient temperature prior to 90 minutes 
agitation with either cellulose or Sepharose solid-phase 
polyclonal TSH antibody (SI 17, Scottish Antibody 
Production Unit, Law Hospital, Carluke, Lanarkshire). 
Figure 3.14 displays standard curves obtained adopting 
this protocol. A lower non-specific binding (0.32%) and 
a higher specific binding (46%) was achieved with the 
Sepharose solid-phase in comparison with the cellulose 
preparation (0.68% and 39% respectively). As a result 
of this the signal:noise ratio for Sepharose was more 
than double (146) that for cellulose (58). The results 
suggested that Sepharose was a better solid-phase matrix 
for this system than cellulose because of its apparent 
greater capacity for coupling antibody, and its lesser 
tendency to bind material non-specifically.
c) INCUBATION PROTOCOL OPTIMISATION
For simplicity, single-step incubation protocol was 
attempted with a 60 minute agitation incubation with 
Sepharose solid-phase antibody. However, the binding
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Figure 3.14
Standard curves with cellulose and Sepharose as the solid-phase 
material
achieved was poor, of the order of 16%, and the non­
specific binding high, 0.5%, giving a signalrnoise ratio 
of only 32 and an insensitive assay (Figure 3.15).
Standard curves (0-100 mU/1 TSH) were performed with 
cellulose and Sepharose solid-phase antibodies to 
optimise the first incubation step (incubation of 
standard with labelled antibody). Incubation times of 
30 minutes, 1 hour, 3 hours and 5 hours were selected 
with the agitation incubation remaining constant at 90 
minutes. Non-specific binding ranged from 0.41% 
(Sepharose, 1 hour) to 0.90% (cellulose, 5 hours). 
Specific binding ranged from 28% (cellulose, 30 minutes) 
to 44% (Sepharose, 5 hours) (Figure 3.16). The optimal 
signal:noise ratio was achieved with the 1 and 3 hour 
Sepharose systems and a 2 hour first incubation step was 
therefore adopted.
However, although the specific binding looked promising 
for such a system, the non-specific binding was still 
unusually high for a two-site IRMA employing a 
monoclonal antibody. A possible explanation for the 
high blank phenomenon was inadequate washing of the 
assay, 3 washes being the adopted protocol to date. As 
a quick, simple experiment, before proceeding to 
optimise the agitation incubation, the Sepharose (1 
hour) curve was further washed, resulting in an
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Figure 3.15
Standard curve produced after a single-step incubation protocol was 
attempted with a 60 minute agitation incubation with Sepharose 
solid-phase antibody
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Optimisation of first incubation step (incubation of standard with 
labelled antibody) with cellulose and Sepharose solid-phase antibodies
improvement in the non-specific binding from 0.41% to 
0.16% and in signal:noise ratio of 92 to 225 (Figure 
3.17).
Standard curves (0-100 mU/1 TSH) were performed with 
both cellulose and Sepharose solid-phase antibodies to 
optimise the agitation incubation. Incubation times of 
30 minutes, 1 hour, 3 hours, 5 hours and 17 hours for 
both solid-phase matrices were selected, the first 
incubation remaining constant at 2 hours. Figure 3.18 
displays the curves obtained. Non-specific binding 
ranged from 0.09% (Sepharose, 1 hour) to 0.27% 
(cellulose, 17 hours). Signal:noise ratios ranged from 
101 (cellulose, 17 hours) to 381 (Sepharose, 3 hours). 
However, there was little difference between the 
signaltnoise ratios for Sepharose, 3 hours (381) and 
Sepharose , 1 hour (365). As a consequence of this, and 
to suit the working day of the routine laboratory, an 
overall incubation protocol of 2 hours first incubation, 
followed by a 1 hour agitation with Sepharose solid- 
phase antibody, was adopted.
OPTIMISATION OF NUMBER OF WASHING STEPS
A TSH standard curve was performed under optimum 
incubation conditions. Post agitation the assay tubes 
were washed 3 to 9 times with 2 ml volumes of Isotonic 
saline containing 0.2% Tween 20, the radioactivity being
40 i
% Bound
30-
20 -
3 Washes
4 Washes
IQ-
10 100 1000.01 1 1
TSH mU/L
Figure 3.17
Dose-response curves obtained after 3 and 4 washes
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Figure 3.18
Optimisation of the agitation incubation with cellulose and Sepharose
solid-phase antibodies
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counted after each washing stage. Washing 3 times was 
found to be totally inadequate, giving a blank of 0.48% 
(Figure 3.19) and a signal:noise ratio of 71. Four 
washes improved the system, yielding a blank of 0.13% 
and a signal:noise ratio of 254. No further 
improvements were seen after 6 washes (blank 0.04%, 
signal:noise ratio 733).
e) OPTIMISATION OF WASH VOLUME
Standard curves were washed three and four times with 2 
ml and 2.5 ml volumes of isotonic saline containing 
0.2% Tween 20. Results are shown in Figure 3.20. As 
before, 3 washes were found to be inadequate although a
slight improvement was observed with greater wash 
volume. With 4 washes, an increase in wash volume 
reduced the blank from 0.13% (signal:noise ratio 294) to 
0.08% (signalinoise ratio 503) with the potential of 
producing a very sensitive system. Further increases in 
wash volume had little effect on the blank level but 3 
washes were found to be sufficient when a wash volume of 
3 ml was used. A similar level of non-specific binding 
was noted when isotonic saline without Tween 20 was used 
as the wash solution. Moreover, increasing Tween 20 
concentrations did not appear to affect the blank 
level.
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Figure 3.19
Dose—response curves obtained after washing 3 to 9 times with 2 ml 
volumes of isotonic saline containing 0.2% Tween 20
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Dose-response curves obtained after washing three and four times 
with 2 ml and 2.5 ml volumes of isotonic saline containing 0.2% 
Tween 20
OPTIMISATION OF BUFFER SYSTEM
Standard curves (0-100 mU/1 TSH) were performed in
various buffers, 0.05 mol/1 phosphate pH 7.4, 0.05 mol/1 
phosphate pH 7.4 containing 0.9% NaCl, 0.05 mol/1
barbitone pH 8.6, 0.1 mol/1 EPPS pH 8.0 and 0.1 mol/1 
borate pH 8.0. All buffers also contained 0.5% normal 
sheep serum, 0.2% Tween 20 and 0.05% NaN3 « Similar 
standard curves were obtained for all buffer systems
with the exception of phosphate pH 7.4 which gave a high 
blank (0.44%) and poor specific binding, of the order of 
15% (Figure 3.21). On the basis of ease of preparation
EPPS, pH 8.0 was chosen as assay diluent.
LABEL REPURIFICATION
Aliquots (1 ml) of labelled 5H8 were subjected to 
repurification by column chromatography (Sepharose 6B) 
(Figure 3.22) and by end over end rotation for 10 
minutes with Amberlite, 10 and 30 days post iodination, 
in an attempt to increase the shelf-life of the label. 
Figure 3.23 displays standard curves obtained 10 days 
post iodination for untreated, Amberlite treated and 
column repurified 5H8. The results indicated that after 
10 days little or no benefit was to be gained by label 
repurification. However, after 30 days storage of 
label, specific binding was vastly improved by 
treatment with Amberlite (10% to 17%) and further
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Optimisation of buffer system
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Repurification of labelled 5H8 by column chromatography (Sepharose 6B)
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Standard curves obtained 10 days post iodination for untreated/ 
Amberlite treated and column repurified 5H8
improved to 25% after column repurification (Figure 
3.24). No detrimental effect on non-specific binding 
with label age was observed.
PARALLELISM
Serum samples from six hypothyroid patients were 
serially diluted in assay buffer (EPPS, pH 8.0), and 
assayed in duplicate against a buffer standard curve (0- 
100 mU/1 TSH). Results of 2 of such samples are shown 
in Figure 3.25, indicating that hypothyroid serum 
samples diluted in parallel to the buffer standard 
curve.
HIGH-DOSE HOOK EFFECT
At very high antigen concentration many 
immunoradiometric assays show a phenomena which is 
known as the 'high-dose hook effect'. In this 
situation, where the labelled antibody can only bind a 
fraction of the total antigen concentration, a maximum 
signal is only achieved provided that the antigen 
concentration does not exceed the capacity of the solid- 
phase. When the antigen concentration exceeds the 
capacity of the solid-phase there is a progressive loss 
of signal. This leads to a falsely low antigen 
concentration being measured. For this reason an
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Figure 3.24
Standard curves obtained 30 days post iodination for untreated/
Amberlite treated and column repurified 5H8
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Parallelism studies with serum from 2 hypothyroid patients
examination of whether such an effect takes place must 
be performed before increasing the range of the standard 
curve. An extended buffer standard curve was performed 
covering the range 0-500 mU/1 TSH. Such a curve is 
shown in Figure 3.26. At a standard concentration of 
around 250 mU/1 TSH, the curve began to plateau. This 
was not considered to be a problem since this TSH level 
was generally much higher than the patients' samples to 
be measured.
RECOVERY OF ADDED I.R.P.TSH (WHO 80/558)
In principle, solutions of standard must be diluted in 
the same medium as constitutes the samples to be added
in the assay. For measurement of human serum samples it
is therefore necessary to have access to analyte-free 
serum for standard preparations unless it can be shown
that there are no non-specific serum effects compared
to a chosen buffer medium, on the assay reactions.
Traces of immunoreactive material were removed from 
human serum by immunoadsorption using 100 mg Sepharose 
solid-phase TSH polyclonal antibody. Serum (100 ml) was 
rotated end over end overnight with the Sepharose
preparation, centrifuged for 30 minutes, and the 
immunoadsorbed serum removed and tested. Untreated 
serum gave a binding level of 1.14%, but following 
immunoadsorption this level was reduced to 0.35%.
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High-dose hook effect
To obtain TSH free serum for recovery pools, 5 healthy 
volunteers were given T3 and the following day 20 ml 
of blood was removed. Aliquots of each of the 5 sera 
were spiked with 1, 10 and 50 mU/1 TSH and assayed 
against buffer and serum standard curves (0-100 mU/1 
TSH) under optimum conditions (Figure 3.27). Results 
are displayed in Table 3.12. Better recoveries were 
obtained with the serum standard curve indicating the 
need for a serum standard matrix.
Spiked sera (3) at 1, 10 and 50 mU/1 TSH were assayed
against 3 different serum standard curves (0-200 mU/1 
TSH), human, horse (Gibco, Paisley, UK) and foetal calf 
(Flow Laboratories, UK) sera. Standard curves are 
displayed in Figure 3.28. Results shown in Table 3.13 
indicated that foetal calf serum was a poor substitute 
for human serum as far as recovery of added TSH was 
concerned. Horse serum, on the other hand, gave 
comparable recoveries to those obtained previously with 
human serum and was subsequently selected for the TSH 
standard matrix because of its availability and cost.
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Figure 3.27
Buffer and serum dose—response curves
TABLE 3.12
RECOVERY OF ADDED I.R.P. TSH 80/558 FROM BUFFER AND 
HUMAN SERUM
SERUM SERUM STD. CURVE BUFFER STD. CURVE
A
1 100% 103%
10 76% 70%
50 89% 70%
B
1 90% 90%
10 80% 69%
50 95% 76%
C
1 70% 70%
10 83% 74%
50 96% 81%
D
1 100% 100%
10 83% 75%
50 96% 79%
E
1 90% 100%
10 87% 78%
50 94% 78%
MEAN = 89% MEAN = 81%
100 1
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Human
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100 10001001 01 1
TSH mU/L
Figure 3.28
Human/ horse and foetal calf serum standard curves
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COMPARISON BETWEEN CENTRIFUGATION AND DENSITY
SEDIMENTATION AS A SEPARATION SYSTEM FOR THE SERUM TSH 
IRMA
Standard curves (0-100 mU/1 TSH) were set up in 
duplicate under optimum conditions. One curve was 
separated by the usual centrifugation method (3 x 3 ml 
washes with isotonic saline), the other by density 
sedimentation ( 2 x 3  ml washes with 10% sucrose), as 
described in Chapter 2, Section Vd. Standard curves for 
both systems are shown in Figure 3.29. No difference in 
specific binding was noted between systems, but a vast 
improvement in non-specific binding resulted with the 
density sedimentation system over the centrifugation
system. Precision profile analysis (intra-assay)
(Chapter 1, Section IIIc) was performed, giving 
sensitivities (dose levels at 22% CV) of 0.4 and 0.2 
mU/1 TSH for centrifugation and density sedimentation 
respectively (Figure 3.30). With the centrifugation
system a working range (<10% CV) of 1.2 to 200 mU/1 TSH
was achieved whereas the density sedimentation system 
offered a wider working range of 0.7 to 200 mU/1 TSH.
NORMAL RANGE
To establish a normal range for the TSH two-site IRMA, 
476 normal human serum samples (male and female) were 
obtained from blood donors via the Blood Transfusion
%Bound.
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Figure 3.29
Comparison between centrifugation and density sedimentation as a 
separation system for the serum TSH IRMA
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Figure 3.30
Precision profile analysis (intra—assay) for centrifugation and
density sedimentation separation systems
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Service, Law Hospital, Carluke, Lanarkshire, and each 
sample assayed in duplicate using the density 
sedimentation separation system. Figure 3.31 shows a 
histogram representation of the results produced for the 
476 samples. Figures 3.32 and 3.33 display the normal 
range obtained for males (n=211) and females (n=265) 
respectively. Both groups produced similar sample 
means, 1.51 + 0.73 for males and 1.46 _+ 0.76 for
females. On the basis of this, a normal range (95% of 
the population) of 0.35 to 3.5 mU/1 TSH was 
established, as illustrated in Figure 3.34.
VI DEVELOPMENT OF A TWO-SITE IRMA FOR BLOOD-SPOT TSH EMPLOYING 
LABELLED MONOCLONAL ANTIBODIES AND SOLID-PHASE POLYCLONAL 
ANTISERA
a) INTRODUCTION
An ideal screening assay for neonatal 
hypothyroidism requires to be quick and simple to 
perform, rugged and reliable in routine practice and 
have adequate sensitivity and specificity. With the 
above criteria in mind, the blood-spot assay was 
optimised in a similar manner to that of the serum TSH 
assay.
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Figure 3.31
Histogram representation of the results produced for the 476 normal 
human serum samples (male and female) obtained from blood donors
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Normal range obtained for males (n = 211)
TSH Normal Range / Female
Frequency
30-
20-
10-
0
illr v ir .l.T T .r .r T .r ^r-r T T .r .r .l,..r .l..r  , , v  , , 
O  C\j ^  CD CO T- CVJ TtCO COI CvJ CVJ CD 00 CO CVJ CO O C C \ j CO 00
d d o d  t— t~ t— •»— oJcvicvi oJ coco coco
TSH mU/L
Figure 3.33
Normal range obtained for females (n = 265)
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Figure 3.34
TSH dose-response curve displaying the established normal range
(95% of the population) of 0.35 to 3.5 mU/1 TSH for the serum IRMA
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b) CELLULOSE OR SEPHAROSE AS SOLID-PHASE MATERIAL?
Standard TSH (0-210 mU/1), in the form of a 6 mm
diameter blood-spot, was incubated overnight with 0.2 ml 
labelled 5H8 (100,000 cpm = 4 ng) in 0.1 mol/1 borate pH 
8.0 containing 0.5% normal sheep serum, 0.2% Tween 20 
and 0.05% NaN3 , prior to 90 minutes agitation with 
either cellulose or Sepharose solid-phase polyclonal TSH 
antibody (SI17). The tubes were then washed 4 times 
with 2 ml volumes of 0.9% NaCl containing 0.2% Tween 20. 
Similar results were obtained for both systems, as shown 
in Figure 3.35, each giving a non-specific binding of 
the order of 0.7% and a signal:noise ratio of 35.
c) WASH SOLUTION
Standard curves (0-300 mU/1 TSH) were washed either with 
isotonic saline or isotonic saline containing 0.2% Tween 
20. The results shown in Figure 3.36 indicated that 
there was no requirement for Tween 20 in the wash 
solution for the blood-spot assay, as was the case for 
the serum TSH assay. This was a change brought about by 
the introduction of the monoclonal antibody as label, 
since both serum and blood-spot assays employing 
labelled polyclonal antibodies required Tween 20 in the 
wash solution.
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Figure 3.35
Blood-spot standard curves with cellulose and Sepharose as the solid- 
phase material
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d) EFFECT OF SAMPLE SIZE
Standard curves (0-300 mU/1 TSH) were performed in 
duplicate, either with a 5 or 6 mm diameter disc. 
Results are shown in Figure 3.37. A dramatic decrease 
in specific binding was observed with the 5 mm disc (18% 
to 11%) and a corresponding decrease in signaltnoise 
ratio, indicating the importance of sample size.
e) RECOVERY OF ADDED I.R.P. TSH (WHO 80/558).
TSH was added to TSH free serum, before mixing with 
packed red cells, to give recovery pools with values of 
25, 50 and 100 mU TSH/1 whole blood. These recovery
pools yielded mean recoveries of 96%, 103% and 110% 
respectively when assayed against a blood spot standard 
curve
VI1 2-MONOCLONAL IRMA FOR SERUM TSH
IgG fractions of monoclonal antibodies 2G2, 4F12, TS5, TQ5 
and TR2 were obtained by treating 5 ml volumes of ascitic 
fluid (tap >3) with 0.5 ml caprylic acid (n-Octanoic acid). 
Each monoclonal antibody IgG fraction (10 mg) was then 
coupled to Sepharose C1-4B (20 ml) prior to assay, with 5H8 
as label. A standard curve (0-185 mU/1 TSH) with polyclonal
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Effect of sample size on the blood-spot TSH IRMA
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TSH antibody coupled to Sepharose C1-4B was also set up as a 
control. Results are shown in Figure 3.38. Three of the 
antibodies, TS5, TR2 and TQ5, gave very poor signalrnoise 
ratios of 10, 2 and 2 respectively, compared with that of the 
polyclonal antibody (138). 4F12 yielded a steeper standard
curve with a signal: noise ratio of 44, but the best 
monoclonal antibody system was obtained with 2G2 with a 
signal:noise ratio of 195, as expected from previous avidity 
and specificity studies (Section Illb).
VIII 2—MONOCLONAL IRMA FOR BLOOD-SPOT TSH
The performance of monoclonal antibodies 2G2 and 4F12 was 
assessed in the blood-spot assay, using 5H8 as label and 
Sepharose solid-phase polyclonal TSH antibody as a control. 
Results are shown in Figure 3.39. Similar blanks were 
obtained for all 3 systems, 0.74%, 0.72% and 0.72% for 2G2, 
4F12 and polyclonal antibody respectively. As before, 4F12 
produced a poor signal:noise ratio (9), whereas 2G2 gave a 
signalinoise ratio of 21, which was comparable to that of the 
polyclonal antibody (22).
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Figure 3.38
Dose-response curves obtained with 5 different monoclonal antibodies 
coupled to Sepharose C1-4B solid-phase using 5H8 as label
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Blood-spot standard curves obtained using 5H8 as label with monoclonal 
antibodies 2G2 and 4F12 as solid-phase reagents
COMPARISON OF 3 SYSTEMS FOR THE MEASUREMENT OF TSH IN DRIED
BLOOD AS A SCREENING METHOD FOR NEONATAL HYPOTHYROIDISM
a) INTRODUCTION
The screening procedure adopted for the detection of 
neonatal hypothyroidism, established in Scotland in 1980 
(Sutherland et al, 1981) employed a two-site
immunoradiometric assay (IRMA) for TSH with sheep 
polyclonal antisera as solid-phase and radiolabelled 
reagents (Sutherland et al, 1982). This assay was 
rapid, but the immunoaffinity purification of antisera 
prior to radiolabelling was expensive, tedious and time 
consuming. These disadvantages were overcome by the 
production of several mouse monoclonal antibodies to 
TSH. These were carefully characterised (Section III) 
and the better avidity antibodies, 5H8 and 2G2, 
gradually incorporated into the screening assay as the 
monoclonal antibody production programme evolved.
Initially, an IRMA with 5H8, a monoclonal antibody 
specific to the 8-subunit of TSH as radiolabel and an 
IgG fraction of a polyclonal TSH antiserum (SI17), 
produced by the Scottish Antibody Production Unit, 
covalently linked to Sepharose C1-4B solid-phase was 
devised. Later modification replaced the polyclonal 
antibody with a second monoclonal antibody, 2G2, of 
alternative epitope specificity to that used as the 
radiolabel.
These IRMA variants were compared using precision 
profiles (Chapter 1, Section IIIc) to establish the best 
combination to use as a screening method for neonatal 
hypothyroidism.
METHOD
Blood-spots (5 or 6 mm diameter discs) were incubated 
for 16 hours at ambient temperature with 0.2 ml of 
labelled antibody. The assay tubes were then agitated 
for 90 minutes with 0.2 ml of solid-phase antibody 
(approximately 1 mg) prior to 4 wash/centrifuge cycles 
with 3 ml of isotonic saline. The tubes were then 
counted for one minute, the total assay time being less 
than 24 hours.
RESULTS
Standard curves and precision profiles are illustrated 
in Figure 3.40 to Figure 3.42 for all IRMA variants 
using 5 and 6 mm blood-spots. The results obtained are 
summarised in Table 3.14. The IRMA employing a
monoclonal antibody as radiolabel and a solid-phase 
polyclonal antibody appeared to be the best combination 
with respect to precision and sensitivity. No further 
improvements were observed with the introduction of a
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Figure 3.40
Dose-response curve and precision profile for the polyclonal/poly­
clonal IRMA using a 6 mm blood-spot
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Dose-response curves and precision profiles for the monoclonal/ 
polyclonal IRMA using 5 and 6 mm blood-spots
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TABLE 3.14
COMPARISON OF 3 SYSTEMS FOR THE MEASUREMENT OF TSH IN DRIED 
BLOOD AS A SCREENING METHOD FOR NEONATAL HYPOTHYROIDISM
2 POLYCLONAL 
IRMA
MONO./POLY. 
IRMA
2 MONOCLONAL 
IRMA
SENSITIVITY 10 (6 mm) 5 (6 mm) 7 (6 mm)
(mU/L) 9 (5 mm) 11 (5 mm)
C.V. <10% 27-210 (6 mm) 23-375 (6 mm) 23-375 (6 mm)
(mU/L) 31-375 (5 mm) 31-375 (5 mm)
BLANK 3.4 (6 mm) 0.72 (6 mm) 0.74 (6 mm)
(%) 0.69 (5 mm) 0.60 (5 mm)
200/0 6 (6 mm) 15 (6 mm) 16 (6 mm)
RATIO 10 (5 mm) 11 (5 mm)
second monoclonal antibody. However, the development of 
the two-site IRMA for TSH using two monoclonal 
antibodies directed against different epitopes raises 
the possibility, currently under exploration of adapting 
the system to microtitre plate technology.
CHAPTER 4
CLINICAL ASSESSMENT OF THE MONOCLONAL - POLYCLONAL IRMA AS APPLIED 
TO THE MEASUREMENT OF TSH IN HUMAN SERUM
I INTRODUCTION
The measurement of TSH in serum is now to be regarded as a 
routine test in most Clinical Biochemistry Laboratories in 
the UK. The reason for this relates to the key role of TSH 
in thyroid physiology (Chapter 1, Section IV). An individual 
with no history or symptoms of thyroid disease will have a 
detectable TSH within fairly tightly defined limits, the 
release of TSH will be pulsatile and a diurnal rhythm will 
exist. As a result T4 and T3 are controlled within 
euthyroid reference ranges.
Thyroid disease is very common, occurring in over 2% of the 
population, especially in middle aged women (F:M ratio 12:1) 
(Hall et al, 1980). In adults there are basically three 
types of thyroid disease
(1) goitre - this is a swelling of the neck and can either 
be diffuse or focal. It is often not accompanied by 
abnormal thyroid hormone secretion, therefore, the TSH 
level is normal and for this reason this type of thyroid 
disease is not discussed further.
hypothyroidism - this is almost always primary in 
origin, characterised biochemically by a low T4 and a 
raised TSH. OccQ^i crvalWj
hypothyroidism is autoimmune with the production of 
blocking auto-antibodies which bind to the TSH receptor 
but do not mimic TSH action. The clinical features 
include lack of energy, cold intolerance, dryness of the 
skin and hair, weight gain, constipation, hoarseness of 
the voice, typical facial appearance and prolongation of 
the relaxation phase of the tendon reflexes. All 
patients with symptomatic hypothyroidism require therapy 
with T4 .
hyperthyroidism (thyrotoxicosis) - in the UK this is 
almost always primary in origin, characterised 
biochemically by a raised T4 and T3 and a low TSH. The 
3 main presentations in the UK are Graves' Disease, 
toxic multinodular goitre and single thyroid toxic 
adenoma. The aetiology of hyperthyroidism is commonly 
auto-immune with the production of thyroid stimulating 
auto-antibodies. The clinical features include heat 
intolerance, weight loss, diarrhoea, irritability and 
nervousness. Hyperthyroidism can be treated with 
anti thyroid drugs, radioactive iodine or by surgery to 
remove part of the thyroid gland. From the above it 
will be clear that serum TSH in association with some 
index of T4 (or FT4 ) or T3 (or FT3 ) status is vital in 
the investigation of thyroid disease. Numerically TSH
assays are used most frequently to a) exclude thyroid 
disease in view of the non-specific symptoms referred to 
above, b) monitor the treatment of thyroid disease and 
c) diagnose thyroid disease.
The remainder of this Chapter seeks to illustrate the 
clinical role and suitability of the monoclonal- 
polyclonal serum TSH assay developed in this project and 
described in detail in Chapter 3, Section V.
DIAGNOSTIC VALUE OF THE MONOCLONAL - POLYCLONAL SERUM TSH 
ASSAY
a) INTRODUCTION
In order to demonstrate the clinical value of the 
developed assay, the TSH reference ranges need to be 
established in unequivocal untreated thyroid disease.
b) PATIENTS AND METHODS
Serum samples from a total of 170 patients attending the 
Thyroid Clinic at Glasgow Royal Infirmary, collected and 
stored from the time of the initial diagnosis of their 
thyroid disease, were studied. Of these, 109 were 
diagnosed as having primary hypothyroidism on the basis
of their symptoms, a low or low normal serum T4 result 
and an elevated serum TSH result in the polyclonal - 
polyclonal IRMA previously used routinely in this 
laboratory. The remaining 61 subjects were diagnosed as 
having hyperthyroidism on the basis of their symptoms 
and an elevated serum total T4 and/or serum total T3 
(reference range for T4 = 55-144 nmol/1 and T3 = 0.9-
2.8 nmol/1). Serum TSH was analysed in these serum
samples by the developed monoclonal polyclonal assay.
RESULTS
The TSH levels obtained are displayed in Figure 4.1. 
The reference value obtained from 476 blood donors 
(Chapter 3, Section V.L) is displayed as a shaded 
area. It is clear that the monoclonal - polyclonal 
serum TSH assay successfully distinguishes all cases of 
primary hypothyroidism as having an elevated serum TSH 
and all cases of hyperthyroidism as having an 
undetectable serum TSH (<0.2 mU/1 - Chapter 3,
Section V.K).
DISCUSSION
The monoclonal - polyclonal In-house IRMA performs as
might be expected from our understanding of thyroid 
physiology and literature about other TSH assays. On
the basis of this information, together with the
.01
Hypo Hyper
Figure 4.1
TSH reference ranges in unequivocal untreated thyroid disease. The 
shaded area represents the reference value obtained from 476 blood 
donors
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performance data described in Chapter 3, the assay was 
introduced in 1984 as the 'routine' serum TSH assay for 
the laboratory at Glasgow Royal Infirmary, processing 
some 20,000 serum specimens per annum.
Ill COMPARISON OF IN-HOUSE IRMA WITH COMMERCIALLY AVAILABLE 
ALTERNATIVES (1984/85)
a) INTRODUCTION
During the period of development of the In-house TSH 
IRMA a number of commercial immunometric assay systems 
for measuring serum TSH became available. It was 
considered important to compare both the clinical and 
technical performance of the in-house assay with these 
systems. Three such systems were chosen for this study 
and each will be described briefly below. In each case 
a minimum of 6 kits (600 tubes/wells) were evaluated 
with a protocol that aimed to assess intra-assay 
precision and accuracy from a variable number of 
clinically defined serum samples. Because of the timing 
of these comparisons it was not possible to measure the 
TSH from the same serum samples in all four assays.
COMMERCIAL TSH METHODS EMPLOYED:
1) TSH IRMA MAIACLONE (SERONO DIAGNOSTICS LTD)
This is a magnetic antibody immunoradiometric
method. Standard (0.5, 1.0, 5.0, 10, 30 and 50
ulU/ml) or sample (0.2 ml) was incubated with 0.1 
ml 125i Anti-TSH reagent for 2 hours at room 
temperature. TSH IRMA Separation Reagent (0.2 ml) 
was added and the tubes agitated prior to 
incubation for 5 minutes, again at room 
temperature. The tubes were then placed in the 
Magnetic Separator for 2 minutes and the 
supernatant decanted (Figure 4.2). Finally, the
tubes were washed in phosphate-saline buffer 
containing BSA and NaN3 (0.5 ml) before counting 
for at least 2 minutes.
2) SUCROSEP™ TSH IRMA (BOOTS-CELLTECH DIAGNOSTICS
LTD)
The TSH IRMA that was originally developed at 
Boots-Celltech was based on the non-centrifugation 
sucrose separation system (SUCROSEP^). Standard 
or sample (0.1 ml) was reacted with 125i_iaben e<j 
antibody to produce an antibody-antigen complex. 
Subsequently, a second antibody, coupled to solid- 
phase, which recognises a second, distinct epitope 
on the analyte was added. The solid-phase of the
1. SLIDE IN 2. STAND 2 MIN
4. TAP FIRMLY ON BLOTTER3. DECANT SLOWLY
Figure 4.2
TSH IRMA MAIACLONE magnetic separation technique
SUCROSEP™ assay is based on Pharmacia's Sephacryl 
S300. Separation was brought about by employing 
the sucrose layering technique developed by Hunter 
(Wright and Hunter, 1983) (Figure 4.3). Sephacryl 
S300 solid-phase falls relatively quickly under 
gravity without the need for centrifuges or rare 
earth magnets. Agitation was required during the 
incubation period to maintain the solid-phase in 
suspension and allow the reaction to proceed (1) At 
the end of the incubation, wash buffer was added 
and the solid-phase was allowed to settle for about 
5 minutes (2) This step enhances separation 
efficiency. A relatively dense sucrose solution 
(10%) was then layered below the incubate by 
running it through a hollow probe resting on the 
bottom of the tube (3) This raises the incubate 
above the sucrose layer and lifts the solid-phase 
(bound fraction) at the interface of the two 
layers. Over a period of 15 minutes the 
particulate solid-phase falls through the sucrose, 
leaving behind the incubate and the remaining 
labelled antibody (free fraction) (4) The upper 
layer of incubate and most of the sucrose were 
removed by aspiration through a second probe (5) 
This left 0.3-0.5 ml of sucrose containing all the 
solid-phase at the bottom of the tube, ready for 
counting (6) For optimum sensitivity and precision 
this separation procedure was repeated.
Figure 4.3
TM
The principle of SUCROSEP separation (see text for details)
DELFIA™ TSH IFMA (PHARMACIA DIAGNOSTICS LTD)
'DELFIA™' is a solid-phase, two-site 
immunofluorometric assay (IFMA) which employs two 
monoclonal antibodies directed against different 
antigenic determinants on the 6 subunit of the TSH 
molecule. One monoclonal antibody is physically 
adsorbed to a microtitre strip-well in which the 
assay is performed. The other monoclonal antibody 
is labelled with a europium (Eu) chelate. 
Europium is the label of choice because it has a 
wide excitation wavelength band, a narrow emission 
wavelength band, a large Stokes shift and a long 
fluorescence decay time relative to other 
conventional fluorophores. Before measuring 
fluorescence, an enhancement solution is added to 
promote the dissociation of Eu-^ + cations from the 
labelled antibody into solution where they form 
highly fluorescent chelates with components of the 
enhancement solution. Non-specific background 
fluorescence is minimised by counting in the time- 
resolved mode, whereby a delay of 400 us elapses 
after excitation prior to measurement of the 
fluorescence. During this delay, virtually all 
short-lived fluorescence disappears. The whole 
excitation/counting cycle is completed in Is. A 
flow chart for the method appears in Figure 4.4.
96-Well Microtitre plate 
Wells coated with anti-TSH monoclonal Ab
i'
Wash once 
(Skatron strip washer)
Eu-labelled anti-TSH 
monoclonal Ab
Shake at R.T. for 4 hrI
Wash six times
200 i'll
Enhancement solution
Shake for 1 min 
Cover for 15 mins
I
Measure fluorescence counts in ARCUS 1230 FLUOROMETER
J
Results print-out
TOTAL ASSAY TIME - 5 hr 30 min
QC's
Samples
Standards
(0/0.25/1.5,9.0,54,324)
50 pi
200 pi
Figure 4.4
TM
Flow chart of DELFIA TSH assay protocol
RESULTS
Typical standard curves and intra-assay precision 
profiles for the TSH IRMA MAIACLONE, SUCROSEP™ TSH 
IRMA, and DELFIA™ TSH IFMA are displayed in Figures 
4.5, 4.6 and 4.7 respectively. The mean intra-assay
imprecision data obtained for each assay system 
displayed in Table 4.1. Linear regression analysis was 
performed on the results obtained from each of these 
commercial TSH assays with the corresponding results 
from the In-house polyclonal - monoclonal IRMA and this 
data is summarised in Table 4.2. The serum TSH results 
obtained from each assay in defined clinical situations 
are presented as follows: euthyroid reference value in 
Table 4.3, reference value for individuals with various 
non-thyroidal illnesses in Table 4.4, subjects with 
untreated hypothyroidism in Table 4.5 and subjects with 
untreated thyrotoxicosis in Table 4.6.
DISCUSSION
The objective of this study was to compare the 
practicability and performance of four high sensitivity 
TSH assays. Whilst all four assays showed 
characteristics much improved from traditional
radioimmunoassays for TSH, no single high sensitivity 
TSH assay out-performed its competitors. An assay by 
assay summary is given below:
TSH IRMA MAIACLONE
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Figure 4.5
Typical standard curve and intra-assay precision profile for the 
TSH IRMA MAIACLONE
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Figure 4.6
Typical standard curve and intra-assay precision profile for the 
SUCROSEP™ TSH IRMA
DELFIA™ TSH IFMA
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Figure 4.7
Typical standard curve and intra-assay precision for the DELFIA
TSH IFMA
TABLE 4.1
MEAN INTRA-ASSAY IMPRECISION DATA OBTAINED FOR FOUR DIFFERENT SERUM 
TSH ASSAYS
Euthyroid Hypothyroid
Assay Mean-mU/1 Mean-mU/1
(CV) (CV)
In-house IRMA 1.63 26.8
(7.3%) (4.7%)
TM
DELFIA hTSH 1.20 82.1
(6.3%) (3.9%)
TSH MAIACLONE 1.34 17.1
(4.5%) (3.1%)
TM
SUCROSEP TSH 0.61 42.3
(10.6%) (3.2%)
TABLE 4.2
CORRELATIONS WITH IN-HOUSE IRMA
Assay n m c r
DELFIA™ hTSH 45 1.04 +0.06 0.991
TSH MAIACLONE 45 1.10 +0.52 0.995
TM
SUCROSEP TSH 45 1.05 +0.73 0.964
TABLE 4.3
EUTHYROID REFERENCE RANGE FOR SERUM TSH
Assay Mean (mU/1) Range (mU/1) n
In-house IRMA 1.51 0 . 3 5 - 3 . 5 0  476
DELFIA™ hTSH 1.52 0.47 - 3.84 83
TSH MAIACLONE 2.40 0.5 - 8.5 57
TM
SUCROSEP TSH 2.46 0 . 2 1 - 8 . 0  70
TABLE 4.4
SERUM TSH VALUES IN NON-THYROIDAL ILLNESS
Assay Mean (mU/1) Range (mU/1) n
In-house IRMA 1.60 <0.13 - 4.9 21
DELFIA™ hTSH 1.63 0.12 - 4.1 21
TSH MAIACLONE 2.26 0.26 - 6.1 21
TM
SUCROSEP TSH 2.21 0.22 - 5.7 21
TABLE 4.5
SERUM TSH VALUES IN UNTREATED PRIMARY HYPOTHYROIDISM
Assay Range (mU/1) n % >Top Std.
In-house IRMA 8.1 - >185 116 1.8
TM
DELFIA hTSH 15 - >324 28 3.6
TSH MAIACLONE 8.0 - >50 33 32
TM
SUCROSEP TSH 8.4 - >240 58 14
TABLE 4.6
SERUM TSH VALUES IN UNTREATED THYROTOXICOSIS
Assay 2.5 SD Sensitivity n n > Sensitivity
(mU/1)
In-house IRMA 0.13 43 -
T'M
DELFIA hTSH 0.022 46 1 (0.05)
TSH MAIACLONE 0.20 21 1 (0.50)
TM
SUCROSEP TSH 0.06 41
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1) IN-HOUSE IRMA
This assay uses a practicable 0.1 ml serum sample 
to achieve a sensitivity of 0.13 mU/1 (+ 2.5 SD) 
and a working range (<10% CV) of 0.65 - 185 mU/1.
The assay requires relatively complex 
manipulations and all reagents have to be made 
locally. However, it is very much cheaper to run 
than the commercial kits (4 p per tube excluding 
labour). The assay also tends to read 
approximately 5% lower than the other assays and 
has poor precision on a 0.30 mU/1 recovery pool.
2) TSH MAIACLONE
This IRMA is heavy on serum (0.2 ml) and requires 
at least one additional standard to extend the 
working range beyond 50 mU/1. TSH MAIACLONE is the 
least sensitive of the assays tested (0.20 mU/1 [+ 
2.5 SD]) but appears to have adequate sensitivity 
for clinical discrimination. The kit struggles to 
achieve good precision on a low level recovery 
pool, but it is simple to use and relatively cheap 
to run (62 p per tube).
SUCROSEP™ TSH
This kit uses a convenient sample volume (0.1 ml) 
to achieve a very wide working range of 0.60 - 254 
mU/1 and a sensitivity of 0.06 mU/1 (+ 2.5 SD). 
However, the assay is rather 'clumsy^ to perform. 
SUCROSEP™ TSH is a medium cost assay (70 p per 
tube) that is capable of excellent clinical 
discrimination.
DELFIA™ hTSH
This kit employs only 0.05 ml of serum to achieve a 
sensitivity of 0.02 mU/1 (+ 2.5 SD) and a working 
range (<10% CV) of 0.20 - 324 mU/1. It requires at 
least one additional standard. The kit is easy to 
use, although thorough washing is vital for optimal 
performance. At a list price of 100 p per tube, 
the DELFIA™ hTSH kit is too expensive for many 
laboratories.
Considering the small numbers of specimens 
analysed, the intra-assay imprecision data 
obtained on all TSH assays tested was satisfactory. 
The correlation coefficient obtained from the 
comparisons with the In-house IRMA indicated 
excellent ranking of specimens in all cases. 
However, the gradient from the linear regression 
analyses differed for each of the assays. This
fact is borne out by the different euthyroid 
reference values obtained (Table 4.3) and this 
formed the basis of the next Study to be described 
in this Chapter.
As far as the euthyroid reference range was 
concerned, the TSH MAIAC L O N E  and S U C R O S E P ™  TSH 
yielded higher results than the other two methods 
(Table 4.3). However, discrimination between 
clinical groups for untreated patients was 
excellent with all methods (Table 4.5 and 4.6). 
Samples from patients with non-thyroidal illness 
(n=21, mean T4 = 49 nmol/1; mean T3 = 0.3 nmol/1)
were also subjected to analysis by all 4 methods 
and a separate reference range established (Table 
4.4). In all cases this reference range agreed 
well with the corresponding euthyroid reference 
range displayed in Table 4.3.
The results from this study were presented at the 
1986 Meeting of the UK EQAS participants held in 
Cardiff.
A STUDY OF POTENCY DIFFERENCES IN IMMONOMETRIC ASSAYS FOR
SERUM TSH
a) INTRODUCTION
Whilst comparing the TSH results obtained with the 
polyclonal-polyclonal and monoclonal-polyclonal In-house 
assays and the commercially available assays described 
in the previous section, it became apparent that there 
was a variable bias between the results obtained from 
these assays. To investigate this systematically a 
study was designed.
b) PATIENTS AND METHODS
This study was divided into two sections. Four 
different serum TSH assays were employed in each section 
of the study - (i) In-house polyclonal-polyclonal IRMA 
(ii) In-house monoclonal-polyclonal IRMA (iii) 
SUCROSEP™ TSH IRMA (iv) DELFIA™ TSH IFMA.
In the first section of the study formal recovery 
experiments were performed for each of the TSH assays 
examined using different additions of the 2nd 
International Reference Preparation for TSH (WHO 
80/558).
In the second section of the study ten women, newly 
diagnosed for primary hypothyroidism were studied prior 
to any replacement thyroxine and following one month of 
regular replacement with each of three daily doses of 
thyroxine (i) 0.05 mg (ii) 0.01 mg (iii) 0.15 mg.
RESULTS
1) RECOVERY OF ADDED TSH 80/558
Recovery experiments were performed at three
different levels of added TSH for each of the four
assays. The data displayed in Table 4.7 w
obtained from ten replicates in every experiment.
Within the precision limits of the study it can be 
concluded that all four assays recover added TSH
quantitatively.
2) SERUM TSH LEVELS IN UNTREATED AND TREATED HYPO­
THYROIDISM
Table 4.8 records the mean serum TSH result (+_SEM)
obtained from the ten hypothyroid women prior to
and following stepwise replacement therapy with T4 . 
For each assay the untreated mean serum TSH level 
is taken as 100% and the mean serum TSH level for 
each replacement dose is expressed as a percentage 
of this. It is apparent that there are marked
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differences between assays in the measured levels 
of TSH in the untreated hypothyroid subjects. 
However, the percentage suppression of TSH with 
each successive dose of T4 agrees very well between 
assays.
DISCUSSION
The results confirm a systematic difference between 
measured TSH levels and may help to explain the 
differences in reference values observed in the previous 
study. A likely explanation for this phenomenon is that 
differences exist between the carbohydrate content of 
I.R.P. TSH and that of circulating TSH. The extent of 
the observed difference is determined by the antibodies 
used in each assay. In particular, monoclonal 
antibodies will only recognise a single epitope on the 
TSH molecule and the affinity of binding of this epitope 
may well differ according to the nature of carbohydrate 
moieties attached to the protein backbone of the TSH 
molecule. It is quite probable that the carbohydrate 
content of TSH 80/558 will have been modified during its 
isolation and purification. In the absence of an 
independent assessment of the true accuracy of a TSH 
assay, validation must rely upon the ability to recover 
80/558. By this latter criterion all four of the TSH
184.
assays studied were valid but it is not possible to 
determine which, if any, of them measures the "true' 
serum TSH level.
This work was presented at the 1985 British Endocrine 
Societies' Meeting in Oxford and was the first 
documented example of such potency differences which 
are now widely recognised for glycoprotein hormones such 
as TSH, LH, FSH and tumour markers such as 
carcinoembryonic antigen (CEA).
V EVALUATION OF THYROID FUNCTION SCREENING TESTS IN THE 
SCOTTISH AUTOMATED FOLLOW-UP REGISTER
a) INTRODUCTION
The Scottish Automated Follow-up Register (SAFUR) is a 
computerised follow-up scheme providing a service for 
over 8,000 patients derived from endocrine clinics in 
five main hospital centres. All abnormal results are 
screened by a thyroid specialist after the first contact 
and before the final decision is made on further 
investigation and treatment (Hedley et al, 1984; Toft, 
1983).
The principal aim of this study was to evaluate the 
clinical and economic benefits of using new technology 
thyroid function tests (immunoradiometric assay and 
immunofluorometric assay), compared to the conventional 
radioimmunoassays for TSH and T4 .
PATIENTS AND METHODS
1) Phase 1: 1135 consecutive specimens were obtained
from the SAFUR during 1985/86. The vast majority
of these were from patients who had been treated
previously by radioiodine, surgery or drugs for 
thyrotoxicosis. At the time of sampling 711 
subjects were receiving maintenance thyroxine. The 
remaining 424 were receiving no therapy.
Serum total T4 was measured by conventional RIA in 
the Department of Chemical Pathology at Aberdeen 
Royal Infirmary under the direction of Dr Ivan 
Reid. Serum TSH was measured in Glasgow by two 
methods - (i) In-house monoclonal-polyclonal IRMA 
and (ii) DELFIA IFMA.
2) Phase 2 : As a result of the data obtained in Phase 
1 , it was decided to study a smaller number of 
subjects in depth. Accordingly six categories of 
subject were defined on the basis of the TSH 
results obtained with the In-house IRMA:
(i) Thyroxine TSH <0.35 mU/1
(ii) Thyroxine TSH 0.35 - 3.50 mU/1
(iii) Thyroxine TSH >3.50 mU/1
(iv) Non-thyroxine TSH <0.35 mU/1
(v) Non-thyroxine TSH 0.35 - 3.50 mU/1
(vi) Non-thyroxine TSH >3.50 mU/1
The main computer at the University of Glasgow was 
used to allocate the 1135 specimens from Phase 1 of 
the study into each of these six categories and to 
present them in random order within each category. 
The first 37 specimens from each category (with 
adequate serum volume >1 ml) were selected for 
further study. In one category, only 34 specimens 
were available for further study.
Serum total T4 and two measurements of TSH were 
already to hand from Phase 1 of the study. In 
addition, serum free thyroxine (FT4 ) and free tri­
iodothyronine (FT3 ) were measured using the 
appropriate Amerlex-M radioisotopic assay (Amersham 
International pic).
RESULTS
1) Phase 1: The serum T4 results obtained from the
1135 specimens covered a wide range of values (66- 
265 nmol/1). The agreement between the TSH results 
obtained by the two methods was excellent
(r=0.991). Of the specimens measured, 484 (43%) 
gave undetectable results (<0.20 mU/1) in the in- 
house IRMA whilst 494 (44%) gave undetectable
results (<0.05 mU/1) in the DELFIA assay.
2) Phase 2 : Results are expressed in terms of the
total T4 , FT4 and FT3 concentrations measured in 
each of the specimens in the six categories
specified in the Patients and Methods Section.
This data presented in Figures 4.8-4.10
inclusive.
DISCUSSION
1) Phase 1: The high percentage of undetectable TSH
results obtained in this study (approximately 43%) 
was unexpected and was not consistent with the 
opinion being expressed at the time of the study 
that an undetectable TSH result was indicative of 
active hyperthyroidism (Toft, 1985; Allen et al, 
1985). Clinical assessment of these patients (data 
not presented) certainly did not support the view
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that 43% of the subjects had symptoms of 
hyperthyroidism. Therefore, it was decided to 
study a sub-population of this group of patients in 
more detail in order to evaluate the significance 
of an undetectable TSH result (Phase 2).
Since the completion of this study, several other 
groups have produced data to show the high 
percentage of undetectable TSH results in subjects 
who have been treated for thyroid disease (Pollock 
and Ratcliffe, 1986). It is now widely accepted 
that an undetectable TSH result in such patients is 
not necessarily indicative of active 
hyperthyroidism.
Phase 2: The total T4 data presented in Figure 4.8
indicate that in all cases the mean T4 level was 
higher in the thyroxine treated group than in the 
corresponding category of non-thyroxine treated 
patients although these differences did not always 
achieve statistical significance. By the same 
token the mean T4 level for both thyroxine treated 
and non-thyroxine treated patients was higher in 
the undetectable TSH groups than in either of the 
other categories. However, there was considerable 
overlap between categories.
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The FT4' data presented in Figure 4.9 accord well 
with the total T4 data discussed above and the same 
conclusions apply.
The FT3 data presented in Figure 4.10 reveal no 
significant differences between any of the patient 
categories.
It may be concluded from this study that a 
sensitive TSH assay offers no obvious clinical
and/or economic benefit to SAFUR since the high
level of TSH undetectability was not in any way
consistent with the clinical status of patients.
The conclusion from Phase 2 of the study is that 
there is a very poor correlation between serum TSH 
and any of the indices of T4 or T3 measured which 
calls into question the value of performing thyroid 
function tests to monitor the progress of subjects 
who have been treated for thyroid disease. This 
topic is addressed in more detail in the next
study.
The data from this study have been presented in part 
at the UK EQAS Users Group Meeting in Cardiff in 
1986 and to the Scottish Society for Experimental 
Medicine in Edinburgh in 1987 (Hedley et al, 
1987).
ARE BIOCHEMICAL TESTS OF THYROID FUNCTION OF ANY VALUE IN
MONITORING PATIENTS RECEIVING THYROXINE REPLACEMENT?
a) INTRODUCTION
The development and application of analogue free thyroid 
hormone assays (Midgeley and Wilkins, 1981) and
sensitive thyroid stimulating hormone assays (Wehmann 
and Nisula, 1984) during the past five years has led to 
the reappraisal of the best biochemical tests of thyroid 
function in different disease states. There is 
considerable controversy over which tests should be used 
to monitor patients receiving thyroxine replacement for 
primary hypothyroidism, in whom the detection of over­
replacement poses a problem. Different authors have 
claimed that over-replacement is best detected by 
measuring the serum concentration of total thyroxine 
(Jennings et al, 1984), total triiodothyronine (Rendell 
and Salmon, 1985), free thyroxine (Beckett et al, 1985), 
or free triiodothyronine (Pearce and Himsworth, 1984). 
The value of some of these tests has been questioned 
(Oldfield et al, 1985; Caldwell et al, 1985), while
others have recommended measuring both thyroid 
stimulating hormone, using a sensitive method, and free 
triiodothyronine (Toft, 1985; Allen et al, 1985).
Euthyroid patients receiving thyroxine replacement have 
higher serum thyroxine and free thyroxine concentrations
than normal euthyroid subjects. This is not so for 
serum triiodothyronine and free triiodothyronine 
concentrations (Pearce and Himsworth, 1984; Johansen et 
al, 1978; Kurtz et al, 1980).
This study was undertaken to establish a reference range 
for thyroid function tests in patients receiving 
thyroxine replacement and to try to select the best test 
or combination of tests to monitor treatment.
This study was conceived at about the same time as the 
data were- beginning to emerge from the SAFUR study 
discussed previously. However, the present study was a 
collaboration with a different group of physicians and 
the data from the SAFUR study in no way influenced the 
design of this study.
PATIENTS AND METHODS
A prospective study was carried out in 148 hypothyroid 
patients (with primary hypothyroidism or after 
radioiodine treatment or thyroidectomy) attending a 
thyroid outpatient clinic. There were 131 female and 17 
male patients aged, respectively, 14-89 (mean (SD) 52.9 
(15.1)) years and 18-75 (52.6 (13.6)) years. They had 
been taking thyroxine replacement for more than three 
months, and none were taking drugs known to interfere 
with thyroid hormone metabolism, protein binding, or the
assays used'. The prescribed daily dose of thyroxine 
varied from 50-300 ug (mean 124.6 (49.5)). The patients 
were classified as clinically euthyroid, hyperthyroid, 
or hypothyroid by the examining physician after a full 
history and clinical examination and with use of a 
modified Wayne clinical diagnostic index (Wayne, 1960). 
The clinical assessments were carried out by three 
Consultants and a Registrar, who were experienced in 
thyroid disease. Subsequently blood samples were taken 
between 0900 and 1130 and the serum stored at -20°C 
before assay.
Total thyroxine and triiodothyronine concentrations were 
measured by in-house radioimmunoassay and thyroid 
stimulating hormone by the in-house monoclonal- 
polyclonal immunoradiometric assay described in Chapter 
3, Section V The detection limit for the assay of 
thyroid stimulating hormone was 0.1 mU/1 (Biggart et 
al, 1985). Analogue free thyroxine and free
triiodothyronine were measured using Amerlex Kits 
(Amersham International).
RESULTS
On clinical examination, supported by the Wayne index, 
108 patients were judged to be euthyroid, 22 to be 
hyperthyroid and 18 to be hypothyroid. Table 4.9 shows 
the results of biochemical tests in these three groups.
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To test whether individual clinicians showed bias in 
diagnosing hypothyroidism or hyperthyroidism the 
distribution of the Wayne index scores assigned to 
patients by each of the four clinicians was examined by 
Kruskal-Wallis analysis of variance. There was no 
significant difference in the four median scores (Figure 
4.11).
The mean dose of thyroxine received by patients who were 
hyperthyroid was higher (137 (42) ug) but not
significantly different from the dose received by 
patients who were euthyroid (128 (50) ug). Hypothyroid 
patients received a significantly lower dose (88 (38)
ug) than euthyroid patients (p<0.01). There was no 
significant difference in the mean age of the patients 
in each clinical group.
Table 4.10 shows the conventional reference ranges and 
new reference ranges for euthyroid patients receiving 
thyroxine (95% confidence intervals of the cumulative 
frequency distribution). Table 4.11 shows the number 
of patients in each clinical group who were 
misclassified by the conventional and new reference 
ranges. Thyroid stimulating hormone was undetectable by 
the sensitive assay - that is, below 0.1 mU/1 - in 34 of 
the euthyroid patients, nine of the hyperthyroid 
patients, and three of the hypothyroid patients. Thyroid 
stimulating hormone concentration was raised in 21
30 „
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Figure 4.11
Distribution of modified Wayne index scores assigned to patients by
the four examining clinicians. Horizontal bars represent median
scores
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euthyroid patients (range 5.0-19.7 mU/1) and four
hyperthyroid patients (range 5.0-11.4 mU/1).
Table 4.12 shows the diagnostic sensitivity, 
specificity, and false positive rate (Galen and Gambino, 
1975) for each test, calculated using the conventional 
and new reference ranges.
DISCUSSION
The major assumption in this study is that the clinical 
assessment of patients receiving thyroxine replacement 
by doctors experienced in thyroid disease is correct. 
This study attempted to establish the role of 
biochemical measurement of thyroid hormone 
concentrations in helping this diagnosis.
At present there is no variable that can readily be 
measured satisfactorily to assess the end organ response 
to thyroid hormone action in patients receiving 
thyroxine replacement. The serum concentration of 
thyroid stimulating hormone is unsatisfactory as the 
thyrotrophs in the anterior pituitary are more sensitive 
to changes in the concentration of thyroxine in the 
circulation than other tissues, which rely more on 
triiodothyronine (Larsen et al, 1981).
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The data indicate that the reference ranges for serum 
total thyroxine, analogue free thyroxine, and thyroid 
stimulating hormone in patients receiving thyroxine 
replacement are different from conventional reference 
ranges. It is clear from Table 4.12 however, that serum 
thyroid hormone and thyroid stimulating hormone 
concentrations cannot be used with any degree of 
confidence to classify patients as receiving 
satisfactory, insufficient, or excessive amounts of 
thyroxine replacement. There is little difference 
between the ability of concentrations of total and 
analogue free thyroxine to detect over-replacement; the 
poor diagnostic sensitivity and high false positive rate 
associated with such measurements render them virtually 
useless in clinical practice. Concentrations of total 
triiodothyronine, analogue free triiodothyronine and 
thyroid stimulating hormone are also incapable of 
satisfactorily indicating over-replacement. The tests 
perform equally badly in detecting under-replacement.
A question that remains to be answered convincingly is 
whether it is clinically necessary to measure thyroid 
hormone concentrations in patients receiving thyroxine 
replacement. The standard replacement dose in Europe 
and America was 200-400 ug a day until 1973, when it was 
halved to 100-200 ug a day on the basis of biochemical 
measurements of thyroid hormone concentrations (Evered 
et al, 1973; Stock et al, 1974). No study has shown 
that this reduction in the standard dose has had any
clinically beneficial effects. Different groups have 
shown changes in sodium metabolism (Bell et al, 1983), 
hepatic enzyme activity in serum (Beckett et al, 1985)
and systolic ejection time intervals (Jennings et al, 
1984) in patients receiving high doses of thyroxine, but 
such measurements have not been shown to be of any 
relevance to patient care.
This study indicates that biochemical tests of thyroid 
function are of little, if any, value clinically in 
patients receiving thyroxine replacement. Most patients 
are rendered euthyroid by a daily dose of 100 or 150 ug 
of thyroxine. Further adjustments to the dose should be 
made according to the patient's clinical response. In 
this laboratory 36% of all thyroid function tests are 
performed to monitor thyroxine replacement. To stop 
doing these tests in such patients would cause 
considerable saving in the costs of reagents in 
laboratories using commerical kits.
These findings emphasise the need for laboratories to 
make their users aware that the reference ranges for 
serum thyroxine, free thyroxine, and thyroid stimulating 
hormone concentrations in patients receiving thyroxine 
replacement are considerably different from the 
conventional ranges; they should also point out the 
limitations of these ranges. This is especially 
important for General Practitioners and non-specialists, 
who generally rely on the biochemical findings more than
197.
specialist • endocrinologists do in managing these 
patients. The conclusions in this study also have major 
implications for schemes such as the Scottish Automated 
Follow-Up Registry as described in the previous study.
This work was published in the British Medical Journal 
(Fraser et al, 1986).
VII THYROID DYSFUNCTION AND HYPERCHOLESTEROLAEMIA IH THE GENERAL 
POPULATION
a) INTRODUCTION
Hypercholesterolaemia, one of the three major risk 
indices for coronary heart disease, is common in the 
United Kingdom. Many factors such as diet, genetic
predisposition and hormonal imbalance contribute to its 
high prevalence. It has been shown that in the general 
population the mean plasma cholesterol is significantly 
higher in subjects with marginal increases in plasma TSH 
concentration (Tunbridge et al, 1977). This is more 
marked in females than males (Tunbridge et al, 1977). 
The contribution of hypothyroidism to hypercholesterol­
aemia in the United Kingdom is unknown. This study 
examines the prevalence of thyroid dysfunction in hyper- 
cholesterolaemic subjects in the general population.
PATIENTS AND METHODS
A cohort of 2250 males and females (age range 25-59 
years) was selected at random from the population of the 
East-end of Glasgow as part of a coronary risk factor 
screening programme (Guyer et al, 1985). Plasma 
cholesterol measurement was made after a 12 hour 
overnight fast. Blood was collected in plastic EDTA 
tubes, centrifuged at 1000 g, at room temperature for 10 
minutes and plasma separated and stored at 4°C. Plasma 
TSH measurements were made on all subjects from this 
study with a fasting plasma cholesterol ^8.0 mmol/1 and 
in the first 100 subjects with cholesterol levels ^7.0 
mmol/1. Non-fasting plasma cholesterol and TSH 
measurements were also made in a control population of 
500 blood donors. This group had an age range from 18- 
65 years and were seen by the Glasgow and West of 
Scotland Blood Transfusion Service.
A TRH test was performed, in all, except two, of those 
subjects with TSH 5-25 mU/1 to help assess the 
significance of borderline TSH results. The TRH test 
(Ormston et al, 1971) was performed by giving 200 ug of 
TRH (TRH-Roche, Roche Products Ltd, Welwyn Garden City, 
AL7 3AY, UK) as a bolus intravenous injection. Blood 
was collected for TSH measurements immediately before 
and 20 minutes after the injection.
Cholesterol' was determined by the cholesterol CHOD-PAP 
Enzymatic Method (Boehringer Mannheim GMbh Diagnostics) 
using a centrifugal analyser (Encore; Baker 
Instruments). Plasma TSH was measured by the "in-house" 
monoclonal-polyclonal immunoradiometric assay
described in Chapter 3, Section V Serum T4 and T3 were 
measured by "in-house" radioimmunoassays employing 
antisera obtained from the Scottish Antibody Production 
Unit, Law Hospital, Carluke, ML8 5ER, UK, with 125i- 
labelled T4 and T3 obtained from Amersham International 
(Amersham International pic, Buckinghamshire, HP7 9LL, 
UK).
RESULTS
The mean + SD cholesterol level in the screened 
population (5.81 + 1.18 mmol/1) was higher than that in 
the control group of blood donors (5.53 + 1.25 mmol/1). 
Ninety individuals in the former group (4% of the 
population) had plasma cholesterol values >8.0 mmol/1 
while in 261 the concentrations were between 7.0 - 8.0
mmol/1. Thus, overall plasma cholesterol exceeded 7.0 
mmol/1 in 15.6% of the population.
The distribution of the TSH levels in the 90 subjects 
with cholesterol levels >8.0 mmol/1 and in the first 100 
subjects identified by the screening programme with 
cholesterol levels >7.0 mmol/1 are given in Table 4.13.
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Table 4.14 shows the distribution of TSH levels in the 
90 subjects with cholesterol values ^8.0 mmol/1; and 
Table 4.15 documents the thyroid function test results 
of those with abnormal TSH levels. The 10 females in 
this group of 12 subjects with abnormal TSH levels were 
all more than 40 years old.
DISCUSSION
Hypothyroidism is a readily treatable common cause of 
hypercholesterolaemia and as such ought not to be 
missed. This study was set up prospectively to 
establish the value of screening for hypothyroidism as 
part of screening programmes for hypercholesterolaemia.
Subjects 1, 2, 3 and 4 were hypothyroid, though they 
did not consider themselves to have symptoms which
necessitated a visit to their General Practitioner. 
This is not an uncommon feature of hypothyroidism as one 
blood donor felt fit enough to give blood with TSH 
levels of 187 mU/1. None of the subjects with
borderline TSH levels, in whom a TRH test was performed, 
were taking medication which might have interfered with 
the biochemical thyroid function tests. In all cases
hypothyroidism was not suspected on the basis of the
history or clinical examination, yet their response to 
TRH was abnormal and consistent with mild primary
hypothyroidism.
TABLE 4.14
THE DISTRIBUTION OF TSH LEVELS IN FEMALE AND MALE SUBJECTS WITH
CHOLESTEROL LEVELS >8.0 mmol/1. THESE HAVE BEEN COMPARED WITH THOSE 
FOUND IN THE BLOOD DONORS USING X-SQUARED TEST
SCREENED POPULATION WITH CHOLESTEROL ^8.0 MMOL/L
TSH Females Males
(mU/1) No of Subjects No of Subjects
< 5.0 38 40
> 5.0 10 (p<0.001) 2
>1 0 . 0 6 (p<0 .0 0 1 ) 1
>25.0 3 (p<0.01) 1
TABLE 4,15
THYROID FUNCTION TESTS IN THE 12 SUBJECTS WITH FASTING PLASMA
CHOLESTEROL >8.0 MMOL/L WHO HAD RAISED TSH LEVELS. IN 'rHE SIX
SUBJECTS IN WHOM A TRH TEST WAS PERFORMED THE SERUM TSH LEVEL (20
MINUTES POST TRH STIMULATION), :IS ALSO GIVEN. SUBJECTS 4* AND 12*
WERE MALES
[The laboratory reference range for TSH = 0.35-5.0 mU/1 ; T4 = 55-
144 nmol/1 and T = 0 .9-2.8 nmol/1 ]
Cholesterol TSH TSH
T4 T3
(mmol/1 ) (mU/1) (mU/1) (nmol/l) (nmol/1 )
Post TRH
1 8.65 185 - 35 1.3
2 8.75 1 0 2 - 23 0.7
3 8 . 1 0 1 0 0 - 26 1.1
*
4 8.3 35 - 45 1 . 6
5 8.25 16.0 - 67 1 . 8
6 8.95 14.0 65 87 1.9
7 8.05 13.0 - 71 1.4
8 8 . 2 1 1 . 0 67 63 1 . 6
9 9.15 9.6 145 96 2.2
1 0 10.7 7.8 40 45 1.2
11 9.1 7.0 65 97 1.7
★
12 8 . 6 6.4 38 , 1 0 0 1 . 6
The significance of a borderline elevated TSH level in 
patients who are clinically euthyroid is uncertain. It 
has been suggested that "borderline hypothyroidism" is a 
risk factor in women for coronary artery disease (Dean 
and Fowler, 1985), although this has not been 
universally accepted. The finding in this study that 
this group is selected by looking at hyper­
cholesterolaemia lends weight to the argument that they 
do indeed have significant thyroid disease which may put 
them at increased risk of coronary artery disease 
(Becker, 1985).
The prevalence of hypercholesterolaemia in females 
rises markedly during the fifth decade of life. In the 
cohort examined 0.8% of the 25-39 year old females had 
cholesterol ^8.0 mmol/1. This increased to 5.1% in the 
40-59 year old age group. No such changes were noted in 
males. This increase has previously been attributed to 
menopausal changes. The data from this study indicated 
that thyroid disease may be an important additional 
contributory factor in as many as 20% of cases of 
hypercholesterolaemia in females over 40 years old.
The results of this study confirm that screening for 
thyroid disease is worthwhile but it must be selective. 
Screening patients with cholesterol ^7.0 mmol/1 showed 
no significant enrichment of hypothyroid patients over 
the general population. In subjects with cholesterol
^8.0 mmol/1 a significant number had unsuspected hypo­
thyroidism and there was an unequivocal increase in the 
frequency of abnormal thyroid function tests. Whether 
or not people who appear clinically euthyroid, but have 
borderline elevations in their TSH, should be treated 
with thyroxine because they have an increased risk of 
developing coronary heart disease warrants further
investigation.
This study has been published in Clinica Chimica Acta 
(Series et al, 1988).
CHAPTER 5
SCREENING FOR CONGENITAL HYPOTHYROIDISM IN SCOTLAND
I INTRODUCTION
Almost a century ago a role was recognised for thyroid
extract in treating cretinism - the physical and mental 
manifestation of congenital hypothyroidism. During the past 20 
years several well designed studies have shown a clear benefit of 
thyroxine therapy in treating the mental defects of congenital 
hypothyroidism but it has become clear that early diagnosis is 
necessary in order to maximise the chances of the affected infant 
having a normal intelligence quotient (IQ) later in childhood 
(Klein et al, 1972; Macfaul & Grant, 1977; Money et al, 1978; 
Aim et al, 1978; Brock Jacobsen & Brandt, 1981). With this
objective in mind screening programmes for congenital
hypothyroidism were commenced.
The first pilot screening programmes were set up in Quebec 
with the measurement of T4 concentration in filter paper blood 
spots (Dussault et al, 1975) and in Pittsburgh with the
measurement of TSH concentration in cord blood (Klein et al, 
1974). Modifications of these programmes were used by other 
screening centres in North America and Europe. Committees of the
American and European Thyroid Associations were formed to
deliberate and suggest optimum strategies for screening. In 1979, 
at the time of the first International meeting in Quebec, much of
North America, Japan, Australia and Europe had screening 
programmes in operation (Burrow & Dussault, 1980). Progress was 
much slower in the United Kingdom and in 1981 health authorities 
were recommended to start screening. By 1983, all regions had 
instituted screening programmes mainly using the existing 
phenylketonuria screening blood spots. Most screening
laboratories relied on pre-existing radioimmunoassay expertise and 
in Scotland, Northern Ireland and Wales, screening has been 
concentrated in the centres of Glasgow, Belfast and Cardiff 
respectively. In England there are 23 laboratories involved in 
screening for congenital hypothyroidism. Some of these, such as 
in the North Thames area, screen a large population with 90,000 
births a year, whereas in other areas, such as Yorkshire where six 
screening centres exist, some laboratories screen only 3,000 
births a year.
A scheme for the external quality assessment of the
measurement of TSH in blood spots was established from Manchester 
and run in conjunction with the UK EQAS for thyroid hormones. 
This scheme now operates from Birmingham. UK screening centres 
can participate in this as well as similar schemes operating from
France and Germany. A decision was made early on by the Medical
Research Council to set up a register, similar to that for 
phenylketonuria, to record all cases of congenital 
hyporthyroidism detected by the screening programmes. The data 
that are collected on these infants should provide evidence of the 
efficacy of the screening programmes in the UK, and the
epidemiological and clinical information will be useful in 
assessing the factors of importance in the aetiology of thyroid 
failure.
In normal neonates birth is the trigger for profound changes 
in the activity of the thyroid gland. Thus, there is a marked TSH 
surge (plasma levels up to 100 mU/1) within 30 minutes of birth 
which subsides at 24 hours and returns towards baseline by 3 days 
of age. The TSH surge causes a rise in serum T4 levels and a more
marked rise in serum T3 as there is a switch of peripheral T4
metabolism to T3 rather than to the metabolically inactive reverse 
T3 (Fisher & Klein, 1981). Healthy pre-term infants who are 
delivered before full maturation of the thyroid - pituitary axis 
show similar changes with lower TSH and T4 concentrations, so that 
at birth T4 levels are generally lower than full-term infants.
It will be clear from the preceding paragraph that in normal
infants aged greater than 3 days the pituitary - thyroid axis has 
matured to resemble that of the adult so that a heel-prick blood 
spot taken at 5-10 days of age should reveal relatively low levels 
of TSH and relatively high levels of T4 , both within reasonably 
tight reference values. Against this background, it is clearly 
possible to determine the elevated levels of TSH associated with a 
deficient thyroid gland as revealed in congenital hypothyroidism 
although there are some differences as to the action limit for TSH 
concentration in neonatal blood.
Most screening programmes regard a TSH concentration greater 
than 20 mU/1 (expressed as whole blood) as positive (Mitchell et 
al, 1978), whereas in other programmes a higher figure of 50 mU/1
is taken as a cut-off value. In the Scottish screening 
programme (Figure 5.1), TSH results less than 25 mU/1 are regarded 
as normal; at between 25 and 50 mU/1 a second blood spot is 
collected for a repeat estimation; and above 50 mU/l, the infant 
and mother are seen by paediatrician and a full clinical and
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biochemical evaluatibn is carried out. When the clinician is 
alerted by a positive screening test and clinical evidence of 
hypothyroidism is also present, treatment can be started. Not all 
infants who are subsequently confirmed to have congenital 
hypothyroidism will have clinical signs; the decision to treat 
these while awaiting a confirmatory serum result may rely on local 
experience.
In the majority of cases, the diagnosis is in no doubt as the 
serum results show the classic changes of a low total T4 and free 
T4 with a raised TSH. T4 treatment in these infants should be 
started without delay. Problems arise in those infants who 
display normal concentrations of T4 with only slightly elevated 
TSH concentrations. In some of these, if left untreated, the TSH 
level returns to normal within a few weeks or even months. In 
others, the TSH starts to rise with falling T4 and free T4 
concentrations. In the large New England screening programme a
diagnosis of hypothyroidism is made when the infant's serum TSH 
concentration is greater than 40 mU/1 (New England Congenital 
Hypothyroidism Collaborative, 1982). Further serum samples 
are requested if it is between 20 and 40 mU/1, and a diagnosis of 
hypothyroidism is only made when the TSH concentration exceeds 40 
mU/1 or is greater than 20 on three occasions. It was found that 
only six out of 36 infants with TSH values in the 20 to 40 mU/1 
range required thyroxine therapy, whereas the remainder eventually 
displayed normal hormonal concentrations and were clinically well. 
Clinically and biochemically, these infants pose a difficult 
problem and a full investigation with a careful questioning of the 
mother as to her exposure to any anti thyroid compounds needs to be 
made. Serum T4 concentrations can be decreased in low birth
weight premature babies which emphasises the requirement for 
normal thyroid function values to be adjusted for gestational age 
and birth weight (Brock Jacobsen et al, 1977; Oddie et al, 1977; 
Cuestas, 1978).
Once the diagnosis of congenital hypothyroidism has been 
confirmed it is normal practice to perform a thyroid scan to 
determine the aetiology of the defect (De Groot & Reilly, 1981), 
although other less invasive techniques, such as the measurement 
of thyroglobulin (Czernichow et al, 1983; Black et al, 1982; Gons 
et al, 1983) or ultrasound (Dammacco et al, 1985) may also
distinguish between the infant with no thyroid gland or ectopic 
thyroid tissue.
Before the institution of screening for congenital 
hypothyroidism retrospective studies had revealed the incidence of 
the condition to be in the range 1/6000 - 1/7000 (Brock Jacobsen & 
Brandt, 1981; Aim et al, 1978). With screening programmes, the 
incidence has been remarkably constant in many parts of the world 
at about one in 4000. This is more common than phenylketonuria, 
with an incidence of approximately one in 14000. In the UK in the 
3 years up to the end of 1984, over 2 million births have been 
screened, with 607 babies identified as hypothyroid, giving an 
incidence of one in 3515 (Table 5.1). This higher incidence seen 
in screening programmes is probably due to their sensitivity in 
detecting the mildest forms of hypothyroidism in infants who would 
previously have maintained sub-optimal levels of thyroid hormones. 
In some of these, further failure of their thyroid gland occurs 
and they would have presented to a paediatrician at a later age, 
but it may be that in a proportion they can function more or less 
normally with reduced thyroid hormone reserve.
TABLE 5.1
NUMBERS OF BABIES SCREENED AND INCIDENCE OF CONGENITAL HYPOTHYROIDISM
BETWEEN 1982 AND 1984 IN THE UK
Numbers of
Babies
Screened
Positive
Cases Incidence
N Ireland 
(Belfast)
81 799 26 1:3146
Wales
(Cardiff)
105 014 27 1:3889
England 1 749 175 502 1:3484
Scotland
(Glasgow)
197 844 52 1:3805
Totals 2 133 832 607 1:3515
Figures for England, N Ireland and Wales are taken from the annual 
returns to the MRC Register for congenital hypothyroidism.
The reported frequency of various types of defect differs and 
this might be due to differences in the studied populations or may 
be due to technical problems in identifying the defect. The most 
common forms of defect identified by thyroid scanning have been 
the various dysgeneses of the thyroid which make up 80-90% of all 
cases (Naruse & Irie, 1983). About one third of these had an 
ectopic gland, the other two-thirds had a hypoplastic or aplastic 
gland. Approximately 10% had normal glands and a smaller 
percentage had large glands suggesting the presence of one of the 
dysho rmonogenes is.
Although the cause of the thyroid gland dysgenesis is
unknown, its occurrence in those areas of the world where
screening takes place has been very similar. Genetic factors may 
well play a part as there is a greater chance of thyroid disease 
in affected families. Congenital hypothyroidism is twice as 
common in girls as boys. It may be too soon to say if there are 
real differences in incidence amongst racial groups, but it 
appears that it may be uncommon in Spanish and Negro infants 
(Brown et al, 1981) and a high incidence was found amongst Asian 
infants in Birmingham (Griffiths et al, 1985). It seems that 
there is an increased incidence of congenital hypothyroidism in 
Down's Syndrome and in one study the incidence was 1:141, or about 
28 times greater than in the general population (Fort et al, 
1984). The cause of the thyroid dysfunction was unclear as none 
had agenesis or ectopia of the thyroid gland. In most cases their 
biochemical abnormality was mild, but in some there was subsequent 
progression to hypothyroidism.
The common occurrence of subjects with thyroxine binding
globulin (TBG) deficiency has also been revealed by screening with
thyroxine. Approximately one in 9000 infants are affected. It 
has an X linked dominant inheritance (Fisher et al, 1979) and is 
an entirely harmless condition. Apart from confirming a low TBG 
concentration, it does not require any further treatment.
Treatment for congenital hypothyroidism is oral replacement 
with sodium L-thyroxine, usually at an initial dose of 10 ug/kg 
per day. If there is any diagnostic difficulty, some advocate 
that replacement therapy should be started; it is better to 
reassess early and withdraw treatment at a later date. The dosage 
can be gradually increased during the early years to the adult 
dosage of 100-200 ug per day by 12 years of age. The correct 
dosage can be monitored by the absence of clinical signs or 
symptoms of hypothyroidism or hyperthyroidism and by the serum 
concentrations of T4 and TSH. The majority of infants will show 
normal levels of T4 and TSH with replacement but some will have 
persistently raised serum TSH concentrations despite being 
clinically euthyroid and having a normal T4 concentration. This 
occurs in infants with evidence of intra-uterine hypothyroidism 
and is thought to be due to impairment of normal feedback control 
of iodothyronine on TSH secretion (Schultz et al, 1980). Any 
attempt to suppress TSH concentrations to normal in these infants 
will induce clinical thyrotoxicosis and may be associated with 
impaired neurological development and possible development of 
craniosynostosis (Weichsel, 1978; Penfold & Simpson, 1975).
II THE SCOTTISH SCREENING PROGRAMME FOR CONGENITAL
HYPOTHYROIDISM
The screening programme for congenital hypothyroidism in 
Scotland was commenced at Stobhill Hospital (National Inborn 
Errors Laboratory) in mid 1979. At first the assay was performed 
only on blood spots from infants born in West of Central Scotland 
but by 1980 it had been extended to a National Service. Initially 
a commercial system was used for measuring the blood spot TSH 
concentrations but in 1980 the two polyclonal IRMA of Sutherland 
et al (1981) was introduced with reagents being provided by the 
Department of Clinical Biochemistry at Glasgow Royal Infirmary. 
This ran routinely until the end of 1983 when it was replaced by 
the monoclonal - polyclonal IRMA developed as described in this 
thesis. In 1981 the UK EQAS for blood spot TSH measurement was 
introduced and the Scottish Scheme has participated in every 
distribution made by the EQAS since that date.
Ill RESULTS OBTAINED FROM THE SCOTTISH SCREENING PROGRAMME FOR 
CONGENITAL HYPOTHYROIDISM
Between 1979 and the end of 1987 more than 95% of babies 
born in Scotland were entered in the Scottish Screening Programme. 
The number of infants screened each year and the number of 
positive cases of congenital hypothyroidism identified are 
recorded in Table 5.2. Overall a total of 546,965 infants were 
screened during this period and 141 cases of congenital
TABLE 5.2
NUMBER OF INFANTS SCREENED AND NUMBER OF POSITIVE CASES OF CONGENITAL 
HYPOTHYROIDISM BETWEEN 1979 AND 1987 IN SCOTLAND
Year
No of Infants 
screened
No of +ve 
cases
Method
used
1979 10,036 5 Commercial Kit
1980 68,784 13 2 Poly. IRMA
1981 69,572 17 2 Poly. IRMA
1982 66,864 13 2 Poly. IRMA
1983 65,137 23 2 Poly. IRMA
1984 65,843 16 Mono./Poly. IRMA
1985 67,338 21 Mono./Poly. IRMA
1986 66,187 13 Mono./Poly. IRMA
1987 67,204 20 Mono./Poly. IRMA
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hypothyroidism were ’ identified, giving an overall incidence of 
1/3879 births. In Table 5.3 are recorded the cumulative 
statistics and predictive values of the data obtained from The 
National Screening Programme with the two In-house IRMA TSH 
assays. For comparative value the corresponding data from the 
Welsh National Screening Programme has been extracted from the 
work of John (1987) and also included in Table 5.3. It is 
apparent from th^s^data that all three assay systems have produced 
almost identical clinical performance characteristics. The one 
false negative result from The Scottish Screening Programme was 
correctly classified by the assay but incorrectly transcribed by 
the operator.
The analytical performance of the blood spot TSH assay has 
been judged internally by the inclusion in each assay of three 
quality control pools. Each month the coefficient of variation is 
derived from the results obtained on approximately 20 observations 
of each pool. A summary of thes^ internal quality control data is 
displayed in Figure 5.2.
The results obtained from The Scottish Screening Programme in 
the UK EQAS for blood spot TSH measurement are recorded in Figure 
5.3. Throughout Figure 5.3 the Scottish result has been compared 
with the 'target' result from EQAS rather than with the all 
laboratory trimmed mean (ALTM). Significant differences between 
the 'target' and ALTM results have been shown in EQAS, reflecting 
the inherent difficulties of preparing standards for blood spot 
TSH assays and of recovering TSH quantitatively from the blood 
spots.
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IV DISCUSSION
The analytical challenge of measuring TSH concentrations in a 
few microlitres of blood eluted from a filter paper disc is a very 
great one. It is hardly surprising, therefore, that the mean 
assay imprecision revealed in Figure 5.2 is greater than that 
encountered for the serum TSH assay based on the same reagents in 
which some 20 times the volume of serum is taken for assay. By 
the same token, the EQAS performance data recorded in Figure 5.3
leaves considerable room for improvement, although the assay has
performed as well as most of the assays registered in EQAS during 
the past 7 years.
It is fortunate that blood spot levels of TSH tend to be very 
elevated in positive cases of congenital hypothyroidism for such 
discrimination partially offsets the problems of assay 
imprecision. The clinical performance characteristics displayed 
in Table 5.3 make satisfying reading for they compare well with
the best data published from around the world (John, 1987) and
they reveal that the monoclonal - polyclonal IRMA developed with 
the work described in this thesis has continued to maintain the 
excellent clinical data obtained from the Scottish Screening 
Programme.
Future developments on assays for measuring blood spot TSH 
must seek to reduce the assay imprecision. Such an improvement is 
likely to be forthcoming with the modification of the very 
sensitive systems now being used for serum TSH. Such systems, 
often based on non-isotopic labels of very long shelf-life, should 
result in an improvement in precision at the critical TSH level of
25 mU/1 in the blood' spot eluate. This greater assay precision 
will give confidence to the operator although it is unlikely to
make any major difference to the clinical performance
characteristics of the National Screening Programme.
The determination of the value of screening programmes for 
congenital hypothyroidism may be assessed both in terms of the 
benefit to the mental development of the individual and also as 
the cost savings to the health care budget.
The infants from the first screening programmes are now 
approaching life in their teens. Assessment of these patients 
will show whether the opportunity of early diagnosis and
treatment, made possible by screening, provides a favourable 
outcome in terms of normal development and avoidance of 
neurological disturbances. The results so far are very 
encouraging. Treating early avoids the major stigmata of 
cretinism and in the large New England collaborative study it was 
shown that the IQ and mental development were the same in patients 
who were on adequate replacement as in controls (New England 
Congenital Hypothyroidism Collaborative, 1984). At 2 years of age 
there was no difference between patients and controls by the
Bayley Mental Development Index and at 3, 4 and 5 years the
Stanford-Binet IQ scores were the same in each group. No
significant correlation with ultimate IQ was found for any 
clinical or laboratory data except for adequate T4 replacement.
In the only other report from a large centre the Quebec group 
demonstrated that their patients had significantly lower scores 
than did the controls and lower intelligence was found in those
with lowest T4 , T3 and retarded bone age at time of diagnosis
(Glorieux et al, 1983). Others have found normal IQ values in
children tested but there is some evidence that there might be 
minor problems in other neurological areas such as fine motor co­
ordination and speech disorders (Naruse and Irie, 1983). It is 
not known whether this is related to the age on diagnosis, 
previous deficit of thyroid tissue or adequacy of replacement and 
most treated infants are too young to assess whether these 
difficulties will persist or improve.
In the first mass screening programme in Quebec the analysis 
of the cost of providing a screening service and the savings from 
the long-term care of patients without screening showed that there 
was an appreciable cost benefit to screening (Burrow and Dussault, 
1980). Using the criteria of cost - benefit analysis, the costs 
were computed within the framework of a universal health care 
assurance scheme (a) with an existing PKU screening programme, (b) 
without a programme and (c) in a free-enterprise system. The 
costs in the first example would include the cost of reagents, any 
additional equipment and technical and computer facilities 
required to provide the hypothyroid screening within an existing 
PKU screen. In the last option, the costs would include hospital 
costs, sample collection including recalls, treatment, laboratory 
space and medical fees. Any savings in costs would come from the 
elimination of costs needed to look after an undiagnosed case. It 
was assumed that at least 50% of these cases would end up with an 
IQ of less than 85, would require some light to moderate care in 
an institution and spend on average 1 week in hospital before 
diagnosis or for treatment of complications. Over a 5 year period 
the benefits' ratios in each instance are (a) 3.9, (b) 1.8 and (c) 
1.2. It was only when screening for hypothyoidism was introduced 
that their genetics screening programme changed from a net deficit
with PKU and tyrosinaemia screening to one of net economic 
benefit. This was due to the absence of any effective long-term 
treatment for tyrosinaemia and the low incidence of PKU of one in 
35,000 births. The introduction of hypothyroid screening and the
eradication of a treatable form of mental retardation, even
without a favourable cost benefit, must be looked on as one of the 
major advances in preventive medicine.
The previous section of this Chapter has provided strong 
evidence of the clinical value of a screening programme for 
Congenital Hypothyroidism both to the individual and to the health 
care budget. Thus, screening programmes are likely to continue 
for many years to come, although there are now some interesting 
developments which may lead to a reassessment of the programmes in 
the long-term.
Thus whilst most children seem to benefit sufficiently from 
existing screening programmes, for some, the ability to detect in 
utero-hypothyroidism and to start treatment before birth may 
improve their chances of avoiding some of the behavioural
disorders. Ultrasonography has been used to detect a goitre in a 
foetus and measurement of TSH in the amniotic fluid revealed a 
raised level so that thyroid hormone replacement could be 
commenced on the first day of life (Kourides et al, 1984). The 
low levels of TSH in amniotic fluid from third trimester
pregnancies of less than 0.15 to 0.55 mU/1 could only be measured
after prior concentration of the amniotic fluid (Kourides et al, 
1982), but these levels in unconcentrated fluid may well be 
detected by the more sensitive assays for TSH now available. The 
problem remains of the appropriate choice of patients for
amniocentesis, but mothers at known risk, such as those with 
familial goitre or those taking antithyroid medication, warrant 
further study.
The recent detection of thyroid - growth blocking antibodies 
in the blood of 15 out of 34 mothers who subsequently gave birth 
to hypothyroid infants could lead to a pre-natal diagnostic test 
(Van Der Gaag et al, 1985). Using a cloned rat thyroid cell line 
(FRTL5 ), Dussault has shown that in cells deprived of TSH for 5 
days, after the addition of TSH and maternal immunoglobulin, there 
was a significantly greater increase in 125j uptake by the thyroid 
cell membranes, in those mothers of hypothyroid infants compared 
with mothers of normal infants (Dussault and Bernier, 1985) The 
mechanism by which these maternal antibodies are responsible for 
increasing the iodine uptake by the cell membranes remains to be 
elucidated. This has encouraged him to start screening 25,000 
pregnant women to evaluate the false-positive and false-negative 
rate of this test and its role in predicting a pregnancy at risk 
of producing a hypothyroid infant. Foetal therapy has 
already been attempted by injecting T4 intramuscularly to the 
foetus, or into the amniotic fluid (Van Merle et al, 1975), or in 
rats by giving 3,5-dimethyl-3-isopropyl-l-thyroxine to the mother. 
This is a thyroid hormone analogue which crosses the placenta, and 
prevents foetal goitre formation (Comite et al, 1978), so that 
foetal diagnosis and treatment becomes a real possibility.
CHAPTER 6
GENERAL DISCUSSION
I EVOLUTION OF TSH ASSAYS
a) THE USE OF 125I AS THE LABEL IN IMMUNOMETRIC ASSAYS
Using radioiodine labelled reagents, it is possible to 
measure concentrations of substances down to 1 0  ^ molecules/ml 
(approx. lO-!^  mol/litre) (Ekins, 1987). But aside from the 
sensitivity which the use of radioactive isotopes confers 
upon immunoassays, an important attribute to radioactive 
measurement is its relative invulnerability to environmental 
interference. Radioisotopic disintegration is not affected 
by physical or chemical factors, and provided counting 
conditions are standardised, highly accurate estimates of 
radioactive content can readily be made using cheap and 
easily operable equipment.
However, notwithstanding these advantages, considerable 
pressure has existed for some years to find substitutes for 
radioisotopes for use in the present context. Amongst the 
principal reasons for this are the widespread public
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perception and fear of health hazards associated with 
radioactivity (leading to legal constraints on the use of 
radioisotopes in many countries), the logistic and quality- 
control problems arising from the limited shelf-life of
radiolabelled reagents and the expense of (automatic) 
radioactive sample measuring equipment. A further 
disadvantage of radioisotopes stems, paradoxically, from the 
very invulnerability of radioactive disintegration to 
environmental influence referred to above, implying that it 
is impossible to devise simple "homogeneous" assay systems in 
which labelled reaction products do not require physical 
separation prior to measurement.
Some of these arguments are of doubtful validity. For
example, the amounts of radioactivity involved are 
exceedingly small, and the health hazards that they present 
in the normal hospital laboratory negligible, being often 
outweighed by the potential dangers arising from carcinogens, 
viruses and other toxic agents which often form part of the 
laboratory environment. Similarly, the costs attaching to 
the use of radioactive techniques are generally greatly 
exaggerated. Counting equipment, the only specialised 
apparatus normally required, is now cheap and reliable, the
cost of the more sophisticated types of sample counter
arising primarily from the automatic sample changing and data 
processing facilities which they provide. Indeed no 
currently visualised alternative non-isotopic methodology
offering comparable sensitivity and precision to the
radioisotopic techniques, and having similar sample handling 
capacity, has any chance of being significantly cheaper.
In short, the various labels utilised for immunoassay 
purposes each possess individual attribute, any one (or 
combination) of which may be of special advantage in 
particular situations; none is likely to emerge as a 
"universal" label, applicable in all the varied
circumstances in which immunoassays find application.
However, analyte concentrations below lO? molecules per 
millilitre lie below the detection limits of current methods. 
Though it is sometimes argued that it is unnecessary to 
develop techniques of sufficient sensitivity to penetrate 
into this region, specific examples occur, even in
endocrinology, in which it would be clinically or otherwise 
useful to increase the sensitivity of present techniques.
In order to fully exploit the advantages of non-competitive 
assay designs, it is clearly necessary to identify labels of 
higher specific activity than that of commonly used 
radioisotopes thus non-isotopic techniques form the 
necessary basis on which major improvements in immunoassay 
sensitivity will inevitably rest.
ALTERNATIVE' HIGH SPECIFIC ACTIVITY LABELS IN IMMUNOMETRIC
ASSAYS
Alternative high specific activity labels have been utilised 
for immunoassay purposes. The conversion of many molecules 
of substrate by a single enzyme molecule implies an 
amplification of the specific activity of enzyme-labelled 
antibody molecules assuming high sensitivity of detection of 
the reaction product. Examples of high sensitivity enzyme- 
labelled antibody techniques that have exploited this 
phenomenon are the USERIA technique of Harris et al (1979) 
and the method of Shaleve et al (1980), relying on 
radioactive and fluorogenic substrates respectively. More 
recently, somewhat more complex methods of amplification of 
the enzyme - generated signal have been devised which rely, 
not on direct observation of the reaction product per se, but 
on observation of the latter's catalytic effect on a 
secondary enzyme system, which remains essentially dormant 
until thus activated (Stanley et al, 1985; Johannsson et al,
1985). Typical systems governed by this principle have been 
utilised in the development of "ultrasensitive" immunoassays 
for TSH and other comparable analytes.
Chemiluminescent labels, in spite of quantum efficiencies 
generally considerably lower than 1 0 0%, are also, in 
principle, capable of yielding higher specific activities 
than radioactive isotopes, and hence higher immunoassay
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sensitivities, enabling, for example, TSH to be measured at 
concentrations down to 0.01 mU/1 or lower (Weeks et al, 
1984; Kemp et al, 1984).
Another form of chemiluminescent assay combines the 
attributes of luminometric measurement with the signal 
amplification provided by the use of enzyme labels. 
Originating from the studies of Whitehead et al (1983), 
assays based on the use of antibodies labelled with 
horseradish peroxidase and luminescent substrates have 
recently been launched by Amersham International Enhancement 
of the luminescent yield of the peroxidase system may be 
achieved by the use of phenols (Thorpe et al, 1985), 
resulting in further signal amplification and an increase in 
assay sensitivity.
Fluorescent labels are potentially capable of yielding very 
high specific activities since each labelled molecule may be 
induced to yield many photons in response to exposure to a 
high energy light input. Fluorescent markers also have a 
number of other attractive features, including the 
possibility of repeated, confirmatory, measurements on the 
same sample, and of observation of their spatial distribution 
on a solid surface (thus allowing the ready development of 
multiple immunoassays in the same sample). The major 
drawbacks associated with conventional fluorescent 
measurements are the background fluorescence generated by 
many biological substances, plastics etc and the bleaching 
effects deriving from continuous exposure of the
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fluorophore to high intensity light. These effects conspire 
to limit the assay sensitivities which are conventionally 
attainable by such methods. However, these disadvantages may 
be largely overcome by recourse to pulsed-light, time- 
resolving fluorescence measurement techniques.
In conclusion, advantages stem, in practice, from the 
combined use of "non-competitive" immunoassay designs and 
high specific activity non-isotopic labels. Most of the 
newer techniques now becoming commercially available reflect 
this concept. Consequently they are closely comparable in 
overall performance, such minor differences as exist 
primarily reflecting differences in the characteristics of 
the immunological systems on which the assays are based 
(deriving from the qualities of the antibodies used, etc) 
rather than in the particular labels used. Therefore, in 
practice, the decision as to which of the commercially 
available systems to use is likely to be dictated more by 
such considerations as cost, the range of kits available, the 
necessity for, and dependance on, fully automated equipment, 
ease of servicing, etc, rather than on scientific performance 
per se.
IMPLICATIONS OF THESE DEVELOPMENTS FOR THE SERUM TSH ASSAY
SERVICE IN GLASGOW ROYAL INFIRMARY AND THE SCOTTISH SCREENING 
PROGRAMME FOR CONGENITAL HYPOTHYROIDISM
It will be clear from the previous two sections that the use 
of 125i_based immunometric assays for TSH will diminish in 
the years ahead and the implications of this trend must be 
considered in the local environment in order to ensure that 
the best possible service will be maintained.
There is much still to learn about the physiology of thyroid 
hormones, especially in subjects treated for thyroid disease 
(see Section II). However, it is almost certain that the 
clinical value of a serum TSH assay will be enhanced by 
improving the detection limit from 0.2 mU/1 to 0.02 mU/l. 
Such an improvement is not possible with the existing 
monoclonal and polyclonal antibodies and an ^25x-iabel. The 
most straightforward way to achieve this improvement is to 
move to a non-isotopic label that is compatible with the 
available antibodies.
The Delfia serum TSH assay (Pharmacia Diagnostics Ltd) has 
been shown to have the required additional sensitivity, but 
it is expensive to run (see Chapter 4, Section Hid). 
Therefore, for an experimental period of 6 months it was 
decided in October 1988 to introduce the Delfia TSH assay 
into Glasgow Royal Infirmary as a back up assay to the in- 
house IRMA. The Delfia assay will only be performed on those
serum specimens yielding a TSH result of <0.5 mU/1 in the in- 
house IRMA. It is anticipated that approximately 10% of the 
routine TSH work load will be processed by this back up 
assay. An assessment of the cost/benefit ratio of the Delfia 
TSH assay is expected to be made in early 1989.
A more long-term solution to the problem may lie in the local 
production of europium labelled TSH monoclonal antibody for 
use in a Delfia type of assay. Collaborative work between 
other members of the Glasgow Laboratory and Dr T Lovgren of 
Pharmacia, Finland have established the feasibility of this 
approach and Pharmacia Diagnostics Ltd have recently agreed 
to supply Glasgow with the necessary europium chelates and 
methods to effect local manufacture.
The implications of these developments for the screening 
programme for congenital hypothyroidism are slightly 
different. Improved blood spot TSH sensitivity is unlikely 
to improve substantially the predictive values obtained from 
the screening programme (Chapter 5, Section III) despite an 
improvement in imprecision around 25 mU/1. However, the
adoption of a non-isotopic label will enable the production 
of large batches of reagent of long shelf-life and this 
should greatly simplify the task of reagent provision for the 
screening programme. Such a change will require to be 
accommodated within existing budgets and so the use of the 
Delfia assay itself (or any other fully commercial system) is 
contraindicated. However, the use of a Delfia type of assay
based on local reagents is likely to be feasible and this 
will almost certainly represent the next phase of assay 
development for the screening programme.
II THE INTERPRETATION OF SERUM TSH RESULTS IN SUBJECTS BEING 
TREATED WITH ORAL THYROXINE
It is now well established that highly sensitive assays for 
serum TSH can reliably distinguish the undetectable levels found 
in thyrotoxic patients from normal levels (Seth et al, 1984). 
However, the role of sensitive TSH assays in monitoring patients 
receiving thyroxine replacement has still be to be fully 
evaluated.
The work presented in Chapter 4 of this thesis (Sections V 
and VI) has shown that many patients receiving T4 replacement 
therapy have undetectable serum TSH levels, both in the in-house 
IRMA and using the Delfia assay. These data have been confirmed 
by other workers (Semple et al, 1985). Does this mean that all 
these patients are receiving excessive doses of oral T4 ? This 
question remains to be answered fully but it is generally
recognised that the pituitary differs from some other tissues in 
that T3 derived from local conversion from T4 within the cell 
occupies a greater proportion of T3 nuclear receptors than T3 
derived from serum (Larsen, 1982). This greater sensitivity of
the pituitary to serum T4 has led to the assumption that it is an
unrepresentative target tissue regarding the assessment of
overtreatment with T4 .
As alternatives to the more sophisticated measurements of 
peripheral tissue responses described (Goolden et al, 1971;
Jennings et al, 1984; Wilcox and Levin, 1986; Coindre et al,
1986), Gow et al (1987), used simple measurements of constituents 
in serum known to be altered in patients with overt thyroid 
disease and related these to TSH secretion. High concentrations 
of alanine aminotransferase (ALT), liver-specific glutathione S- 
transferase (GST), sex hormone-binding globulin (SHBG), and 
angiotensin-converting enzyme (ACE) have all been described in 
hyperthyroidism (Beckett et al, 1985; Ashkar et al, 1971; 
Anderson, 1974; Smallridge et al, 1983), whereas concentations of 
T4 ~binding globulin (TBG) and creatinine may be decreased (Ahmed 
and Smethurst, 1980; Bradley et al, 1974). Elevated
concentrations of creatine kinase (CK) are found in hypothyroidism 
(Doran and Wilkinson, 1975). Changes in the concentrations of 
these analytes reflect altered entry to (due to changes in 
synthesis or membrane permeability) or clearance from the blood. 
These markers are arguably crude and insensitive indicators of 
thyroid status which cannot serve to assess thyroid status in an 
individual. However, when many of these markers are measured in 
groups of patients with overt hyperthyroidism, unequivocal 
statistically significant abnormalities are found.
Gow et al (1987), demonstrated a relationship between the 
serum markers used to assess tissue thyroid status and TSH levels 
measured by a sensitive assay in patients taking T4 . Such a 
relationship was not found between the serum markers and free T3 
measurements. Some patients had abnormally high ALT, GST, SHBG, 
and ACE levels at higher T4 doses. These abnormalities were not 
as marked as those in patients with untreated overt
hyperthyroidism, but in addition to the complete suppression of 
TSH secretion, they provided evidence of a generalised tissue 
over-exposure to thyroid hormones. On the basis of this work, Gow 
et al (1987) concluded that TSH secretion could be used as a 
sensitive and representative test of peripheral tissue exposure to 
thyroid hormones in patients receiving T4 replacement therapy.
Recently a study has been set up by Carr et al (1988) to 
examine the results of TRH tests using a sensitive IRMA for TSH, 
along with FT3 and FT4 measurements and clinical observations in a 
group of treated hypothyroid patients, each of whom was tested on 
a series of different daily thyroxine dosages. The objective was 
to collect data at the dosage which resulted in a normal response 
to TRH for each patient, and at dosages slightly above and below 
this. The data were used to examine the variation in TRH 
responsiveness, FT3 and FT4 , with slight changes in thyroxine 
dosage, and to test the hypothesis that the basal TSH (IRMA) level 
in a patient receiving thyroxine replacement is capable of 
indicating a normal or abnormal response to TRH, and can be useful 
as a guide to biochemically correct dosage.
The data of Carr et al (1988) indicated that clinical 
observations were relatively insensitive and failed to detect 
significant differences between patients receiving thyroxine at 
various dosages within the narrow range studied. The measurements 
of FT3 and FT4 levels, while showing significant variations over 
this dosage range for the whole group of patients, were also poor 
indicators of thyroxine dosage for individual patients.
In contrast, the TRH test showed great sensitivity to small 
changes in thyroxine dosage; in the majority of cases a change of 
dosage of only 25 ug was sufficient to modify the TRH response 
from a normal to a clearly abnormal value.
Furthermore, patients receiving thyroxine in a dosage which 
resulted in the most normal response to TRH, all appeared 
clinically euthyroid. It was concluded that the TRH test was able 
to determine a replacement dosage of thyroxine which equated with 
the patient being clinically euthyroid, and which correlated well 
with results of circulating thyroid hormone measurements in 
individuals and a population of patients, and it was also 
sensitive to small changes in thyroxine dosage. Basal TSH alone 
correlated well with TRH response (within the critical range close 
to normal) and was only slightly less sensitive than the TRH test 
itself to changes in dosage of thyroxine (Carr et al, 1988).
It has been stated that lack of fine tuning has never been 
shown to have deleterious consequences (Pearce and Himsworth, 
1984), though no long-term study has been conducted to explore 
this by the deliberate use of replacement regimes based on high 
and low dosage in relation to a standard such as the TRH test.
In the meantime, the value of routinely adjusting thyroxine 
dosage according to any test of thyroid function remains 
controversial.
Ill CONCLUSIONS AND FUTURE DEVELOPMENTS
The original aims of this thesis have largely been fulfilled. 
Techniques for the production of mouse monoclonal antibodies to
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human TSH have been developed and methods for the characterisation 
of such antibodies established in order to select those reagents 
suitable for use in immunometric assays. A variety of two-site 
immunoradiometric assays for human TSH based on the monoclonal 
antibodies produced and available polyclonal antisera have been 
developed and optimised and their use validated for the 
measurement of TSH in serum and in neonatal blood spots. Finally, 
the value of the monoclonal - polyclonal immunoradiometric assay 
for human TSH has been assessed in a variety of clinically based 
situations.
At the time this work was being carried out, non-isotopic 
systems for the measurement of TSH were beginning to become 
commercially available. Such assays offered greater sensitivity 
than those employing iodine as label. In this laboratory the 
future should see the replacement of iodine with a non-isotopic 
label and the subsequent development of assays for both serum and 
neonatal blood spot TSH.
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